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Abstract 
The hallmark feature of many neurodegenerative diseases, including amyotrophic 
lateral sclerosis (ALS), is the accumulation of cytoplasmic inclusions of key disease-
linked proteins. Two of these proteins, TDP-43 and SOD1, represent a significant 
proportion of sporadic and familial ALS cases, respectively. The population of 
potentially aggregation-prone partially-folded states on the folding free-energy landscape 
may serve as a common mechanism for ALS pathogenesis. A detailed biophysical 
understanding of the folding and misfolding energy landscapes of TDP-43 and SOD1 can 
provide critical insights into the design of novel therapeutics to delay onset and 
progression in ALS. 
Equilibrium unfolding studies on the RNA recognition motif (RRM) domains of 
TDP-43 revealed the population of a stable RRM intermediate in RRM2, with residual 
structure localized to the N-terminal half of the domain. Other RRM domains from 
FUS/TLS and hnRNP A1 similarly populate RRM intermediates, suggesting a possible 
connection with disease. Mutations, which enhance the population of the RRM2 
intermediate, could serve as tools for deciphering the functional and misfolding roles of 
this partially-folded state in disease models, leading to the development of new 
biomarkers to track ALS progression.  
ALS mutations in SOD1 have been shown to destabilize the stable homodimer to 
result in increased populations of the monomeric and unfolded forms of SOD1. 
Mechanistic insights into the misfolding of SOD1 demonstrated that the unfolded state is 
a key species in the initiation and propagation of aggregation, suggesting that limiting 
 viii 
these populations may provide therapeutic benefit to ALS patients. An in vitro time-
resolved Förster Resonance Energy Transfer assay to screen small molecules that 
stabilize the native state of SOD1 has identified several lead compounds, providing a 
pathway to new therapeutics to treat ALS. 
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Chapter I - Introduction 
 
 
Protein Folding and Relationship to Disease 
Life is dependent on the natural ability of polypeptide chains to spontaneously 
fold to their native three-dimensional structure(s) to achieve proper functionality in 
organisms (1). These functions are diverse, ranging from RNA-binding and regulation (2, 
3) to enzyme catalysis (4), and lead to a wide range of outcomes to propagate life. In 
most cases, proteins are synthesized and fold rapidly (within seconds) to their native 
conformation (5). Work performed by Levinthal in the 1960’s demonstrated that if a 
protein were able to sample all possible conformations, the protein would take millions of 
years to fold to its native conformation, an unsuitable time scale for life to occur. Thus, 
he demonstrated that the sequence of the protein must contain sufficient information to 
favor and eliminate possible conformations to drastically increase the rate of protein 
folding (6). Several decades of research into this field has demonstrated that most 
proteins fold via funnel-shaped energy landscape model (7–10). As depicted in Figure 1, 
the highest energy species are typically the unfolded state ensemble, which comprises a 
multitude of rapidly interconverting conformations. As the proteins proceeds to fold 
down the energy landscape, the overall energy decreases while simultaneously limiting 
the conformational entropy of the system to populate the native conformation (Fig. 1.1).  
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Figure 1.1: Energy Landscapes for Folding and Aggregation (1, 11–14). Unfolded 
polypeptides populate an ensemble of low stability conformations (top of funnel). During 
the folding reaction, these chains fold productively to the native functional conformation 
(blue). This reaction can occur via a single cooperative step or through the formation of a 
partially-folded species or intermediate state (purple). These states can serve a dual 
purpose during the folding reaction by allowing the protein to adopt conformations that 
may be intrinsically aggregation-prone and result in the non-productive formation of 
misfolded states (red). Unlike the reversible folding reaction, misfolding can result in the 
formation of irreversible aggregate formation often associated with numerous human 
diseases. Mutations in numerous genes or disease stresses disrupt the population of the 
functional native state (blue) towards these higher energy states (boxes with partial 
structure formation) and often result in aggregation (red), which can disrupt cellular 
homeostasis and cause eventual cell death. 
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In some cases, proteins can fold via partially-folded intermediate state(s), which may 
contain both native and non-native interactions, and serve to limit the conformations 
populated during folding and direct the formation of the native state (15–19).  
Recently, these higher energy states, including intermediate and unfolded states, 
have been investigated for their role in mediating protein misfolding and aggregation 
(Fig. 1.1)(1, 11–14, 20) as these species may serve to form misfolded conformations or 
expose aggregation prone regions (21–24). As Figure 1.1 shows, the energy landscapes of 
folding and aggregation are intricately linked through these partially folded and unfolded 
states which may serve as templates or platforms for mediating further misfolding and 
aggregation (16, 25). Under normal cellular conditions, a quality control network, 
consisting of a wide-range of protein chaperones, proteasomes and checkpoints, 
maintains cellular homeostasis and limits the accumulation of damaged, misfolded or 
aggregated proteins inside cells (26–29). However, certain conditions, through repeated 
cellular stress, inherited mutations or a combination of both events, impair these 
pathways with subsequent accumulation of post-translationally modified, insoluble 
proteinaceous aggregates (30–36). These inclusions are observed in a host of human 
diseases including multiple types of neurodegenerative disease (11, 37–44) and 
amyloidoses (21, 22, 45–47). 
 
Amyotrophic Lateral Sclerosis (ALS) 
 ALS is a highly progressive and devastating neurodegenerative disease affecting 
1-5 in 100,000 individuals with death occurring rapidly after disease diagnosis, typically 
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within 3-5 years (48). The hallmark feature of many neurodegenerative diseases 
including ALS, frontotemporal lobar dementia (FTLD), Huntington’s disease and 
Alzheimer’s disease among others (30, 39–43, 49) is the accumulation of cytoplasmic 
inclusions in the central nervous system neurons, including the brain and spinal cord. 
Approximately 10% of ALS cases (fALS) have been linked to inheritable mutations in a 
variety of proteins (Fig. 2B), including superoxide dismutase 1 (SOD1)(50), TAR-DNA 
binding protein of 43 kDa (TDP-43)(30, 49), fused in sarcoma (FUS/TLS)(51), profilin 
(52) among others, while the remaining cases arise through unknown causes (sALS) (53–
55) (Fig. 1.2A). Two of these proteins, SOD1 and TDP-43, represent a significant 
proportion of fALS and sALS, respectively (53) (Fig. 1.2). Intriguingly, SOD1 
aggregates are specific for ALS (56) while TDP-43 has been linked to multiple 
neurodegenerative diseases, including ALS and FTLD, suggesting an overlapping 
mechanism of progression between the two diseases (30, 49). Since their discovery in 
1993 (50) and 2006 (30, 49), respectively, missense mutations have been identified in 
each protein that support a direct causality to the initiation and propagation of the disease 
(57). Roughly 20% of all fALS cases are a result in mutations in SOD1, which 
encompass the entire molecule without clustering at one particular site or region (58). By 
contrast, 5% of fALS and sALS mutations reside in TDP-43 and cluster in the C-terminal 
region with few mutations elsewhere (57). A vast majority of patients with inclusions 
consisting of TDP-43 lack missense mutations suggesting that the wild-type protein is 
sufficient for aggregation and potential toxicity (Fig. 1.2C) and TDP-43 may serve as a 
general response marker in neurodegeneration.  
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Figure 1.2: The proteins, SOD1 and TDP-43, play an important role in familial 
(fALS) and sporadic ALS (sALS), respectively (53). A. Approximately 10% of all ALS 
cases are familial with known genetic causes. The remaining 90% of ALS cases from 
unknown causes with a small percentage arising from sporadic mutations in c9orf72 
(~6%), TDP-43, FUS/TLS and SOD1 (~1% each). B. A significant proportion of fALS 
result from a GGGGCC-repeat expansion in an intron of the c9orf72 gene and mutations 
in the SOD1 gene with smaller contributions from mutant TDP-43 and FUS/TLS. Less 
than 1% of cases arise from a small number of mutations in a host of other genes (Other) 
including hnRNP A1, matrin-3, VAPB, profilin and tubulin among others. C. Greater 
than 95% of all ALS patients have cytoplasmic aggregates comprised of TDP-43 with the 
remaining cases consisting of aggregation of other proteins, including SOD1 and 
FUS/TLS.  
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SOD1 and TDP-43 Structure and Domain Architecture 
 Despite their common link to neurodegeneration, SOD1 and TDP-43 have 
drastically different structures and functions. SOD1 is a homodimeric protein (Fig. 1.3) 
expressed predominantly in the cytoplasm and mitochondrial intermembrane space (59). 
Indeed, some mutant variants, including G93A, show nuclear exclusion in cell culture 
models (60). Each 153 amino acid SOD1 monomer consists of an Ig-like eight-stranded 
β-barrel with two disordered loops, the zinc binding and electrostatic loops. These loops 
are inserted between β4-β5 (Zinc Binding Loop) and β7-β8 (Electrostatic Loop) and 
assist in the coordination of two metal ions, zinc and copper (61–63). The zinc ion 
contributes to the overall thermodynamic stability of the protein (64) while the copper ion 
is essential for the catalytic functionality (59) (Fig. 1.3) In the cell, SOD1 serves as an 
oxygen radical scavenger to reduced reactive oxygen species (ROS) through the 
dismutase catalysis of superoxide (O2) into hydrogen peroxide (H2O2) and molecular 
oxygen (O2) (59). A disulfide bond between Cys57 in the zinc binding loop and Cys146  
 
 
 
on β8 provides additional stability to the dimeric form of SOD1 (65, 66). These post-
translational modifications (PTM) are achieved through the binding of the chaperone, 
copper chaperone for SOD1 (CCS), which simultaneously inserts copper and promotes 
disulfide bond formation at the correct cysteine pair (59, 67) prior to dimerization (68). 
The cellular location of this maturation step of SOD1 is unclear (68). However, CCS and 
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Figure 1.3. Sequence and topology of SOD1. A. SOD1 is a 153-amino acid member of 
the Ig-like family of proteins containing all β-structure with 8 β-strands (β1-β8) and two 
disordered loops, the zinc binding (cyan) and electrostatic (green) loops, with a single 
external intramolecular disulfide bond (red dashed line). B. SOD1 is a homodimer with 
each monomer containing 8 β-strands arranged in a greek-key β-barrel motif, similar to 
other members the Ig-family. In the case of SOD1, β1, β2, β3 and β6 and β5, β4, β7 and 
β8 form the two respective halves of the β-barrel. The zinc binding (cyan) and 
electrostatic (green) loops are necessary to coordinate two metal ions: one zinc (gray) and 
ion copper (yellow) ion per monomer that aids in the stability of SOD1 (zinc) or is 
essential to the enzymatic function of protein (copper). An intramolecular disulfide bond 
(red) between Cys57 in the zinc binding loop and C146 in β8 further increases the 
stability of SOD1 and promotes its dimerization. 
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SOD1 have similar localizations in the mitochondria and cytoplasm (69, 70) suggesting 
this maturation step may occur in the reducing environment of the cytoplasm. X-ray 
crystal structures indicate the dimeric interface between the SOD1 monomers is 
composed of residues localized in β1, β8 and the zinc-binding loop, further implicating 
the disulfide bond in maintaining the stability of SOD1 (71) 
In contrast to SOD1, TDP-43 is a 414-amino acid RNA-binding protein 
containing two RNA recognition motifs (RRM), RRM1 and RRM2, a nuclear 
localization sequence (NLS), a nuclear export sequence (NES) in RRM2 and a glycine-
rich C-terminal disordered domain (48) (Fig. 1.4). Each RRM domain has a classical (β-
α-β)-repeat topology with an extra β-strand (β4) (72–74) (Fig. 1.4B). These domains have 
similar nuclear magnetic resonance (NMR) structures with similar amino acid sequences, 
particularly in the N-termini of each domain (Fig. 1.5B-D). Recent evidence also 
indicates the N-terminal domain (NTD) adopts a well-folded axin 1-like topology (75) 
that may mediate TDP-43 oligomerization or assist in proper TDP-43 function (76, 77). 
TDP-43 is ubiquitously expressed but localizes and functions mainly in the nucleus 
where its involvement in the regulation of various RNA processes including mRNA 
splicing and stability, microRNA biogenesis, gene transcription among others (44, 78, 
79), has been well established (Fig. 1.5). TDP-43 has even been shown as a critical 
determinant in the negative feedback regulation of its own mRNA to limit TDP-43 
protein overexpression (80). TDP-43 binds specifically to (UG)-repeat sequences with 
high affinity mainly through interactions with RRM1 (72, 73) as removal of this domain 
or mutation of key phenylalanine sequences is sufficient to completely abolish splicing  
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Figure 1.4. Domain Architecture of TDP-43. A) TDP-43 is a 414-amino acid protein 
containing two RNA recognition motifs (RRM1, RRM2), a well-folded N-terminal axin 
1-like domain (NTD) and a disordered C-terminus (Glycine-rich region). A strong 
bipartite nuclear localization signal (NLS, purple) resides upstream of RRM1 while a 
nuclear export sequence (NES, yellow) is buried within the folded RRM2 domain. B1. 
The RRM domains are ~75 amino acids in length with the classical RRM β-α-β -repeat 
topology with an extra beta strand (β4). The β-strands are shown as blue arrows and α-
helices are colored in red. The RRM sequences are colored to identify the residues 
contributing to a specific secondary structure element with the β-strands in blue and α-
helices in red. The cyan box and underlined sequence in RRM2 highlight a region within 
RRM2 that is cleaved in patient samples and the NES, respectively. The sequence 
homology of the two RRM domains is indicated below with asterisks (*) and colon (:) 
indicating identical and similar residues, respectively. C and D. NMR structures of 
RRM1 (pdb: 2cqg) and RRM2 (pdb: 1wf0) labeled with β-strands (β1-β5) and α-helices 
(α1, α2). The canonical RNA-binding phenylalanine residues (RRM1: F147, F149; 
RRM2: F229, F231) and intrinsic fluorescence aromatic residues (RRM1: W113, W172; 
RRM2: Y214) are shown as sticks for each domain. Residues removed following 
cleavage from RRM2 as observed in patients are shown as cyan and comprise β1 and a 
region of α1. E. NMR structure of the tethered RRM construct bound to a cognate RNA 
sequence (pdb: 4bs2). Whereas most dual RRM-containing proteins bind with RRM1 at 
the 3’ sequence, the RRM domains of TDP-43 bind in a unique manner with RRM2 at 
the 3’ sequence and RRM1 at the 5’ end (72). 
 
1Panels B-E are reprinted from the Journal of Biological Chemistry. Brian C. Mackness, 
Meme T. Tran, Shannan P. McClain, C. Robert Matthews and Jill A. Zitzewitz. Folding 
of the RNA Recognition Motif (RRM) Domains of the ALS-linked Protein TDP-43 
Reveals an Intermediate State. Journal of Biological Chemistry. 2014; 289:8264-8276. © 
the American Society for Biochemistry and Molecular Biology." 
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activity in cell culture models (81). Indeed, the functionality of RRM2 is highly debated 
as this domain binds weakly to RNA (73) and its removal has little to no effect on 
splicing (81). Immediately adjacent to these RRM domains is a glycine region containing 
multiple glutamine/asparagine (Q/N)-rich repeats essential for binding protein partners in 
the RNA processing complexes, including other similar heteronuclear ribonucleoproteins 
(hnRNPs), such as hnRNP A1 and A2/B1 (82–85). This domain architecture with RNA-
binding domains tethered to sequences specific for protein-protein interactions likely aid 
in scaffolding of TDP-43 in splicing and microRNA complexes through specific RNA 
and protein interactions (86, 87). Although the SOD1 and TDP-43 genes encode proteins 
with dramatically different structures and functions, SOD1, TDP-43 and the other genes 
linked to neurodegeneration may initiate disease pathogenesis through a similar 
mechanism. 
 
Mapping the Energy Landscape of SOD1  
 A biophysical analysis of the free-energy folding landscape of other disease-
linked proteins, including transthyretin (TTR) and β-microglobulin in multiple amyloid 
diseases among others (20, 88–93), have revealed increased populations of partially-
folded and unfolded states during the folding reactions. In the case of the tetrameric TTR, 
mutations increase the population of the monomer resulting in misfolded conformations 
(88) with subsequent aggregation (94). These data suggest that higher energy states, 
including partially-folded and unfolded species on the free-energy folding landscapes, 
could serve as targets for therapeutic development to stabilize the native conformations to  
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Figure 1.5: The Functional Roles of TDP-43. TDP-43 (black circles and lines) is a 
predominately nuclear RNA-binding protein with major roles in various RNA processes 
including RNA splicing, transcriptional regulation and microRNA processing through its 
RNA-binding (blue line) and protein-protein interaction (green circle) capabilities. 
Evidence also has also shown that TDP-43 shuttles between the nucleus and cytoplasm, 
where it is thought to regulate mRNA stability, translation and stress granule formation. 
In contrast to SOD1, the dominant hypothesis for how TDP-43 exerts its toxicity in 
neurodegeneration is through a loss-of-function mechanism. In this model, TDP-43 
aggregation depletes the normal functional protein and disrupts its RNA-processing 
functions including the autoregulation of its own mRNA. This disrupts results in 
increased protein TDP-43 protein expression and further aggregation and toxicity. 
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reduce potentially aggregation-prone intermediates (95). Indeed, in the case of TTR, the 
natural ligand, thyroxine, served as a scaffold molecule for structure-based design of 
stabilizers of the native tetrameric TTR complex (95–97). These compounds reduced the 
population of the partially-folded monomers and unfolded state through the Law of Mass 
Action and have shown promise in clinical trials (98). This methodology of targeting the 
native states of disease-linked proteins to reduce misfolding and aggregation has been 
further applied to other protein systems (99). These results suggest that stabilizing the 
native conformations of disease-linked proteins through the use of small molecules may 
serve as a powerful tool to mitigate the population of non-native conformations and 
possibly delay disease onset and progression. 
 Since its discovery as an ALS-linked protein in 1993, biophysical studies on 
SOD1 have been widespread with focus on the impact of mutations, disulfide bond 
reduction and demetallization on the populations of species on the free-energy folding 
landscape (64, 65, 100–105) (Fig. 1.6). The equilibrium and kinetic unfolding pathway of 
the apo-SOD1 (demetallated) revealed that the unfolded SOD1 monomers fold via a 
monomer intermediate state before association to the native dimer (2U D 2M D N2) 
(105, 106). The monomer folds slowly with a highly persistent unfolded state (>10 sec) 
followed by near diffusion limited association to form dimers. As a result of this rapid 
association the monomeric forms are populated less than 0.5% during the folding reaction 
(105, 106). Indeed, the incorporation of zinc provides significantly increased stability, as 
urea is no longer sufficient to denature the enzyme (64). Studies have shown the holo-
enzyme (containing zinc and copper) is enzymatically active, even in 8 M urea  
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Figure 1.6: The Free-energy Landscape of G93A, A4V and WT SOD1. A. Reaction 
coordinate of SOD1 folding as a function of stability. The SOD1 native dimers fold in a 
three-state manner from the unfolded state (red line) with the formation of a transiently 
stable monomer intermediate (circle) prior to dimerization (dual circles). Mutations 
disrupt the folding reaction of the native SOD1 dimer through destabilization of the 
monomer folding (G93A, green), the monomer-dimer association reaction (A4V, orange) 
or both to result in decreased stability compared to WT (blue) SOD1. B. Populations of 
the unfolded, monomer and native dimer for G93A (green), A4V (orange) and WT (blue) 
SOD1. As a result of destabilization of the native dimer stability in mutant SOD1 
variants, the populations of non-native conformations, including the monomer (A4V) and 
unfolded (G93A) states, are increased compared to the WT. 
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(107, 108). However, demetallation and reduction of the disulfide bond results in severe 
destabilization of the dimer, to the extent that the monomeric species is the dominant 
state at equilibrium (65, 109, 110). Over 150 causative mutations have been associated 
with SOD1 and ALS and are scattered throughout the primary sequence with no 
clustering in specific regions of SOD1 (100). These mutations have varying biophysical 
effects: S134N, in the absence of metal ions, appears thermodynamically similar to wild-
type, G93A dramatically destabilizes the monomer while A4V specifically targets the 
monomer association reaction (106). Indeed, a comprehensive mutational analysis of a 
host of SOD1 mutations, in the context of the demetallated protein, reveal a wide range 
of effects in a similar manner as described above or in some combination where both the 
monomer and dimer stabilities are perturbed (103, 106). The overall implication of the 
SOD1 mutations indicates that the equilibrium is shifted away from the highly stable 
dimer towards greater populations of monomers and the unfolded state (Fig. 1.6). These 
higher energy species contain aggregation-prone regions and amyloid-forming sequences 
(111) that may be buried in the native dimer but become exposed upon population of 
these species when mutations are present. 
 
Targeting Partially-Folded Conformations with Small Molecules 
 Currently, only one therapeutic has been approved for the treatment of ALS, 
riluzole. While this small molecule has shown modest effects to increase longevity by an 
average of three to six months, largely through disruption of glutamate receptors, riluzole 
does not directly target known ALS-causing genes or proteins (112–115). Targeting the  
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Figure 1.7: Targeting the native conformations of SOD1 for therapeutic 
development. A. Reaction coordinate of a mutant variant of SOD1 in the absence 
(dashed line) and presence (solid line) of a small molecule (purple hexagon) stabilizer of 
the native dimeric SOD1. B. The mutation (dashed line) disrupts the folding and stability 
of SOD1 to enhance the population of the monomer and unfolded states. These states 
may serve as key species to initiate SOD1 misfolding and aggregation observed in ALS 
patients (A, red arrows). Targeting the dimer of mutant proteins through the binding of 
small molecules (purple hexagon) or antibodies would stabilize the native conformation 
and reduce the populations of these potentially toxic partially-folded species. 
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native dimeric state of SOD1 could serve as an alternative therapeutic approach to limit 
the population of the potentially aggregation prone monomeric and unfolded species 
(Figs. 1.6-1.7). This type of approach has been used successfully in stabilizing the 
tetrameric protein, TTR, by manipulating the scaffold of the natural TTR ligand, 
thyroxine, (116–118) to reduce the monomeric species in several TTR mutants (88, 119). 
The introduction of a non-natural cysteine at position 148 in SOD1 (V148C) has been 
shown to form an intermolecular disulfide bond between the monomer subunit and 
drastically reduce the aggregation potential of SOD1 (120). A similar approach using 
crosslinking at Cys111 showed increased melting temperature compared to non-
crosslinked SOD1 (121). A computational screen targeting the dimeric interface with 
small molecules initially yielded several potential candidate small molecules (122), but 
their effectiveness in reducing aggregation is controversial (122, 123). Small molecules 
have been effective as protease, signaling and aggregation inhibitors in various diseases, 
including diabetes (124–126), HIV (127–130), and Huntington’s disease (131, 132), 
among others (133, 134) and may provide a valuable diagnostic tool for stabilizing the 
native conformation of disease-related proteins. 
 
The Interplay Between Order and Disorder in TDP-43-mediated ALS  
 Upon the identification of the RNA-binding protein, TDP-43, in a vast majority of 
ALS and FTLD cases (30, 49), research into the mechanisms through which TDP-43 
induces toxicity has been rapid with the creation of multiple animal and cell models (44, 
135–137). A common method to understand which regions contribute to the aggregation 
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and toxicity observed in patient tissues was the creation of TDP-43 constructs comprising 
individual, tethered and/or fragments of TDP-43 fused to green fluorescent protein 
(GFP)(138–141). These studies revealed that although a majority of ALS-mutations 
reside in the C-terminus, this domain alone is insufficient to cause disease phenotypes. 
Indeed, the most severe phenotypes were attributed to fragments containing the 
disordered C-terminus as well as the structured RRM2 domain (138–141). These 
fragments resemble those observed in patient samples where cleavage by proteases (139, 
142–147) at several positions, including D90, R208 and D219, result in C-terminal 
fragments of TDP-43 (49, 139, 142). This data suggests that the interplay between 
structured and disordered regions of TDP-43 may contribute between the functional roles 
and misfolded states that may contribute to disease. However, a detailed biophysical 
characterization of the folding free-energy landscapes, like those performed on SOD1, is 
lacking, largely a result of the insolubility and instability of TDP-43 in vitro. A major 
focus of biophysical based studies has centered on the structures and RNA-binding 
capabilities of the isolated and tethered RRM domains (72–74) and the aggregation 
propensity of specific TDP-43 sequences (148–152). The role of mutations in perturbing 
normal TDP-43 function is unclear. Functional and aggregation studies of TDP-43 ALS-
variants in the C-terminus have revealed that mutant proteins have a longer half-life 
compared to wild-type TDP-43 (153), have increased aggregation propensity (35) and 
affect RNA processing activity (154, 155). A mapping of the free-energy folding 
landscape would provide critical insights into the states which can lead to the productive 
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folding and function or misfolding and aggregation of TDP-43 in neurodegenerative 
diseases. 
  
Models of Disease Pathogenesis 
 While the mechanism through which the ALS-related proteins exert their toxic 
effects is poorly understood, a powerful tool to investigate these mechanisms has been 
the use of transgenic animal models. The SOD1 knockout transgenic mouse develop few 
abnormalities, unless the animals were subjected to axonal stress where the loss of SOD1 
resulted in increased neuronal death (156) or abnormalities in muscle innervation (157). 
These results suggested that the loss of SOD1 function was not completely responsible 
for ALS pathology. ALS-linked mutations in SOD1 drastically affect the populations of 
higher energy species (103, 106) yet can have varying impacts on the functionality of the 
enzyme, from complete loss (158) to fully wild-type-like (159) SOD1 activity. Indeed, 
mouse models have shown multiple effects from mutant SOD1 expression, including 
oxidative stress (160), axonal excitotoxicity (161–163), mitochondrial dysfunction (164, 
165), misfolding and aggregation (166–169) among others (170). Together, these data 
suggests the toxicity observed in SOD1 ALS patients is a direct result of a gain-of-
function mechanism (171) through the formation of SOD1 oligomers and/or aggregates 
through increased populations of monomer or unfolded intermediates (172–174) rather 
than a loss-of-function of the enzyme.  
In comparison with SOD1, a complete knockdown of TDP-43 is embryonic lethal 
(175) and has resulted in the creation of over-expression (154, 176–178) and conditional 
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knockdown (179–181) animal models to investigate the role of this protein in 
neurodegeneration post-fertilization. A common feature in the over-expression models is 
the accumulation of ubiquitinated mutant TDP-43 fragments in the cytoplasm of motor 
neurons, the hallmark feature of neurodegeneration (176–178). However, the role of these 
aggregates in the propagation of ALS is unclear as the accumulation of these inclusions 
depends largely on the over-expression of TDP-43 compared to endogeneous levels. 
Furthermore, at high levels of TDP-43 overexpression, the mice display some ALS-like 
phenotypes but typically die as a result of other unrelated causes (177, 178). At 1.5X 
endogeneous levels little to no cytoplasmic accumulation of either mutant of WT TDP-43 
has been observed but these increased TDP-43 concentrations resulted in large-scale 
changes in alternative splicing and RNA misregulation (154). A TDP-43 construct 
lacking the strong NLS resulted in cytoplasmic TDP-43 localization and more severe 
motor defects compared to the WT (182). These results suggest that while cytoplasmic 
aggregation may not be required for ALS, the nuclear localization of TDP-43 is a prime 
determinant in disease outcome, likely due to its involvement in numerous nuclear RNA 
processes (44, 78, 80, 81). In a similar manner, the conditional knockout mice with 
partial reduction in TDP-43 expression show motor neuron defects similar to 
neurodegeneration and ALS (179–181), with effects on RNA metabolism, similar to 
TDP-43 overexpression (181). All of this evidence suggests TDP-43 acts through a loss-
of-function mechanism (183) whereby TDP-43 aggregation can alter the functional pool 
of nuclear TDP-43 and impair various RNA processes necessary for normal cell function 
and survival.  
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Common Mechanism of Disease 
SOD1 and TDP-43 are ideal targets for therapeutic intervention as these two 
proteins have been associated with large percentages of familial and sporadic ALS, 
respectively (Fig. 1.2). Mutations in SOD1 (Fig. 1.2B) can drive the formation of 
potentially toxic oligomeric and aggregated species, while aggregates of WT TDP-43 
have been observed in >95% of all ALS cases (Fig. 1.2C) (53). These two proteins are 
functionally and structurally dissimilar (Figs. 1.3B and 1.4) and have been proposed to 
exert their toxic effects through different mechanisms. The prevalent hypothesis for 
SOD1 suggests that toxicity arises from a gain-of-function mechanism (171), where 
oligomers or aggregates are inherently toxic and directly result in cell death. However, 
TDP-43 may act through a dominant-negative effect with toxicity contributions from 
both loss- and gain-of-function mechanisms (183), suggesting the disruption of normal 
TDP-43 function as well as aggregation can contribute to disease pathogenesis. 
A biophysical investigation into the folding and misfolding free-energy 
landscapes of ALS-related proteins may provide critical insights into understanding the 
commonality between SOD1 and TDP-43. ALS mutations in SOD1 have been shown to 
destabilize the native dimeric form of SOD1 to favor the populations of the monomer and 
unfolded states (103, 106). Enhanced populations of these partially-folded states could 
serve as a decision point between the productive formation of the native state and 
misfolding and aggregation observed in misfolding diseases (Fig. 1.1). The biophysical 
characterization of TDP-43 has been limited as a result of the aggregation-prone nature of 
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the full-length protein, in addition to the complexities associated with a multi-domain 
protein. In this thesis, the folding energy landscape of the RRM domains of TDP-43 will 
be explored to identify whether partially-folded states play a role in TDP-43-mediated 
ALS.  
Limiting the population of partially-folded conformations in ALS patients may 
reduce protein misfolding and aggregation and directly mitigate disease toxicity. 
Decreased pools of partially-folded conformations would reduce the formation of toxic 
SOD1 oligomers and aggregates, as well as, possibly restore the functional pool of TDP-
43. Thus, specifically targeting partially-folded and misfolded conformations in ALS-
linked proteins to favor the formation of the native, functional protein may delay ALS 
disease onset and progression and provide therapeutic benefit to ALS patients. 
 
Scope of this thesis 
 This thesis focuses largely on two structurally and functionally different proteins 
linked to the neurodegenerative disease, ALS, TDP-43 and SOD1. TDP-43 is one 
amongst several RRM-containing RNA-binding proteins involved in multiple aspects of 
RNA biology, while SOD1 is an enzyme responsible for reducing the ROS, superoxide, 
inside cells. An extensive biophysical analysis on SOD1 has identified increased 
populations of higher energy states upon mutation, loss of metal binding and the loss of 
the disulfide bond and suggests a common mechanism for misfolding diseases. However, 
the insolubility and instability of TDP-43 in solution has hindered the biophysical 
characterization of this aggregation-prone protein.  
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 In the subsequent chapters, I have investigated: (Chapter II) The equilibrium 
folding free-energy landscapes and RNA-binding activities of the RRM domains of TDP-
43, (Chapter III) The residual structure of the RRM2 intermediate state in TDP-43, 
(Chapter IV) The commonality of an RRM intermediate in the ALS-linked RRM-
containing proteins, FUS/TLS, matrin-3 and hnRNP A1, (Chapter V) The effect of ILV 
mutations on the population of the RRM2 intermediate, (Chapter VI) The effect of ALS-
inducing mutations on the aggregation of SOD1 and (Chapter VII) The use of small 
molecules to stabilize the native A4V SOD1 dimer. 
 In Chapter II, we investigated the equilibrium unfolding pathways of the isolated 
and tethered RRM domains of TDP-43, including a disease-relevant fragment of RRM2 
at room temperature and under physiological conditions. In addition, the RNA-binding 
capabilities of each isolated and the tethered RRM constructs were determined. Here, we 
determined that RRM2 contains a highly populated intermediate on its equilibrium 
unfolding pathway that is absent in RRM1. Furthermore, interactions between RRM1 and 
RRM2 result in stabilization of both domains, a reduced population of the RRM2 
intermediate state under native conditions, and enhanced RNA-binding capabilities.  
In Chapter III, in collaboration with Francesca Massi’s group, we identified the 
residual structure in the intermediate in RRM2 of TDP-43 by nuclear magnetic resonance 
(NMR). A combination of near-UV CD and small angle X-ray scattering (SAXS) 
indicates a loss of the native tertiary packing and globular structure in the intermediate, 
however, NMR and far-UV CD studies show residual structure in the RRM domain. This 
 30 
structure localizes in the N-terminal half of RRM2 with the C-terminus largely disordered 
including the TDP-43 NES sequence. 
In Chapter IV, a collaboration with several talented undergraduate students is 
ongoing to probe the equilibrium unfolding energy landscapes of the other ALS-linked 
RNA-binding proteins to identify whether an RRM intermediate is common amongst 
these proteins. Preliminary data has shown that the RRM of FUS and RRM2 of hnRNP 
A1 similarly populate an intermediate state like RRM2 of TDP-43, while the RRM 
domains of matrin-3 fold via a two-state mechanism. 
In Chapter V, in collaboration with S. Erendira Avendano-Vazquez, we prepared 
a series of RRM2 mutants for biophysical and functional studies. The selected residues 
contribute to the large networked hydrophobic cluster of isoleucine, leucine and valine 
(ILV) residues in the core of RRM2. The goal of this study is to identify variants that 
increase the population of the RRM2 intermediate under cellular conditions to monitor 
cellular phenotypes. These mutant constructs could serve as diagnostic tools and 
biomarkers for the population of the intermediate in ALS patient samples. Preliminary 
data has identified several putative mutations whose cellular phenotype closely resembles 
ALS-linked mutations.  
In Chapter VI, we investigated the role of the ALS-inducing mutations, A4V and 
G93A, on the aggregation of SOD1. Using a thioflavin T (ThT)-based assay, the 
aggregation of A4V, G93A and the WT protein were monitored as a function of time and 
modeled to a series of different aggregation models to investigate the kinetic mechanism 
of SOD1-based aggregation. Through these models, the elongation rate is similar 
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between all the variants examined while the lag phase correlated to the thermodynamic 
stability and the population of the unfolded state of SOD1. Furthermore, the critical 
nucleus of this process was determined to be monomeric and was not dependent on 
fragmentation. 
In Chapter VII, we leverage our biophysical understanding of the free-energy 
landscape of the A4V variant of SOD1 to develop a time resolved Förster Resonance 
Energy Transfer (tr-FRET) assay to directly monitor the populations of the monomer-
dimer equilibrium. The lifetime-based analysis provides significantly better signal-to-
noise than fluorescence intensity and is independent of fluorophore concentration. This 
assay was adapted to perform high-throughput screening (HTS) of two libraries, the 
LOPAC and FDA-approved libraries, and obtained several putative lead compounds after 
secondary screening in a fluorescence correlation spectroscopy (FCS)-based assay. 
The final chapter details how biophysics can be used to probe the unfolding 
pathways of disease-related proteins and potential future directions of this project. Two 
key gaps in our understanding about the role TDP-43 and SOD1 play in 
neurodegeneration are the normal functions of the RRM intermediates states identified in 
TDP-43, FUS/TLS and hnRNP A1, as well as, the identification of toxic species that 
leads to neuronal cell death. The partially folded and unfolded species identified on 
folding energy landscapes are ideal conformations that may link normal function to 
misfolding and aggregation. Using this approach, selectively targeting these species on 
the unfolding landscape could lead to the development of potential therapeutics and 
biomarkers for the diagnosis and treatment of ALS and other neurodegenerative diseases. 
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Chapter II – Folding of the RNA Recognition Motif (RRM) Domains of the 
Amyotrophic Lateral Sclerosis (ALS)-linked Protein TDP-43 Reveals and 
Intermediate State 
 
This chapter has been published previously as Mackness BC, Tran MT, McClain SP, 
Matthews CR, Zitzewitz JA (2014) “Folding of the RNA Recognition Motif (RRM) 
Domains of the Amyotrophic Lateral Sclerosis (ALS)-linked Protein TDP-43 Reveals an 
Intermediate State.” J Biol Chem 289 (12 ):8264–8276. 
 
The work presented in the following chapter was a collaborative effort. Meme Tran and 
Shannan McClain were instrumental in the completion of the initial molecular biology 
and characterization of the folding landscapes of the RRM domains. I re-cloned RRM2, 
tRRMs and RRM2c to replace the TEV protease cleavage site with a PreScission 
Protease cleavage site and subsequently repeated all data sets and analysis. Jill Zitzewitz, 
Bob Matthews, Meme Tran and I contributed to the interpretation of the data. Jill 
Zitzewitz, Meme Tran and I wrote the final version of the published manuscript. 
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ABSTRACT 
Pathological alteration of TAR-DNA-binding protein-43 (TDP-43), a protein 
involved in various RNA-mediated processes, is a hallmark feature of the 
neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal lobar 
degeneration (FTLD). Fragments of TDP-43, comprised of the second RNA recognition 
motif (RRM2) and the disordered C-terminus, have been observed in cytoplasmic 
inclusions in sporadic ALS (sALS) cases, suggesting that conformational changes 
involving RRM2 together with the disordered C-terminus play a role in aggregation and 
toxicity. The biophysical data collected by circular dichroism (CD) and fluorescence (FL) 
spectroscopies reveal a three-state equilibrium unfolding model for RRM2, with a 
partially-folded intermediate state that is not observed in RRM1. Strikingly, a portion of 
RRM2 beginning at position 208, which mimics a cleavage site observed in patient 
tissues, increases the population of this intermediate state. Mutually stabilizing 
interactions between the domains in the tethered RRM1 and RRM2 construct reduce the 
population of the intermediate state and enhance DNA/RNA binding. Despite the high 
sequence homology of the two domains, a network of large hydrophobic residues in 
RRM2 provides a possible explanation for the increased stability of RRM2 compared to 
RRM1. The cluster analysis suggests that the intermediate state may play a functional 
role by enhancing access to the nuclear export signal (NES) contained within its 
sequence. The intermediate state may also serve as a molecular hazard linking productive 
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folding and function with pathological misfolding and aggregation that may contribute to 
disease. 
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INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a highly debilitating and progressive motor 
neuron disease affecting approximately one to two out of one hundred thousand new 
people each year, with death occurring two to five years after onset (48). Only 10% of 
ALS cases have been linked to genetic mutations in numerous genes (fALS), while the 
remaining 90% of cases result from an unknown cause (sALS) (53). The pathological 
hallmark of ALS is the presence of ubiquitinated inclusions in the cytoplasm of surviving 
spinal motor neurons.  In 2006, biochemical and immunological approaches identified 
TAR DNA-binding protein 43 (TDP-43) as a major protein found in postmortem brain 
inclusions of patients with both ALS and frontotemporal lobar degeneration with 
ubiquitinated inclusions (FTLD-U), providing a molecular connection between these 
diseases (30, 49).  In the years since this initial discovery, 50 different TDP-43 mutations 
in fALS and sALS patients have been identified (http://alsod.iop.kcl.ac.uk/als/), thereby 
underscoring a direct role for TDP-43 in ALS pathogenesis. Related research has been 
rapid (136), with numerous reports of mouse models, biomarkers and assays for testing 
disease progression and cellular function.  Yet, a molecular level understanding of how 
TDP-43 may lead to disease is still lacking (30), in part because of the poor solubility of 
the full-length protein and its tendency to fragment and aggregate. 
TDP-43 is a 414 amino acid protein that contains two RNA recognition motifs 
(RRM), a nuclear localization sequence (NLS) in the N-terminus, a nuclear export signal 
(NES) within RRM2, and a C-terminal glycine rich domain (accession no. Q13148,  
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FIGURE 2.1. TDP-43 contains both structured and disordered regions.  A. Domain 
architecture of TDP-43 and aggregation (16) and disorder (17) propensity predictions 
based on the amino acid sequence. The aggregation algorithms TANGO (green) and 
WALTZ (blue) predict an aggregation prone stretch in RRM2 (residues 228-233), with 
WALTZ predicting a second region in the glycine-rich domain (residues 314-319) and 
TANGO predicting a region near the nuclear localization sequence (NLS, purple). The 
disorder algorithm PONDR (orange) predicts high amounts of disorder in the C-terminal 
glycine-rich region (orange), where the ALS-causing mutations are located. Regions of 
disorder are also predicted in the linker, which lies between the two RRM domains as 
well as within the NLS. By contrast, very little disorder is predicted within the putative 
nuclear export sequence (NES, yellow). B. The two RRM domains show high sequence 
similarity by ClustalW2 sequence alignment (identical, *: similar, :) Residues in β-
strands and α-helices are colored blue and red, respectively, with the residues removed in 
RRM2c boxed in cyan. The predicted aggregation prone sequence in β3 is highlighted in 
bold, and the putative NES sequence is underlined. C, D. RRM domains are structurally 
similar based on solution NMR (C, RRM1 - 2cqg.pdb and D, RRM2 - 1wf0.pdb).  β-
strands are colored blue, α-helices are red, and loops are gray. The key phenylalanine 
residues identified for RNA binding in β3 are shown as sticks (RRM1: F147 and F149, 
RRM2: F229 and F231), and intrinsic fluorophores for following tertiary structure 
folding are also shown (RRM1 - W113 and W172; RRM2 - Y214). The RRM2c 
construct, a model for the cleavage observed in disease, removes the first β-strand and 
half of the first α-helix (deleted regions shown in cyan) in RRM2. Note that the solution 
structure of RRMc is unknown and predicted to be much different than that mapped on 
RRM2 (1wf0.pdb) due to removal of secondary structural elements in the protein core. E. 
NMR structure of the tethered RRMs with RNA (pdb:4bs2) with RNA shown in gray 
(43). The secondary structure elements are colored as shown in C and D. The RNA-
binding residues and intrinsic fluorophores are shown as sticks. 
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UniProtKB/Swiss-Prot) (Fig. 2.1A).  TDP-43 is ubiquitously expressed and has been 
implicated to play a functional role in many RNA processes, including gene transcription, 
splicing, mRNA processing, and mRNA stability (44, 78, 79).  TDP-43 is localized in the 
nucleus in normal cells, but redistributes to form cytoplasmic aggregates composed of 
hyperphosphorylated and ubiquitinated C-terminal fragments in diseased cells (184). As 
inferred from studies of other protein aggregates involved in neurodegenerative diseases 
(39), TDP-43 aggregates may arise from the population of non-native conformations that 
likely drive the neurodegeneration directly through a gain-of-function or loss-of-function 
mechanism. In these scenarios, the formation and accumulation of TDP-43 aggregates 
generate toxicity or impair normal TDP-43 cellular function resulting in cell death. 
Mounting evidence supports a loss-of-function phenotype (183), where sequestration of 
functional protein into cytoplasmic aggregates would limit the pool of available 
functional nuclear TDP-43.  
Several studies have demonstrated that both RRM2 and the disordered C-terminus are 
required for aggregation and toxicity (138–141). Examination of the domain architecture 
of TDP-43 suggests a possible interplay between structured and disordered sequences 
that may play a key role in toggling between appropriate biological function and 
dysfunction leading to disease (Fig. 1A).  Computer algorithms developed for predicting 
aggregation prone regions in unfolded polypeptide chains (185), WALTZ and TANGO, 
both show a high propensity for aggregation in RRM2 and the C-terminus (Fig. 2.1A). 
The sequence-based disorder predictor algorithm, PONDR, (186, 187) predicts a high 
degree of disorder in the C-terminal region of TDP-43. The two RRM domains share 
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significant sequence (Fig. 2.1B) and structural (Figs. 2.1C and 2.1D) homology. The 
NMR solution structures of the isolated RRM domains (Figs. 2.1C and 2.1D) and the 
tethered RRM domains (Fig. 2.1E) show an α+β structure for each domain, comprised of 
two repeating βαβ motifs with an extra β-strand (β4) inserted within the second βαβ 
motif. Together, these strands form an antiparallel β-sheet across one face of the RRM 
with the α-helices docked on the opposite face. While RRM domains can bind a diverse 
set of targets, including RNA, DNA, as well as peptides and other proteins (188, 189), 
most studies on TDP-43 have focused on the role of the highly conserved phenylalanine 
side chains in β3 for RNA recognition (80, 81, 190).  
To understand how the conformations populated by the RRM domains of TDP-43 
may play a role in disease propagation, the equilibrium unfolding and RNA-binding 
properties of the isolated and tethered RRM domains were probed by a pair of 
complementary spectroscopic techniques. The results identified a novel intermediate state 
in the folding of the RRM2 domain. The population of this intermediate is increased in a 
cleavage fragment but is reduced upon tethering to RRM1. The intermediate state in 
RRM2 may serve as a molecular hazard that may partition between productive folding 
and function, and misfolding and aberrant protein-protein interactions that could lead to 
disease progression. 
 
EXPERIMENTAL PROCEDURES 
Expression and Purification of TDP-43 Fragments – Gene fragments of TDP-43 
encoding RRM1 (amino acids 102-181), RRM2 (190-261), an RRM2 fragment 
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mimicking the disease-relevant proteolytic cleavage site within RRM2 (184) (RRM2c: 
208-261), and the tethered RRMs (tRRMs: 97-261) were purchased from Genescript with 
BamH1 and EcoR1 or Nco1 and BamH1 restriction enzyme digestion sites. The genes 
were inserted into a modified pGEX-6p1 (GE Healthcare Life Sciences) or pET-3d 
(Novagen) vector with a His6-tag and either a PreScission or TEV Protease cleavage site, 
respectively, for His6-tag removal. The proteins were overexpressed in BL21 DE3 E. coli 
cells (Stratagene) grown in LB media until OD600 = 0.8, followed by induction with 1 
mM IPTG for 24 hours at 20 °C (RRM1 and tRRMs) or for 16 hours at 30 °C (RRM2 
and RRM2c). 
Cells were resuspended in lysis buffer (20 mM NaPi pH 7.4, 300 mM NaCl, 30 mM 
Imidazole) and lysed by sonication. RRM2 and RRM2c were only present in the 
insoluble fraction and isolation from cell pellets was performed in the presence of 6 M 
urea. Each construct was bound to His60 resin (Clontech) overnight and washed with ten 
column volumes of lysis buffer before elution with 300 mM Imidazole. The eluted 
protein was dialyzed against protease cleavage buffer (50 mM Tris pH 8.0, 1 mM EDTA 
and 1 mM DTT) followed by subsequent cleavage with PreScission or TEV Protease to 
remove the His6-tag. Minor contaminants were removed through ion exchange 
chromatography using S sepharose (RRM1) or Q sepharose (RRM2, tRRMs, RRM2c) 
before dialysis into 10 mM KPi pH 7.2, 150 mM KCl, 1 mM β-mercaptoethanol (βME) 
for subsequent studies. After cleavage, protein purity was >98% as determined by both 
SDS-PAGE and reverse-phase MALDI-TOF mass spectroscopy carried out at the 
Proteomics and Mass Spectrometry Facility, UMASS Medical School. 
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 RRM2 contains a second Tev Protease-like cleavage site (246-EDLIIKG-252), as 
determined by mass spectrometry, preventing isolation of the intact domain. Thus, all 
RRM2-containing constructs were expressed instead with a PreScission protease site after 
the N-terminal His-tag. Cleavage with Tev Protease (191) results in an N-terminal Gly 
residue before the RRM amino acid sequence, and cleavage with PreScission protease 
leaves an N-terminal GPLGS sequence, with the LGS sequence being required for 
cloning. 
 
Size Exclusion Chromatography to Determine Oligomerization State – Size exclusion 
chromatography was performed on all constructs using a 24-mL Superdex 200 10/300 
GL column run at a flow rate of 0.2 mL min-1. Oligomerization status of the constructs 
was monitored as a function of loaded protein concentration by comparison to protein 
molecular weight standards (GE Healthcare Life Sciences). All size exclusion 
chromatography was performed at 4 °C in 10 mM KPi, pH 7.2, 150 mM KCl and 1 mM 
βME. 
  
Equilibrium Unfolding Experiments – The native-state circular dichroism (CD) 
spectrum of each construct was collected from 190-280 nm on a Jasco-810 
spectropolarimeter with a thermoelectric temperature control system in a 0.1 cm cuvette 
(Hellma). Guanidine hydrochloride (Gdn-HCl)-induced denaturation spectra were 
collected from 260-215 nm at a scan rate of 50 nm min-1 and a response time of 8 s. 
Samples were prepared from native and unfolded stock solutions mixed in precise 
 42 
amounts by in-house software and a Hamilton Series 500 titrator. The resulting solutions 
were incubated overnight at room temperature or at 37 °C before recording CD spectra. 
All Gdn-HCl concentrations were measured using an ABBE Refractometer, and all CD 
measurements were baseline corrected for buffer contributions. Protein concentration was 
measured by A280 absorbance (192), using an extinction coefficient of 15,470 M-1 cm-1 for 
tRRMs, 13,980 M-1 cm-1 for RRM1, and 1490 M-1 cm-1 for RRM2 and RRM2c.  The 
protein concentration was varied from 5 to 60 µM for CD experiments. Each CD spectra 
was normalized for protein concentration and number of amino acids and reported as 
mean residue ellipticity (MRE) (193).  Reversibility was confirmed to be >95% by the 
coincidence of equilibrium profiles for samples prepared from initial protein stocks in 
either buffer or denaturant.  
Steady-state fluorescence (FL) measurements were performed on a Spex Fluorolog-3 
equipped with a wavelength electronics temperature controller. For RRM2 and RRM2c, 
each Gdn-HCl titration sample was excited at 274 nm and tyrosine emission spectra were 
collected from 280-400 nm at 20 °C or 37 °C with 5 nm slit widths. For the tryptophan-
containing RRM1 and tRRMs proteins, excitation was at 295 nm and tryptophan 
emission spectra were collected from 300-500 nm at 20 °C with 5 nm slit widths. 
Denaturation experiments by both CD and FL were performed in replicates of three 
for each construct to ensure reproducibility. The equilibrium folding data for each 
construct were analyzed using an appropriate equilibrium folding model with the in-
house data analysis software Savuka (194). Each data set was subjected to a global 
analysis, where the baselines were local parameters and the free-energy of folding in the 
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absence of denaturant (ΔG°H2O) and the m value were globally linked between data sets. 
All of the Trp and Tyr fluorescence equilibrium profiles, as well as the CD equilibrium 
profile for RRM1, were best fit to a two-state model:  N⇋U. For these experiments, the 
change in free-energy between the native and unfolded states is assumed to depend 
linearly on the denaturant concentration as shown in Eqn. 2.1 (195).    
   
ΔG0=ΔG0H2O-m D                                   (2.1) 
 
The change in free-energy in the absence of denaturant, ΔG°H2O, can be used to determine 
the equilibrium constant, Keq from Eqn. 2.2. 
                         
Keq= exp -
ΔG0H2O-m D
RT
                    (2.2) 
 
For the CD equilibrium unfolding profiles of RRM2 and RRM2c, a three-state model best 
described the transition between the native and unfolded forms of the protein with the 
population of a stable intermediate state (I): N⇋I⇋U. Tethering the two RRM domains by 
the natural 15 amino acid residue linker sequence (tRRMs) results in the population of 
multiple stable intermediates at equilibrium by CD. In this case, the data were best fit 
with a four-state equilibrium model, N ⇋ I1 ⇋ I2 ⇋ U, with the population of two stable 
intermediate states, I1 and I2.  
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The fractional population of the intermediate state for RRM2 and RRM2c at a given 
denaturant concentration was determined from the partition function according to Eqn. 
2.3 (196).     
 FI=
exp -∆G
NI
RT
1+ exp -∆G
NI
RT + exp -
∆GNU
RT
                     (2.3) 
 
Where ΔGNI=𝛥𝐺!NI-mNI[D] and ΔGNU=𝛥𝐺!NU-mNU[D]. The I2 intermediate in the 4-
state model for tRRMs corresponds to the single intermediate for RRM2 and its fractional 
population was calculated as defined in Eqn 2.4.  
FI2=
exp -ΔG
NI2
RT
1+ exp -ΔG
NI1
RT + exp -
ΔGNI2
RT + exp -
ΔGNU
RT
        (2.4) 
 
Where ΔGNI1=𝛥𝐺!NI1-mNI1[D], ΔGNI2=𝛥𝐺!NI2-mNI2[D] and ΔGNU=𝛥𝐺!NU-mNU D . 
  
Nucleic Acid Binding Assays – Electromobility Gel Shift Assays (EMSA) and 
tryptophan (Trp) lifetimes were used to determine the apparent binding affinity of the 
TDP-43 RRM domains to UGUGUGUGUGUG ((UG)6), TGTGTGTGTGTG ((TG)6) and 
TTTTTTTTTTTT (T12) 12-mer oligonucleotides (IDT Technologies). For EMSA, the 
oligos were fluorescently-labeled at the 5’end by 5-carboxyfluorescein (IDT 
Technologies). 
A typical EMSA assay consists of 50 mL reactions of 3 nM nucleotides incubated 
with increasing protein concentrations up to 8 µM. Binding reactions were performed in 
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binding buffer, 10 mM KPi pH 7.2, 150 mM KCl, 2 mM DTT, 10 mg mL-1 tRNA and 
0.01% IGEPAL CA-630 (Sigma-Aldrich) (197), and incubated for 2 hours at room 
temperature. Prior to loading on an 8% polyacrylamide gel, 5 µL of bromocresol blue in 
30% glycerol was added to each reaction and 45 µL of the reaction mixture was added to 
the acrylamide gel. The samples were run for 1 hour at 140 V in 1× tris-boric acid buffer 
followed by subsequent imaging with a Fujifilm FLA-5000 using a 473 nm excitation 
wavelength. The fraction bound DNA/RNA, θ, was measured using the Multi Gauge 
Software (Fujifilm) to quantify the bound fractions (upper bands) and free DNA fractions 
(lower bands) from the polyacrylamide gel. 
θ= Bound DNA
Bound DNA + Free DNA
                                     (2.5) 
 
 Trp lifetime assays were performed in 500 µL reactions consisting of 2 µM 
protein incubated with increasing amounts of nucleic acid in the EMSA binding buffer 
described above. The samples were excited at 295 nm in a 50 µL cuvette (Hellma) using 
an autosampler configuration to prevent Trp photo-bleaching. The laser intensity was 
adjusted using 4 µM N-acetyl-tryptophanamide (NATA) as a standard to ensure a count 
rate between 8×104 – 1×105 per second prior to sample acquisition. Trp lifetime decays 
were measured for 2 min in 30 s intervals for each sample with ~60,000 counts total in 
the peak channel. The Trp lifetime decays were corrected for buffer contributions and 
subsequently fit to two exponential decays, which differed slightly depending on protein 
construct and DNA/RNA. In comparison to samples containing only protein, the 
amplitudes of the ~3.8 ns and ~5.8 ns components decreased and increased, respectively, 
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with increased DNA/RNA concentration. Thus, the amplitude of the faster phase 
represented the unbound protein and the slower phase resulted from the DNA/RNA 
bound protein.  
θ= Amplitude ~3.8 ns
Amplitude ~3.8 ns+Amplitude ~5.8ns
                    (2.6) 
 
The percent bound was determined as a function of DNA/RNA concentration and 
modeled to the quadratic binding equation (Eqn. 2.7) using Igor Pro (Wavemetrics, Inc.) 
to determine the apparent dissociation constant, Kd,app, (198):  
 
      θ=b+ m-b
L+P+kd,app - L+P+kd,app
2
-4LP
2L
        (2.7) 
 
where L is the fixed ligand concentration (EMSA: DNA/RNA, Trp Lifetimes: RRM1 or 
tRRMs), P is the independent variable (EMSA: Protein concentration, Trp Lifetimes: 
DNA/RNA), Kd,app is the apparent dissociation constant, and b and m are the baseline and 
maximum percent bound used to normalize the data sets. 
 
RESULTS 
RRM Domains are Monomeric and Well-folded – Each isolated RRM domain (RRM1 
and RRM2) can be expressed at high levels, is soluble to concentrations exceeding 5 mg 
mL-1 (~0.5 mM), and is monomeric by size exclusion chromatography (Fig. 2.2A). 
Despite their structural similarity by NMR (Figs. 1C and 1D), the circular dichroism 
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(CD) spectra of the two isolated RRM domains were strikingly different from one 
another. Indeed, CD spectra can vary widely between RRM domains, including RNA-
binding proteins that contain a single RRM domain such as FUS/TLS (199) or multiple 
RRM domain-containing proteins such as Musashi-1 (200) and U1A (201). RRM1 
contains prominent minima at 208 and 218 nm, suggesting significant α-helical 
propensity for this domain. RRM1 contains a dramatically increased CD signal compared 
to RRM2 (Fig. 2.2B), consistent in part with the enhanced α-helical structure content of 
RRM1 (25%) compared to RRM2 (20%) as predicted by DSSP (202, 203) based on the 
NMR structures (Fig. 2.1B). The CD spectrum of RRM2 was approximately half as 
intense as that of RRM1, with a minimum at 210 nm and a shoulder at 230 nm. Although 
the two RRM domains have identical β-strand content (30%), the NMR structures 
indicate that RRM1 has more twist to its β-sheet compared to RRM2, consistent also with 
the increased intensity of the CD signal for RRM1 (204).   
 
RRM2 Populates an Intermediate State – To probe the equilibrium folding mechanism 
of the RRM domains and its potential role in ALS, denaturant induced unfolding was 
used to sample other protein conformations. The loss in secondary and tertiary structure 
was monitored by CD and fluorescence (FL), respectively (Figs. 2.3A and 2.3B). Initial 
equilibrium folding studies performed in urea (data not shown) showed that RRM2 
remains partially folded at high urea concentrations (>8 M).  By contrast, both RRM1  
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FIGURE 2.2. The isolated RRM domains are monomeric and contain significant 
secondary structure under physiological salt conditions. A. Analytical size exclusion 
chromatography of the isolated (RRM1, green; RRM2, blue; RRM2c, orange) RRM 
domains reveal that each isolated domain is predominantly monomeric. The tethered 
domains (tRRMs, black) are also predominantly monomeric; however, some higher order 
species are also present, likely due to domain swapping. Arrows indicate retention times 
of molecular weight standards.  B. RRM1 contains significant secondary structure 
compared to RRM2. RRM1 (green) has a minimum at 218 nm with a shoulder at 208 nm 
while RRM2 (blue) has reduced ellipticity with a minimum at 210 nm and a shoulder at 
220 nm. The cleavage fragment, RRM2c (orange) has further reduced ellipticity. All CD 
spectra were taken at 20 ⁰C unless otherwise noted; physiological temperature (37 °C) 
does not alter the secondary structures of RRM2 (red) or RRM2c (purple). Tethering the 
RRMs (tRRMs: black) results in a CD spectrum resembling the sum of the isolated 
domains (black, dashed line). The CD spectrum for each protein, reported as MRE as a 
function of wavelength, did not vary in the range of 5-60 µM, and all proteins showed 
similar unfolded spectra when denatured in 7 M Gdn-HCl (blue, dashed line). 
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and RRM2 were fully unfolded in the presence of 7.5 M Gdn-HCl. 
 RRM1 has a CD spectrum with two prominent minima (Fig. 2.2B) characteristic of 
an α+β protein. The two tryptophan residues, unique to RRM1 (Fig. 2.1C), monitor the 
tertiary structure within this domain upon unfolding. For RRM1 at 20 °C, the CD and Trp 
FL reveal a single cooperative transition between the native folded state and the unfolded 
state (Fig. 2.3A) that is well-described by a two-state model for the free-energy of folding 
in the absence of denaturant; ΔG°H2O  = 3.7 kcal mol-1 (Table 2.1). The midpoints (Cm) of 
the transition between these two states are coincident between the two spectroscopic 
techniques (Figs. 2.4A and 2.4B), consistent with a two-state mechanism of folding for 
the RRM1 domain.  
 In comparison with RRM1, RRM2 contains reduced ellipticity and a single tyrosine 
as a fluorescence probe. The unfolding profile of RRM2 at 20 °C (Fig. 2.3B) monitored 
by CD is significantly different than that of RRM1. A change in the cooperativity 
observed at 4 M Gdn-HCl indicates a three-state unfolding process with contributions 
from a stably populated intermediate state. The transitions in the N D I D U three-state 
mechanism contribute 3.6 kcal mol-1 (NDI) and 3.8 kcal mol-1 (IDU) to the total stability 
of RRM2 (Table 2.1, 7.4 kcal mol-1). The CD and FL transitions are not coincident, 
further supporting the presence of an intermediate state on the RRM2 unfolding pathway. 
The Tyr fluorescence becomes insensitive to denaturant in the second transition (>4 M 
Gdn-HCl), suggesting the region surrounding this residue is unfolded in tyrosine as a 
fluorescence probe. The unfolding profile of RRM2 at 20 °C (Fig. 2.3B) monitored by  
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FIGURE 2.3. The isolated and tethered RRM domains have complex equilibrium 
unfolding profiles at 20 °C. A. Equilibrium unfolding of RRM1 unfolds by a two-state 
mechanism (NDU) by both CD (filled circles, solid line) and Trp FL (open circles, 
dashed line) B. RRM2 unfolds through the population of an equilibrium intermediate 
(NDIDU) by CD (filled triangles, solid line). By contrast, the Tyr FL (open triangles, 
dashed line) unfolds in a two-state process that coincides with the N D I transition 
observed by CD. C. Tethering the two RRMs stabilizes the RRM1 transition, resulting in 
a complex equilibrium unfolding profile with two stable intermediate states 
(NDI1DI2DU) by CD (closed diamonds, solid line). Trp FL (open diamonds, dashed 
line) follows the denaturation of RRM1 only and coincides with the first transition 
(NDI1) by CD. D. A cleavage fragment of RRM2 (RRM2c) unfolds through a three-state 
mechanism by CD (filled squares, solid line) with destabilization of both transitions 
compared to RRM2. Similar to RRM2, the two-state transition observed by Tyr FL (open 
squared, dashed lines) coincides with the CD transition. Each experiment was 
consistently reproduced three times. 
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CD is significantly different than that of RRM1. A change in the cooperativity observed 
at 4 M Gdn-HCl indicates a three-state unfolding process with contributions from a stably 
populated intermediate state. The transitions in the N D I D U three-state mechanism 
contribute 3.6 kcal mol-1 (NDI) and 3.8 kcal mol-1 (IDU) to the total stability of RRM2 
(Table 2.1, 7.4 kcal mol-1). The CD and FL transitions are not coincident, further 
supporting the presence of an intermediate state on the RRM2 unfolding pathway. The 
Tyr fluorescence becomes insensitive to denaturant in the second transition (>4 M Gdn-
HCl), suggesting the region surrounding this residue is unfolded in the intermediate state. 
Using the thermodynamic parameters for the individual transitions (NDI and IDU), the 
population of the intermediate state was calculated as a function of denaturant by Eqn 3. 
As shown in Fig. 2.4C, the intermediate state is maximally populated (80%) at 4 M Gdn-
HCl, and a small proportion (<1%) of RRM2 populates this partially-unfolded 
intermediate state under native conditions (0 M Gdn-HCl).  
 
Intermediate Population is Enhanced by Increased Temperature or Cleavage of RRM2 
– In ALS patient tissues, fragments of TDP-43 comprising the C-terminus and regions of 
RRM2 are present in cytoplasmic inclusions (184). One of these fragments of RRM2, 
starting at position Arg208, results in the removal of β1 and a region of α1 and leads to 
severe aggregation and toxicity in cell models (138, 140, 141). The disruption of the 
native fold in RRM2c could enhance the population of partially- unfolded states. A 
construct consisting of residues 208-261 (RRM2c) of RRM2 was designed, cloned and 
expressed for denaturation studies. RRM2c rapidly precipitates from solution upon  
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FIGURE 2.4. Cleavage and physiological temperatures destabilize RRM2 and 
increase the population of the intermediate state. A. Fraction apparent plot of the Trp 
FL of RRM1 (open circles, green dashed line) and tRRMs (open triangles, black dashed 
line) at 20⁰C reveals a shift towards higher denaturant for RRM1 unfolding upon 
tethering to RRM2. B. Fraction apparent plots of all TDP-43 RRM constructs by CD. 
RRM1 displays a two-state equilibrium profile (green), while RRM2 (20 °C, blue; 37 °C, 
red) and the cleavage fragment, RRM2c (20 °C, orange; 37 °C, purple) display a three-
state profile with the population of an intermediate state. tRRMs (black) displays a 
complex unfolding profile with the population of two stable intermediates. C. RRM2 
intermediate population as a function of denaturant using Eqn. 2.3 for a three-state 
(RRM2, RRM2c) or Eqn. 2.4 for a four-state (tRRMs). Increasing temperature (red) or 
cleavage (orange, purple) within the RRM2 domain (blue) results in an increased 
intermediate population under native conditions (0 M Gdn-HCl) with a shift to lower 
denaturant for the maximum intermediate population. Tethering RRM2 to RRM1 (black) 
reduces the RRM2 intermediate state under native conditions and shifts the maximum 
population to higher denaturant. D. Physiological temperatures destabilizes the N D I 
transition by CD (filled upside-down triangles, solid line) and Tyr FL transition (open 
upside-down triangles, dashed line) with a shift in the Cm to lower denaturant compared 
to RRM2. E. Physiological temperature results in a similar unfolding profile for RRM2c 
to RRM2 at 37 °C (compare filled upside-down triangles with filled hexagons). Tyr FL 
revealed little change between the folded and unfolded states (open hexagons), 
suggesting Y214 resembles the unfolded state at this temperature. Each experiment was 
consistently reproduced three times. 
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addition of salt, suggesting RRM2c adopts a structure that facilitates aggregation under 
cellular ionic strength conditions (151). The fragment was predominantly monomeric by 
size-exclusion chromatography (Fig. 2.2A); however, to enhance the solubility of 
RRM2c in the absence of denaturation, the 150 mM KCl was eliminated from the folding 
buffer.  
 The CD spectrum of RRM2c reveals that cleavage within the domain greatly reduces 
but does not obliterate its secondary structure (Fig. 2.2B). The fragment retains the three-
state behavior of the RRM2 domain upon denaturation at 20 °C (Fig. 2.3D) and 
significant stability (Table 2.1, 4.1 kcal mol-1). The transitions (NDI and IDU) are 
destabilized compared to the intact domain (Table 2.1) and display non-coincident CD 
and tyrosine FL transitions that supports a three-state unfolding model for RRM2c. The 
FL results suggest that the fragment can fold to a conformation that decreases the solvent 
accessibility of the Tyr, even though the Tyr is close to the new N-terminus. Comparing 
the fraction species plot of the intermediate state as a function of denaturant reveals 2% 
of the RRM2c conformational ensemble samples the intermediate state under native 
conditions at 20 °C (Fig. 2.4B, compare orange and blue traces). These results indicate 
that fragments of RRM2 sample partially-folded states to a greater extent than the intact 
domain and may provide a platform for subsequent TDP-43 aggregation (151). 
 Incubation of RRM1 at physiological temperatures (37 °C) resulted in aggregation 
(205, 206), while RRM2 and RRM2c remain in native conformations (Fig. 2.2B) with 
little change in secondary structure. Denaturation of the intact RRM2 at 37 °C (Fig. 2.4C) 
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also follows a three-state unfolding process albeit with a reduction in the overall stability 
(5.7 kcal mol-1 vs. 7.4 kcal mol-1). As with denaturation of RRM2 at 20 °C, the Tyr FL 
data were not coincident with the CD data (Table 2.1), supporting the presence of an 
intermediate in RRM2 even at elevated temperatures. Surprisingly, denaturation of 
RRM2c at 37 °C revealed a three-state unfolding profile coincident with the intact 
domain (Fig. 2.4B), but with a slight increase in total stability upon increasing 
temperature (4.1 kcal mol-1 vs. 4.8 kcal mol-1). The increase in overall free-energy 
suggests either a self-association of RRM2c or that the folding of this fragment is driven 
by the hydrophobic effect, which is stronger at higher temperatures (207, 208). Self-
association is concentration dependent, and thus higher concentration would be expected 
to drive the association reaction and stabilize the protein against denaturation. However, 
our experiments revealed no concentration dependence for the unfolding transition by CD 
in the range from 15-60 µM RRM2c. Further, the lack of denaturant dependence of the 
tyrosine emission spectrum for RRM2c shows that the Tyr is exposed to solvent in this 
RRM2 fragment at physiological temperatures (Fig. 2.4E). This conformation differs 
from the Tyr FL at 20 °C, where the Tyr is at least partially buried in the native RRM2c 
structure. The destabilized native conformations of both RRM2 and RRM2c at 
physiological temperature suggest that the intermediate state becomes more populated 
under native conditions at increased temperatures. Indeed, the intermediate state is 5-10 
fold more populated at 37 °C compared to 20 °C for both the intact RRM2 and the 
fragment of RRM2. Together, these results show that either a cleavage event within the 
RRM2 domain or physiological temperature increases the population of a potentially 
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pathological intermediate state that may contribute to possible misfolding and 
aggregation.  
 
Tethering the RRM Domains Results in Stabilization of RRM1 and Decreased Access 
to the RRM2 Intermediate – Under normal cellular conditions, the RNA binding domain 
of TDP-43 consists of RRM2 tethered to RRM1 by a short 15 amino acid linker. As such, 
the presence of RRM1 may influence the folding of RRM2 through mutual stabilizing 
interactions and decrease the population of the RRM2 intermediate state. The tethered 
RRMs construct (tRRMs), which comprises RRM1, RRM2 and its natural linker, exhibits 
a CD spectrum that is very similar to the additive sum of the individual RRM domain 
spectra (Fig. 2.2B). This observation suggests that tethering the two RRM domains does 
not significantly affect the overall secondary structure of each RRM.  The slight 
differences may arise through a small decrease in a-helical content of the RRM1 domain 
when tethered as suggested by the decrease in the 190 nm band and the shift in the ratio 
of the CD signal at 222 nm to 208 nm for tRRMs compared to the additive spectra (Fig. 
2.2B).   
However, upon denaturation with Gdn-HCl, tRRMs displayed a complex equilibrium 
unfolding profile when monitored by CD that was best described by a four-state model 
(NDI1DI2DU), suggesting the population of two discrete intermediate states (Fig. 
2.3C). To elucidate the extent that each RRM domain contributes to the intermediates, the 
Trp FL data were used as a constraint to define the first transition. As Trp residues are 
only present within RRM1, the Trp FL provides structural insights into the unfolding of 
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only RRM1 when tethered to RRM2. Interestingly, comparison of the Trp FL of the 
isolated RRM1 with the tethered RRMs (Fig. 2.4A) reveals a shift in the transition 
midpoint (Cm) to higher denaturant (1.5 M to 2.3 M) upon tethering.  These results 
suggest that RRM1 and RRM2 interact in the absence of RNA with interdomain 
interactions stabilizing the native state of each RRM domain by 0.9 kcal mol-1 (Table 
2.1). Indeed, a recent NMR study on the tethered RRM domain revealed that in the 
absence of RNA the two RRMs do not tumble independently of one another (72), further 
supporting mutual stabilizing interactions between the domains. The Trp FL also suggests 
RRM1 is completely unfolded at the first intermediate, I1, of the CD equilibrium 
unfolding profile. The extent of the RRM2 folding at the I1 intermediate is unclear as this 
domain lacks Trp residues and the contributions from the single tyrosine residue are 
masked by RRM1. However, the thermodynamic parameters derived from the CD profile 
suggest that RRM2 is at least partially unfolded as the I1DI2 transition of tRRMs is not 
coincident with NDI of RRM2 (Fig. 2.4B).  
The third transition in the equilibrium profile of tRRMs (I2DU) corresponds to the 
IDU transition of RRM2 (Table 2.1) as both transitions provide similar stability and 
midpoints. Therefore, the I2 species in the tethered domains likely correspond to the 
same RRM2 intermediate state. Using Eqn 2.4 to identify the population of the RRM2 
intermediate as a function of denaturant reveals tethering shifts the maximal population 
of RRM2 to higher denaturant (5.0 M Gdn-HCl) compared to the individual RRM2 
domain (4.0 M Gdn; Fig. 2.4C), suggesting that RRM1 inhibits the formation of the 
RRM2 intermediate. Indeed, based on the stability measurements from the four-state 
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model, RRM1 contributes ~0.7 kcal mol-1 of stability to the RRM2 native state, which 
would shift the N D I transition to higher denaturant concentration and reduce the 
intermediate state population under native conditions. These results suggest that in the 
intact TDP-43 with RRM2 tethered to RRM1, mutual interactions between these domains 
can serve two purposes:  (1) stabilization of RRM1 against populating unfolded 
conformations and (2) decreasing the RRM2 intermediate to almost negligible 
populations under native conditions (<0.1%). Isolating or fragmenting RRM2 removes 
stabilizing contributions from RRM1 and allows this region of TDP-43 to sample a 
potentially pathogenic partially-folded state. 
 
RRM2 Binds Weakly to RNA and Enhances RRM1 Affinity – TDP-43 is involved in 
multiple RNA processes and thus, RNA likely plays a role in the folding and stability of 
the RRM domains. As shown in Figure 2.4A, RRM1 becomes stabilized against 
denaturation when the two RRMs are tethered, suggesting that this interaction could also 
enhance the affinity of RRM1 and possibly RRM2 for RNA. Two complimentary nucleic 
acid binding assays, the electromobility gel shift assay (EMSA) (Fig. 2.5A) and the 
tryptophan lifetime-based assay (Fig. 2.5B), were used to determine the dissociation 
constant, Kd,app, for each individual and tethered RRM domain. Based on the results of 
previous binding affinity measurements on various TDP-43 constructs (81), the 
oligonucleotides (UG)6 and (TG)6 were selected for comparing the affinities of each 
domain, and T12 was selected as a control oligonucleotide.  
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FIGURE 2.5. Tethering the RRM domains enhances the RNA binding affinity 
compared to RRM1. A. EMSA of increasing concentrations of RRM1 (top) and tRRMs 
(bottom) to a fixed concentration of 5’-carboxyfluorescein (FAM)-labeled (UG)6. The 
upper and lower bands on the native polyacrylamide gel represent the bound and free 
fractions of labeled RNA, respectively. B. Trp lifetimes of RRM1 alone (black) or bound 
by (UG)6 (gray) reveal a decrease in lifetime in the Trp on RRM1 upon binding. Trp 
lifetimes are insensitive to RRM2 due to a lack of Trp in this domain. Trp lifetimes were 
performed as a function of nucleic acid to a fixed concentration of RRM1 and tRRMs. C. 
Quantification of the EMSA. Each data set is an average of 3 independent runs and 
modeled to the quadratic binding equation (Eqn. 2.6). A complete summary of binding 
affinities for tRRMs, RRM1, RRM2 and RRM2c are provided in Table 2.2. 
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In the EMSA assay, RRM2 binds to the UG repeat sequence very weakly with a 
dissociation constant of 17.0 µM (Table 2.2). Strikingly, RRM2c has an enhanced 
binding affinity for UG repeats by ~5-fold compared to the intact domain. This 
enhancement indicates that RRM2c may access conformations that favor RNA-binding 
compared to the intact RRM2 domain. Interactions with DNA were much weaker than for 
RNA (>100 µM) and immeasurable by EMSA. This weak binding of RRM2 and RRM2c 
to RNA suggests that these domains may serve to stabilize RRM1 (Fig. 2.4A) rather than 
provide a major contribution to RNA binding. In fact, RRM1 binds with a Kd,app in the 
nM range compared to the µM range of RRM2 (Table 2.2), supporting RRM1 as the 
major contributor to RNA-binding. Notably, tethering the two RRM domains enhances 
binding affinity by an order of magnitude to result in dissociation constants for UG and 
TG repeat sequences in the low nM range (Fig 2.5C; Table 2.2). Trp lifetimes on the 
RRM domain reveal a reduction of Trp intensity and lifetime upon binding RNA (Fig. 
2.5B) and provide structural insights into the binding interaction, as the Trp residues are 
located on the β-sheet of RRM1. The RNA binding results suggest the presence of RNA 
will play a role in defining the populations of all species on the folding free-energy 
surface of TDP-43 by stabilizing the RRM domains and modulating access to the 
partially-folded state in RRM2. 
 
DISCUSSION 
Although the ALS-linked genes, such as SOD1 (50), TDP-43 (57, 209), FUS/TLS 
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(51), profilin (52) and C9ORF72 (54, 55) among others (210), are functionally different, 
common mechanisms for cellular toxicity and aggregation may govern the folding 
pathways of these proteins to result in disease. Indeed, the RNA-binding proteins, TDP-
43 and FUS/TLS, have been linked not only to ALS but also to other neurodegenerative 
diseases including FTLD-U (48), Alzheimer’s disease (211), and Parkinson’s disease 
(212), suggesting a potential common mechanism of disease pathogenesis between these 
proteins. Here, we performed denaturation and RNA binding studies to probe the 
equilibrium unfolding pathways of the isolated and tethered RRM domains of TDP-43. 
The data revealed a highly populated stable folding intermediate within RRM2 (Figs. 
2.3B and 2.4C) that may link the pathways governing TDP-43 folding and function with 
those of misfolding and aggregation. Specifically, the intermediate state may have a 
normal cellular function in nuclear export, but at the same time populating this 
intermediate state may sow the seeds for misfolding and aggregation in disease. 
A major focus of the TDP-43 field has been to investigate the potential impacts of 
TDP-43 loss-of-function and aggregation propensity on the propagation of ALS and 
FTLD (44, 48, 137, 183, 213). Aggregation studies on RRM2 revealed increased 
formation of fibrillar aggregates with truncated RRM2 and peptide fragments consisting 
of β3 and β5 (152). These results suggest that the core sequences within RRM2 may 
directly participate in driving the aggregation of TDP-43. TANGO and WALTZ (185) 
predict an aggregation prone region, β3, (Fig. 2.1A) localized within RRM2 that may 
serve as a template for aggregation propagation. In combination with the C-terminus, 
intact or fragmented RRM2 was shown to severely enhance cellular aggregation and 
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toxicity in cell models (138, 140, 141, 151, 214). The C-terminus, which also contains a 
particularly aggregation prone stretch (M311-M323), was shown to have increased β-
strand propensity and aggregation tendency (151), while a Q/N-rich region that is critical 
for proper TDP-43 protein-protein interactions was also sufficient for aggregation of GFP 
fused with multiple Q/N repeats (84). Taken together, these results suggest that the 
population of the RRM2 intermediate state could expose aggregation prone residues, such 
as β3 and β5 (152), either through the intact domain, cleavage by caspases (140, 142, 
215, 216) or increased temperatures. This partially folded state could aberrantly interact 
with RRM1 (205, 217), the aggregation prone C-terminal peptides (152, 218), or 
potential sequences within other proteins, such as hnRNP A1 and A2/B1 (82, 83), to 
promote misfolding and propagate the aggregation observed in ALS and FTLD patients.  
Biophysical studies on TDP-43 have been hindered by the poor solubility and 
aggregation tendencies of the full-length protein. Thermal denaturation studies have 
shown that RRM2 remains well-folded and resistant to denaturation beyond 85 °C, while 
RRM1 undergoes a conformational change at 50 °C (73, 151). These results suggest an 
inherent stability difference between the two domains, which are 30% identical in 
sequence by ClustalW2 (Fig. 2.1B). Similarly, in our study, the Gdn-HCl-induced 
denaturation of these domains revealed markedly different equilibrium unfolding profiles 
with significantly different stabilities (Table 2.1). Gdn-HCl denaturation fortuitously 
revealed a partially-folded state that was not evident by thermal denaturation. Thus, 
chemical denaturation provides access to a partially-folded state that may be relevant for 
both function and aggregation.  
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Hydrogen exchange experiments on the TIM barrel protein family have shown that 
clusters of isoleucine (I), leucine (L) and valine (V) residues can accurately predict cores 
of stability (219) and early folding events (220, 221). Using an in-house algorithm 
(http://biotools.umassmed.edu/ccss/ccssv2/basic.cgi; (222, 223)), clusters of the branched 
aliphatic side chains residues in RRM1 (Fig. 2.6D) and RRM2 (Fig. 2.6A) were 
identified using the NMR structures. As shown in Fig. 2.6, RRM2 contains one large 
cluster with twelve ILV residues, eight of which provide multiple contacts (Fig. 2.6C). 
RRM1 (Fig. 2.6E), on the other hand, contains three clusters of ILV residues with two 
single-contact clusters and a remaining cluster that consists of eight loosely connected 
residues. Upon tethering to RRM2 and the addition of RNA, the L106-L177 contact (Fig. 
2.6D and 2.6E; purple) and V161 in α2 are incorporated into the RRM1 cluster and 
possibly enhances the stability of RRM1. In RRM2c (Fig. 2.6B), three ILV residues 
(V193, V195 and L207)(Fig. 2.5D; cyan) are removed and the remaining contacts may 
provide a significantly different hydrophobic core for folding (Fig. 2.2A). This networked 
cluster of ILV residues in RRM2 and RRM2c (Fig. 2.6C) likely contributes to the 
presence of a stable intermediate and increased stability of RRM2 compared to RRM1 
(Fig. 2.6E). 
Alternatively, the RRM2 intermediate may serve a functional role in RNA 
processing. Normal TDP-43 shuttling to the cytoplasm is likely governed by a leucine-
rich NES (224) located within RRM2 (residues 239-250). Alanine mutation of any of the 
hydrophobic residues within this sequence resulted in nuclear mutants and endogenous 
aggregates (225). The NES forms α2 and β4 within RRM2 to possibly sequester the 
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FIGURE 2.6. Extensive and networked ILV cluster in RRM2. A. Solution NMR 
structure of RRM2 (1wf0.pdb) with isoleucine (I), leucine (L) and valine (V) residues 
highlighted that contact other ILV residues (blue). B. Residues from the large cluster in 
RRM2 that are removed in RRM2c are highlighted in cyan, and the NES (residues 239-
250), which is still part of the large cluster in RRM2c, is highlighted in yellow. C. ILV 
cluster contact map for RRM2 displayed on the secondary structure elements of RRM2. 
The RRM2 ILV cluster contains a single highly connected cluster (blue) spanning all α-
helices and β-strands, and the cluster is unaffected by tethering to RRM1. The residues 
removed in RRM2c (cyan) are starred (*). The NES (yellow) contributes three residues to 
the large ILV cluster (L243, L248 and I250), which may contribute to the increased 
stability of RRM2 compared to RRM1. D. RRM1 (2cqg.pdb) contains three small 
clusters (purple, red and green), two of which were single surface residue contacts (red 
and purple). The remaining cluster (green) is small and less connected compared to 
RRM2. E. The RRM1 cluster contains a small ILV cluster with single contacts centered 
in β1-β3. Upon tethering to RRM2 and RNA-binding, the cluster exhibits a few contact 
changes that include the addition of V161 and the purple cluster, resulting in a more 
networked RRM1 compared to the isolated RRM1. 
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hydrophobic residues (L243, L248, I250) and contribute to the ILV cluster (Fig. 2.6B). 
Another ALS-linked protein, FUS/TLS, also contains a NES within an RRM domain 
(226) with low affinity for RNA (227). Strikingly, we have observed that the RRM 
domain of FUS/TLS also unfolds through an equilibrium intermediate state (unpublished 
data). The presence of an intermediate state in the RRM unfolding pathways of TDP-43 
and FUS/TLS suggests that these RRMs may serve to stabilize the other RNA-binding 
domain and sequester the NES within the hydrophobic core to control cytoplasmic 
shuttling or to prevent aggregation. RRM2 must partially unfold to expose the NES for 
recognition by exportin (87), which mediates the transport to the cytoplasm. This 
hypothesis suggests that cleavage within RRM2, loss of RRM1, or external stressors 
would increase the population of the intermediate state and disrupt the normal cellular 
distribution. Up-regulated export to the cytoplasm could increase the formation of 
dysfunctional complexes with other proteins and cytoplasmic aggregates that would 
ultimately decrease the population of functional nuclear TDP-43.  Further experiments to 
investigate the role of the intermediate state on TDP-43 nuclear export would delineate 
the consequences of populating this partially-folded state. 
RRM2 may also enhance the function of TDP-43 through interactions with RRM1 
and RNA. Tethering RRM2 to RRM1 increases the stability of RRM1 (Fig. 2.4C) and the 
affinity to (UG)-rich sequences (Fig. 2.5C). Studies on RNA binding in disease 
progression have indicated that removal of RRM1 or mutational analysis of key 
phenylalanine residues in RRM1 results in non-functional TDP-43 with neurotoxicity and 
aggregation phenotypes (80, 81, 190, 228, 229). A cell-free system revealed that 
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incubation with (UG)6 or (TG)6 resulted in an increase in TDP-43 solubility and reduced 
tendency to aggregate compared to mutant RRM1 TDP-43 (190). These results suggest 
that RNA binding may be playing a critical role in limiting access to the partially-folded 
intermediate in RRM2 and reducing aggregation. RNA binding assays by our group and 
others (73, 81) suggest that RRM2 binds weakly to RNA compared to RRM1 (Table 2.2). 
RRM2 could contribute to RNA binding through two potential mechanisms: (1) RRM2 
may contribute to binding through allosteric interactions with RRM1 and (2) RRM2 may 
indirectly contribute to binding by stabilizing RRM1. In either scenario, mutual 
interactions between RRM1 and RRM2 would reduce access to the RRM2 intermediate 
state. Structural information on the DNA/RNA-bound tethered domains would provide 
critical insights into the RNA-binding modes for each of these domains and could further 
delineate the role of RNA in the RRM folding pathway. 
The thermodynamic and DNA/RNA binding experiments suggest a mechanism for 
potential TDP-43 dysfunction and aggregation through the RRM2 intermediate (Fig. 2.7). 
Normal cellular TDP-43 is involved in multiple RNA processes with protein partners in 
the nucleus. TDP-43 likely exists in equilibrium between two states: the folded TDP-43 
and functional TDP-43 that populates the RRM2 intermediate. This intermediate could 
serve two potential roles: (1) a productive functional intermediate allowing for NES 
recognition by the cellular export machinery or (2) a non-productive misfolding 
intermediate with exposed aggregation-prone peptides, such as β3 and β5, that may 
aberrantly interact with other intact and fragmented TDP-43 as well as other known 
protein partners. Normally, only a small fraction of TDP-43 populates the intermediate 
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FIGURE 2.7. TDP-43 aggregation model through the RRM2 intermediate state. For 
simplicity, TDP-43 is represented with two circles for the RRM domains (RRM1: black, 
RRM2: red) and blacks lines for the disordered N- and C-terminus. TDP-43 can interact 
with other protein partners to form functional complexes represented by a green circle. 
An equilibrium exists where a small percentage of RRM2 can populate its intermediate 
state (RRM2 conversion from red circle to red square) but remain in functional 
complexes. Disease triggers (lightning bolt) can result in loss of RNA binding (dashed 
blue line), protein-protein interactions or cleavage (removal of RRM1 and N-terminus) 
that produces misfolded states (dashed boxes) where the population of the RRM2 
intermediate increases. These misfolded states can result in dysfunctional complexes by 
aberrant protein-protein interactions (spiked green circle) or aggregates with other 
proteins (overlaid TDP-43 molecules). These disease states reduce the available pool of 
functional TDP-43 and lead to the propagation of ALS and FTLD. 
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state and the equilibrium heavily favors the folded, TDP-43 with a properly folded 
RRM2. The NES remains sequestered in the hydrophobic core of the molecule for the 
nuclear localization of TDP-43. However, cellular stresses, such as oxidative damage, 
could result in TDP-43 cleavage, loss in RNA binding or protein partners. Such events 
could potentially shift the equilibrium towards the misfolding of the intermediate state. 
These misfolded, non-functional proteins may increase transport to the cytoplasm where 
exposure of the hydrophobic residues in the NES or aggregation-prone peptides in RRM2 
result in the formation of dysfunctional complexes and aggregates of TDP-43.  In any 
case, the reduced functional pool of TDP-43 in the nucleus would influence neuronal 
death. Thus, the RRM2 intermediate state may link the productive folding and function of 
TDP-43 with non-productive misfolding and aggregation that leads to disease 
progression. Therapeutic intervention strategies can be developed that take into account 
approaches that limit pathological access to this intermediate state, potentially offering a 
viable drug target for treating ALS and FTLD. 
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Chapter III – Residual Structure of the RRM Intermediate in the ALS-linked 
Protein TDP-43 is Unfolded-like and Exposes the Nuclear Export Signal 
 
 
The work presented in this chapter comprises the experimental contributions of a 
combined experimental and molecular dynamic manuscript detailing the structural 
insights into the RRM2 intermediate in TDP-43. This work was a collaborative effort 
between Jill Zitzewitz, Francesca Massi, Brittany Morgan, Sagar Kathuria, Laura Deveau 
and myself. I purified all the RRM2 and tethered RRMs protein samples used in the 
experimental data collection. I collected the near- and far-UV and Tyr FL. Sagar Kathuria 
and I collected the SAXS scattering profiles with Srinivas Chakravarthy at BioCAT at the 
Advanced Photon Source in Argonne, IL. Laura Deveau and I collected the HSQC’s for 
the urea-dependence on the amide backbone. Francesca Massi and I collected the 
assignment experiments for the RRM2 native and intermediate states. Jill Zitzewitz, 
Francesca Massi and I analyzed the data. Jill Zitzewitz, Francesca Massi, Sagar Kathuria, 
Laura Deveau and I contributed to the interpretation of the results. Jill Zitzewitz and I 
wrote the chapter. 
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Abstract 
 Partially-folded higher energy species play a role in mediating both proper folding 
to the native, functional conformation and misfolding and aggregation observed in a host 
of human diseases, including Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal 
Dementia. Recently, a folding intermediate was discovered in the second RNA 
recognition motif (RRM2) of the ALS- linked RNA-binding protein, TDP-43. Here, 
structural insights of the residual structure of the RRM2 intermediate state were obtained 
using urea due to its amenability towards small angle x-ray scattering (SAXS) and 
nuclear magnetic resonance (NMR) studies. Unfolding studies suggest that the RRM2 
intermediate lacks the native tertiary contacts, by tyrosine fluorescence and near-UV 
circular dichroism (CD), and global collapse by SAXS, but contains residual secondary 
structure by far-UV CD. Indeed, NMR revealed that residual secondary structure 
localizes within the N-terminal half of RRM2 under conditions favoring the intermediate 
state. The C-terminal half, consisting of a nuclear export sequence (NES) in α2 and β4, is 
largely disordered in the RRM2 intermediate state. These results suggest that the RRM2 
intermediate state may play a role in normal TDP-43 function through exposure of the 
NES for TDP-43 cytoplasmic transport. Alternatively, the lack of tertiary contacts in the 
RRM2 intermediate state suggests that the residual secondary structure may adopt 
pathological non-native conformations that may template TDP-43 misfolding and 
aggregation. Antibodies or small molecules targeting these conformations would provide 
critical diagnostic and mechanistic insights into the early stages of the TDP-43 mediated 
toxicity in neurodegeneration. 
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Introduction 
Mutations in TAR DNA-binding protein 43 kDa (TDP-43) have been genetically 
linked to Amyotrophic Lateral Sclerosis (ALS), providing direct evidence of its 
participation in disease pathogenesis (57, 230, 231). Not only involved in ALS, TDP-43 
has been associated with a host of other neurodegenerative diseases, including 
Frontotemporal Degeneration with ubiquitinated inclusions (FTLD-U), Alzheimer’s and 
Parkinson’s disease among others (30, 44, 49), suggesting a common mechanism for 
TDP-43-mediated toxicity. A majority of patients with these TDP-43 proteinopathies, 
including those with sporadic ALS, contain two wild-type copies of the TDP-43 gene 
(53), suggesting misfolded or dysfunctional conformations in the wild-type protein are 
sufficient for initiation and propagation of the disease phenotypes. Despite the plethora of 
evidence for the involvement of TDP-43 in neurodegenerative diseases from cellular and 
animal models, the molecular basis of the disease is not yet fully understood (79, 183). 
TDP-43 is a nuclear RNA-binding protein involved in numerous RNA processes 
(78, 87, 228) that is comprised of two RNA recognition motifs (RRM), an well-folded N-
terminal axin 1-like domain (NTD) (75) and a disordered C-terminus with a nuclear 
localization sequence (NLS) prior to RRM1 and a nuclear export sequence (NES) in 
RRM2 (accession no. Q13148, UniProtKB/Swiss-Prot). Evidence suggests that both loss-
of-function and gain-of function phenotypes contribute to ALS pathogenesis (183, 232–
234), where a reduced population of functional nuclear TDP-43 results from the 
accumulation of cytoplasmic aggregates. These aggregates contain hyperphosphorylated 
and ubiquitinated C-terminal fragments and full-length TDP-43 (139, 140, 184), with 
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multiple studies indicating the disordered C-terminus and RRM2 are critical domains for 
the propagation of TDP-43 aggregation and toxicity in cell culture models (138–141). 
These results suggest that the C-terminus and RRM2 may adopt pathogenic 
conformations that lead to cellular toxicity and neurodegeneration. 
While RRM1 has a high affinity for DNA and RNA (73, 81, 235) and is essential 
for proper TDP-43 function , the function of RRM2 is less clear. RRM2 displays a 
relatively weak affinity for RNA (73, 81, 235), is dispensable for the splicing ability of 
TDP-43 (228) and enhances the specificity of interactions with RNA (236). Furthermore, 
equilibrium unfolding studies have revealed that RRM2 populates a stable folding 
intermediate on its equilibrium unfolding pathway (235) (Chapter II). This partially-
folded state may contribute to normal TDP-43 function through the exposure of an 
embedded nuclear export sequence (NES, amino acids 239-250) (224) to regulate 
nucleocytoplasmic transport (225). However, the RRM2 intermediate state may also aid 
in the propagation of TDP-43 misfolding and aggregation via several aggregation-prone 
sequences (152) and/or interactions with known segments of the C-terminus, the NTD or 
other proteins, such as hnRNP A1 (83, 152, 218, 237). It is unclear how the RRM2 
intermediate state connects the normal function and misfolding tendencies of TDP-43 in 
neurodegeneration. Structural insights would fill a key a gap in knowledge pertaining to 
the roles of this partially-folded state in normal TDP-43 cytoplasmic shuttling and disease 
pathogenesis. The residual structure within RRM2 is an ideal candidate for the design of 
diagnostic and therapeutic tools to examine and mitigate the propensity of this partially-
folded conformation in disease models and patient tissue samples. 
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In this study, the residual structure of the RRM2 intermediate state of TDP-43 
was investigated using a combination of low-resolution and residue-level biophysical 
techniques. Unfolding studies using urea as a denaturant suggest that the intermediate 
state is not natively-folded, with a loss of the native tertiary structure contacts by Tyr FL 
and near-UV CD and global collapse by SAXS. However, evidence from far-UV circular 
dichroism (CD) suggests the presence of residual secondary structure. Indeed, nuclear 
magnetic resonance (NMR) under conditions that enhance the population of the RRM2 
intermediate state identified significant secondary structure propensity in the N-terminal 
region of RRM2. Interestingly, the C-terminal portion of RRM2 lacks any defined 
secondary structure, including regions comprising the NES sequence. Therefore, the 
combination of biophysical evidence suggests that the RRM2 intermediate state retains 
elements of secondary structure, that may balance proper TDP-43 function with 
misfolding and aggregation observed in patients with neurodegeneration. 
 
Materials and Methods 
Protein Expression and Purification 
RRM2 was expressed and purified as described previously (235) with the addition 
of a final size exclusion chromatography step (Superdex75, GE Healthcare) in the 
experimental buffer (20 mM MOPS pH 6.8, 25 mM KCl and 1 mM β-mercaptoethanol 
(BME)). For 15N and 13C protein samples, M9 minimal media containing 1 g L-1 of 15N-
NH4Cl and 2 g L-1 13C-glucose was used for protein expression. The tethered RRMs 
(tRRMs: residues 97-261) was purified as described previously (235) and dialyzed into 
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10 mM KPi pH 7.2, 150 mM KCl and 1 mM BME. The protein purity was >98% as 
determined by SDS-PAGE, and MALDI-TOF mass spectrometry carried out at the 
Proteomics and Mass Spectrometry Facility at the University of Massachusetts Medical 
School confirmed the integrity of the samples. Protein concentration was measured by 
A280 absorbance using an extinction coefficient of 1490 M-1 cm-1. 
 
Size Exclusion Chromatography coupled with Small Angle X-ray Scattering (SEC-
SAXS) 
 Native state SEC-SAXS measurements were acquired at the BioCAT beamline at 
the Advanced Photon Source (APS), Argonne National Laboratory (Argonne, IL, USA). 
Scattering images of monomeric RRM2, tRRMs and tRRMs in complex with a (UG)6 
RNA (238) were obtained using an in-line liquid chromatography system prior to X-ray 
exposure to remove larger aggregated species, if present. RRM2, tRRMs and tRRMs-
(UG)6 (>5 mg mL-1) were injected onto a 24-mL Superdex 75 size exclusion column (GE 
Healthcare) at a flow rate of 1 mL min-1. Images were acquired using a Mar165 CCD 
detector (MarUSA, Inc., Evanston, IL) with ~4 sec between ~2 sec exposures. The buffer 
corrected SAXS images of the SEC elution profile were analyzed using Igor Pro 
(Wavemetrics, Inc., Lake Oswego, OR) to obtain the concentration dependence, radius of 
gyration (Rg) and pairwise distribution (P(r)) functions, which were required to 
determine the average electron density envelopes using ATSAS (239). The NMR 
structure of RRM2 (pdb: 1wf0) and the RNA bound tRRMs (pdb: 4bs2) were modeled 
into the electron density envelopes using Chimera (240).  
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Equilibrium Unfolding Experiments 
Samples were prepared using in-house software coupled with a Hamilton Series 
500 titrator and incubated overnight. All equilibrium unfolding experiments were 
performed at 25°C unless specified otherwise. All urea concentrations were measured 
using an ABBE refractometer. Urea-induced unfolding spectra monitored by far- and 
near-UV CD and steady-state FL were collected as previously described (235) using a 
Jasco-810 spectropolarimeter with a 0.2 cm cuvette and a Spex Fluorolog-3 equipped 
with a wavelength electronic temperature controller, respectively. For near-UV 
experiments, spectra were collected with 0.5 mg mL-1 RRM2 using a 5 cm cuvette 
(Hellmanx) and averaged over twenty scans.  
SAXS measurements were acquired for ~1.5 mg mL-1 RRM2 at increasing urea 
and Gdn-HCl concentrations using the same setup as described above with an exposure 
time of ~1 sec. The R(g) and I(0) for each concentration of urea was determined by the 
Guinier approximation (Rgqmax <1.3) in Igor Pro using Equation 3.1: 𝑙𝑛 𝐼(𝑞) = 𝑙𝑛 𝐼(0) – !"!!!!        (Eqn. 3.1) 
where the linear region of a plot of the natural logarithm of the scattering intensity (ln 
I(q)) as a function of the square of the scattering angle (q2) yields a slope of !"!!  and an 
intercept of the intensity at q = 0 (ln I(0)). The deviation of the Rg from the theoretical 
value for an unfolded random coil peptide was calculated using the Rg dependence on 
amino acid length (241).  
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Two-dimensional 1H-15N HSQC spectra at increasing denaturant concentrations 
were obtained using a Varian 600-MHz spectrometer at 25°C using 1.5 mg mL-1 RRM2 
in 92% H2O / 8% D2O over 64 scans. The native-state assignments were used until ~4.5 
M urea, where slow exchange dominated the equilibrium and required the assignment of 
the RRM2 intermediate state, whose assignments were used at high urea concentrations. 
The fraction native state for each residue was determined from the peak intensities at 
each concentration of urea for the native and intermediate state assignments using 
Equation 3.2:  𝜃 = ! !! ! ! ! !      Eqn. 3.2 
where θ is the fraction native and I[N] and I[I] are the intensities of the native and 
intermediate cross peaks, respectively, at a given concentration of urea. The chemical 
shift perturbation (CSP) with increasing denaturant in the native baseline was determined 
using the native spectrum of RRM2 as a reference using Equation 3.3 (242):
𝐶𝑆𝑃 = ((!"(!)!!"(!))! )! + (𝛿𝐻(!) − 𝛿𝐻(!))!     (Eqn. 3.3) 
where δN(D) and δN(0) are the chemical shift of the amide nitrogen at denaturant 
concentration, D, and under native conditions, respectively and δH(D) and δH(0) are the 
chemical shifts of the amide hydrogen under the same urea conditions as the amide 
nitrogen’s. 
All urea denaturation experiments, including near-UV, Tyr FL and SAXS 
measurements, were modeled to a two-state thermodynamic transition, N D I/U (235), as 
the unfolded state is not significantly populated at high urea concentrations (>9 M). The 
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I(0) values as a function of denaturant was modeled to a linear regression. The unfolding 
profiles using NMR were modeled to this single transition, as RRM2 does not 
significantly populate the unfolded state at high urea. The far-UV CD urea denaturation 
unfolding profile was modeled to a three-state transition using the baseline and slope of 
the unfolding baseline of RRM1 as these baselines have been previously been shown to 
be similar under high concentrations of Gdn-HCl (235). All reported free energies in the 
absence of denaturant (ΔG°), m-values (m) and transition midpoints (Cm) are the global 
fit to three independent experiments. SVD analysis of the far-UV CD spectra as a 
function of denaturant to obtain the component spectra of the native, intermediate and 
unfolded states of RRM2 in urea and Gdn-HCl was performed as previously described 
(243). 
 
NMR Assignment and Residual Structure Determination 
 Triple resonance assignment experiments were performed using a 13C,15N-labeled 
4 mg mL-1 RRM2 sample in the native (0 M urea) and intermediate (6.5 M urea) states. 
Chemical shifts for each states backbone (HN, N) and side chains (Cα and Cβ) were 
obtained through HSQC, HNCA, HN(co)CA, CBCA(co)NH, HNCACB experiments. 
The native state was further supplemented with carbonyl (CO) assignments using HNCO 
and HN(ca)CO experiments. Due to inherent aggregation and degradation of native 
RRM2, the sample was exchanged with fresh protein between subsequent assignment 
experiments. The spectra were processed using NMRPipe (244) and assigned and 
analyzed using Sparky (T. D. Goddard and D. G. Kneller, SPARKY 3, University of 
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California, San Francisco). Secondary structure propensity (SSP) in the RRM2 native and 
intermediate states were determined using the appropriate chemical shifts as described by 
Marsh et al (245), TALOS+ (246) and CSI 2.0 (247). 
 
Results 
RRM2 contains residual secondary structure at high urea 
Low-resolution structural insights were obtained through a combination of 
biophysical experiments to probe the residual structure of high energy states observed in 
RRM2 of TDP-43. Previous studies identified a partially-folded intermediate state in the 
Gdn-HCl-induced unfolding of RRM2 that is weakly populated in the absence of 
denaturant (235). In order to investigate the unfolding energy landscape of the RRM2 
domain in greater detail, we chose to use the denaturant, urea, as it is more amenable to 
SAXS and NMR studies. Because urea is a weaker denaturant compared to Gdn-HCl 
(195), urea may also serve to identify potential conformations on the equilibrium 
unfolding pathway of RRM2 that are invisible or merged when unfolded in the presence 
of Gdn-HCl.  
Far-UV CD (Fig. 3.1A, closed circles) was used to probe the changes in 
secondary structure as RRM2 populates these higher energy species at higher denaturant 
concentrations. Unlike Gdn-HCl, where RRM2 is completely unfolded at concentrations  
>7 M, RRM2 retains residual far-UV CD signal in urea, even at concentrations exceeding 
9 M (Fig. 3.1A). Thus, RRM2 was modeled to a three-state transition with the population 
of a stable partially-folded state, where the unfolded baselines were fixed to those 
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Figure 3.1. The RRM2 intermediate state lacks the native state tertiary structure 
but retains residual secondary structure. A. CD spectra of the RRM2 native (solid), 8 
M urea (dotted) and 8 M Gdn-HCl (dashed) denatured states. 8 M urea does not 
completely unfolded RRM2, unlike 8 M Gdn-HCl. B. Urea denatured equilibrium 
unfolding profiles of RRM2 monitored by far-UV CD between 220-235 nm (CD220, 
closed circles) and 240-250 nm (CD245, open circles) were modeled to a three-state (N D 
I D U) and two-state (N D I/U) mechanism, respectively. The CD220 reveals a break in 
cooperativity at ~7 M urea while CD245 is insensitive to the I D U transition. C. Near-UV 
CD wavelength scans of the RRM2 native (solid line) and the 7 M urea intermediate 
(dotted line) states reveal a loss of tertiary structure and aromatic packing in the 
intermediate state. D. Urea induced equilibrium unfolding profiles of RRM2 monitoring 
tertiary structure changes via near-UV at 274 nm (closed squares) and Tyr FL (open 
squares) were modeled to a two-state mechanism, suggesting a loss of the native tertiary 
contacts at high denaturant and population of the RRM2 intermediate state. 
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obtained from the urea unfolding of RRM1, because the Gdn-HCl-induced unfolded 
baselines of RRM1 and RRM1 were previously shown to be similar (235). Wavelength 
scans between 220 and 250 nm, revealed two distinct spectroscopic regions of RRM2 
urea unfolding. One region between 220 and 235 nm (CD220, Fig. 3.1B, closed circles) 
monitors the changes in secondary structure upon addition of urea and unfolded in a 
three-state manner (N D I D U). The N D I and I D U transitions of the CD220 global fit 
contribute 4.30 ± 0.10 kcal mol-1 and 3.38 ± 0.13 kcal mol-1 to the overall stability (Table 
3.1), resulting in a total free-energy in the absence of denaturant of 7.68 ± 0.16 kcal mol-
1, a similar value to the stability obtained in Gdn-HCl (235). The second region resides 
between 240 and 250 nm (CD245, Fig. 3.1B, open circles) and has been associated with 
the packing of the secondary structure and hydrophobic packing (204). This region, 
unlike the CD220 region, displayed a two-state behavior with indistinguishable 
intermediate and unfolded states (N D I/U), that was not observed in Gdn-HCl (235), 
possibly due to salt contributions. The midpoint of the N D I transition from the CD220 
(5.89 ± 0.21 M) and the N D I/U transition of CD245 (4.73 ± 0.25 M) are not coincident 
and suggests the presence of complexity on the unfolding energy landscape of RRM2.  
An SVD analysis of the urea and Gdn-HCl induced unfolding profiles by far-UV 
CD  (Fig. 3.2) revealed three component species that contribute to the spectra obtained at 
each concentration of denaturant that correspond to the RRM2 native (solid line), 
intermediate (dotted line) and unfolded states (dotted lines). As expected the reconstituted 
native state spectrum are similar between urea and Gdn-HCl; however, slight differences 
arise in the respective intermediate states, with similar overall MRE signal but a slight 
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Figure 3.2: The RRM2 intermediate state is similar in urea and Gdn-HCl. SVD of 
the far-UV CD spectra as a function of denaturant revealed three major components that 
contribute to the measured far-UV CD spectrum at any given concentration of denaturant, 
the RRM2 native (solid line), intermediate (dotted line) and unfolded (dashed line) states. 
The RRM2 native and intermediate states are similar between urea (A) and Gdn-HCl (B), 
with only slight differences in the 225 nm region of the RRM2 intermediate state. The 
differences between unfolded states may arise due to the salt and charge contributions 
from Gdn-HCl. 
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increase in ellipticity between 222 and 226 nm in the urea-induced intermediate state 
(Fig. 3.2A, dotted line) suggestive of additional helical contributions. In addition, slight 
differences in the 230 – 250 nm region of the urea spectra suggest the possibility of 
tertiary rearrangements that are completely absent in the presence of Gdn-HCl (Fig. 
3.2B). Complete denaturation (Fig. 3.2, dashed lines) results in drastically different 
unfolded spectra between urea and Gdn-HCl with a significant 230 nm minimum in the 
presence of urea. The SVD analysis supports similar residual secondary structure in the 
urea- and Gdn-HCl-induced RRM2 intermediate states, however, residual hydrogen 
bonding networks and salt bridges in urea may contribute to the drastic differences 
observed in the apparent unfolded states for both denaturants. 
 
The RRM2 intermediate state is maximally populated at high urea 
A population species plot, derived from the thermodynamic parameters of the 
RRM2 equilibrium unfolding profile obtained by CD220 (235), displays the populations of 
the RRM2 native (Fig. 3A, solid lines), intermediate (Fig. 3A, dotted) and unfolded (Fig. 
3.3A, dashed lines) states at any given concentration of urea. Below 4 M urea in the 
native baseline, the RRM2 native state is the predominant species. At urea concentrations 
between 4 and 7 M, the equilibrium shifts to favor the intermediate state, which becomes  
maximally populated at 7 M urea. Above 8 M urea, the intermediate remains the 
predominate species, as the RRM2 unfolded state does not comprise a majority of the 
RRM2 species until >10 M urea. These results suggest that at high urea concentrations 
between 6.5 and 8.5 M, the RRM2 intermediate is the predominate species and RRM2 is 
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Figure 3.3: The RRM2 intermediate state is highly populated at high urea 
concentrations. A. Population species plot of the RRM2 native (solid), intermediate 
(dotted) and unfolded (dashed) states at a given urea concentration as observed by CD220. 
The native state dominates the RRM2 equilibrium unfolding profile until 4 M urea. The 
RRM2 is significant populated between 6 and 10 M urea, with the maximum population 
at 7.2 M urea. The RRM2 unfolded state is only populated at concentrations >9 M urea. 
B. Fraction apparent plots of CD220 (closed circles), Tyr FL (open squares), near UV-CD 
(closed squares) and CD245 (open circles). The differences in the midpoints suggest the 
presence of complexities on the RRM2 equilibrium unfolding pathway. 
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never completely unfolded in urea, unlike Gdn-HCl (235).  
 
The RRM2 intermediate state lacks the native tertiary contacts 
To further characterize the RRM2 intermediate state, near-UV CD and Tyr FL 
were used to probe whether RRM2 retains any native tertiary structure upon the 
population of these states. The NMR structure of RRM2 (pdb: 1wf0) reveals that five 
aromatic residues (four phenylalanine (Phe) and one Tyr) pack within the hydrophobic 
core of the domain. In addition, five Phe residues are located on the RNA-binding 
surface. These residues can serve as probes to monitor the loss of the native aromatic 
packing as the intermediate state becomes populated at high urea. The native near-UV 
spectrum of RRM2 (Fig. 3.1C, solid line) reveals a positive MRE signal between 255-290 
nm as a result of contributions from the Tyr and Phe residues around 274 nm and 260 nm, 
respectively. However, at high urea concentrations, the native aromatic packing was lost 
and the near-UV CD spectrum resembles those of disordered and unfolded proteins, 
suggesting a complete loss of the aromatic packing in the RRM2 intermediate state. The 
near-UV spectrum as a function of denaturant reveals a single cooperative transition at all 
wavelengths between 255 and 290 nm, which was modeled to a two-state equilibrium 
unfolding model (Fig. 3.1D, closed squares) in a similar manner as CD245. The midpoint 
of this transition (Table 3.1; Near-UV CD: 5.48 ± 0.35 M) was consistent with the 
intrinsic Tyr FL transition (Fig 3.1D; open squares, Tyr FL 5.32 ± 0.07 M) as the tyrosine 
contributes to the aromatic packing in the core of RRM2. Furthermore, the full m-value is 
obtained by the single transition (Table 3.1), which indicates that there is likely little 
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native tertiary structure remaining in the RRM2 intermediate state. However, despite the 
similarities between the midpoints, the slopes of the native baselines differ between the 
Tyr FL, near-UV CD. The deviations in the midpoints (Fig. 3.3B) and the sloped 
baselines of CD245, Tyr FL and near-UV compared to CD220 (Figs. 3.1B and 3.1D) further 
supports the presence of a potentially heterogeneous pool of native RRM2 conformations 
that appear similar by far-UV CD. These alternative native-like conformations may allow 
for interactions with RRM1 (72, 235), RNA (72, 73) or other proteins (83). At high urea 
with the population of the intermediate state, the RRM2 native-like conformations lose 
their native tertiary structure contacts. However, it is unclear whether the residual 
structure observed by far-UV CD can form of a core of stability or consists of multiple 
conformations. 
 
SAXS reveals the presence of residual collapsed structure in the RRM2 intermediate 
state 
 SAXS was used to monitor the overall changes in size and globular structure of 
RRM2. SEC-SAXS measurements at different elution volumes provided a concentration 
gradient of monomeric RRM2, with little tendency to aggregate between 1 – 5 mg mL-1 
(0.1 – 0.5 mM), and an average radius of gyration (Rg) of 14.1 ± 0.1 Å. Using 
DAMMIN, the average electron density envelopes were reconstructed from the scattering 
profiles for ab initio modeling using the RRM2 NMR structure (pdb: 1wf0). This average 
model (Fig. 3.4A) reveals that RRM2 has an overall globular structure under native  
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Figure 3.4: RRM2 loses a majority of its globular structure in the intermediate 
state. A, B. Electron density envelopes of the RRM native (A) and intermediate (B) 
states reveal a loss of globularity at high urea concentrations. The NMR structure of 
RRM2 (pdb: 1wf0) agrees with the electron density envelope obtained from SEC-SAXS, 
revealing a highly globular structure under native conditions. High urea results suggest 
that RRM2 adopts a more elongated structure with the potential for collapsed regions. C. 
Kratky plots of the RRM2 native state (solid line), intermediate state in 6.5 M urea 
(dotted line) and unfolded state in 8 M Gdn-HCl (dashed line). The RRM2 native state 
displays a parabolic kratky plot typical of folded, globular domains. The 6.5 M urea 
Kratky plot, when the RRM2 intermediate is >70% populated, displays a similar plateau 
that was observed in 8 M Gdn-HCl, suggesting the loss of the native globular structure. 
D. Urea-induced equilibrium unfolding profile of RRM2 monitored by SAXS and 
modeled to a two-state mechanism. At high concentrations of denaturant, the Rg value is 
smaller than the theoretical value for the unfolded state (red arrow) suggesting of 
potential collapsed structures in the RRM2 intermediate state. E. The plot of I(0) is linear 
(R2 = 0.965) as a function of denaturant suggesting the increase in Rg2 is attributed to the 
intermediate state and not aggregation.  
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conditions. Similarly, the parabolic shape of the Kratky plot of the native state (Fig. 3.4C, 
solid line) is characteristic of a globular well-folded domain. The SAXS scattering curves 
at increasing concentrations of urea were analyzed using the Guinier method (Eqn. 3.1) to 
obtain the radius of gyration (Rg2) and the intensity at q = 0 (I(0)) at each concentration 
of urea (Fig. 3.4D and 3.4E). The I(0) decreased linearly with increasing urea, indicative 
of a lack of aggregate formation during the unfolding transition (Fig. 3.4E). A plot of the 
Rg2 as a function of urea (Fig. 3.4D) revealed a single cooperative transition between 4 
and 6 M urea, similar to that observed by near-UV CD and Tyr FL, suggesting an loss of 
the native state globularity upon the population of the intermediate state at increased urea 
concentrations. At urea concentrations in the native baseline where the RRM2 native 
dominates the equilibrium (<4 M, Fig. 3.3), the Rg of the native state slightly increases (4 
M urea: Rg = 15.1 ± 0.3 Å) compared to the Rg obtained by SEC-SAXS, likely due to 
local unfolding of RRM2. Modeling the SAXS unfolding profile to a single cooperative 
transition results in a midpoint of 4.78 ± 1.16 M urea, a midpoint within error to those 
obtained by near-UV CD and Tyr FL (Table 3.1). Indeed, the m-value obtained through 
all of these techniques are similar (Table 3.1; near-UV CD: 5.48 ± 0.35 M, Tyr FL: 5.32 
± 0.07 M, SAXS: 4.78 ± 1.16 M) suggesting that both the native aromatic packing and 
the globularity of RRM2 are possibly lost upon population of the intermediate state.  
At >6 M urea, where the RRM2 intermediate is maximally populated (Fig. 3.3A), 
the average Rg observed (23.4 ± 0.4 Å) is smaller that the theoretical Rg value for an 
unfolded state of protein containing 76 amino acids (Rg = 27.7 ± 2.6 Å, (241)), 
suggesting the intermediate has some tendency to form collapsed structure compared to 
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the unfolded state (Table 3.2). Indeed, similar findings were observed in Gdn-HCl (Fig. 
3.5). In the case of Gdn-HCl, the RRM2 native state dominates until 2 M Gdn-HCl, upon 
which the RRM2 intermediate is the major species until 7 M Gdn-HCl, where RRM2 is 
completely unfolded. At the concentration ranges between 3 – 6 M Gdn-HCl, the RRM2 
intermediate state has an Rg of 23.1 ± 0.3 Å, further suggesting similarities between the 
urea and Gdn-HCl-induced RRM2 intermediate states (Table 3.2). At concentrations 
below 3 M Gdn-HCl, the I(0) as a function of denaturant (Fig. 3.5B) displays a deviation 
from linearity suggesting that aggregation occurs at low concentrations of this denaturant, 
which bias the Rg towards larger species at those concentrations. Unlike urea, where the 
RRM2 unfolded state is never significantly populated, high concentrations of Gdn-HCl 
(>6 M) result in significant population of the RRM2 unfolded state (Fig. 3.5A). In this 
case, the RRM2 unfolded state has an Rg of 28.5 ± 1.2 Å, a value similar to the 
theoretical value for an unfolded state. This Rg is larger than the observed Rg for the 
intermediate state by both urea (23.4 ± 0.4 Å) and Gdn-HCl (23.1 ± 0.3 Å) (Table 3.2), 
suggesting that the RRM2 intermediate is not completely unfolded in structure. Indeed, 
an electron density envelope obtained at ~7 M urea (Fig. 3.4B), where the RRM2 
intermediate is ~70% populated (Fig. 3.3A), displays nodes that may comprise residual 
secondary structure. However, as no native tertiary contacts remain in the RRM2 native 
state, the electron density envelope represents the average shape of the RRM2 
intermediate state, as this species may sample multiple conformations. Furthermore, the  
Kratky plot at 6.5 M urea (Fig. 3.4C, dotted) and 8 M Gdn-HCl (Fig. 3.4C, dashed) are 
similar at long scattering angles (q) suggestive of the loss of globular structure. Taken  
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Figure 3.5. A. Equilibrium unfolding profile of RRM2 monitored by SAXS using 
Gdn-HCl as a denaturant. At low concentrations of Gdn-HCl, RRM2 expands and 
maintains this size conformation until 6 M Gdn-HCl. At concentrations > 6 M Gdn-HCl, 
the unfolded state dominates the scattering profile with a similar Rg to the theoretical 
value. B. The plot of the I(0) at each urea concentration is non-linear with increased I(0) 
at < 2 M Gdn-HCl suggesting the expanded conformation at these concentrations are a 
result of sample aggregation and not the population of the RRM2 intermediate. 
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together, the near-UV CD, Tyr FL and SAXS data suggest that the RRM2 intermediate 
lacks the defined aromatic packing and globularity of the native state. The CD and SAXS 
evidence for residual secondary structure and potentially localized regions of collapsed 
structure may play a critical role in the normal functions of TDP-43 or template TDP-43 
misfolding and aggregation.  
  
NMR reveals the RRM2 native and intermediate states may populate an ensemble of 
conformations 
 NMR spectroscopy can monitor conformational changes associated with a host of 
biological functions such as protein folding, coupled folding and binding mechanisms 
observed in intrinsically disordered proteins and protein-protein and protein-nucleic acid 
interactions with residue level resolution (248–251). NMR spectroscopy was used to 
monitor the exchange between the RRM2 native and intermediate states, using urea to 
shift the equilibrium between these two species. The heteronuclear single quantum 
coherence (HSQC) of the native state of RRM2 (Fig. 3.6; red) displays a disperse 
spectrum in both the amide proton (1H) and nitrogen (15N) dimensions characteristic of 
highly globular and structured domains (252), and as observed by SAXS (Fig. 3.4A). 
Although an NMR structure of the isolated RRM2 domain is available (pdb: 1wf0), the 
assignments are not published. The classical triple resonance experiments resulted in the 
assignments for 96% the backbone amide groups (1H, 15N) and the side chains, Cα and 
Cβ. The only unassigned residues are the sequence, 223Pro-224Lys-225Pro, due to the two 
proline residues in close proximity in the primary sequence.  
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Figure 3.6: The RRM2 native state undergoes slow exchange with an unfolded-like 
intermediate state. The HSQC spectrum of the RRM2 intermediate state at 6.5 M urea 
(blue) is collapsed in the 1H dimension compared to the native state (red) and exchange 
on the intermediate NMR time scale at urea concentrations in the N D I transition region 
by far-UV CD. Arrows depict chemical shift perturbations between the RRM2 native and 
intermediate states. Insets, Chemical shifts perturbations in the native (left) and 
intermediate (right) baselines with increasing urea for five residues spanning RRM2: 
V193, E204, M218, I250 and I257. Some residues have reduced intensities at lower 
concentrations of urea, such as I257 and V193, compared to others (E204, I250). 
Similarly, residues can exhibit small (M218) or large (I250) chemical shift perturbations 
with increasing urea. 
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Using urea to increase the population of the partially-folded state, we monitored the 
HSQC spectrum of the amide backbone to identify changes at the residue level as 
exchange occurs between the RRM2 native and intermediate states. As the population of 
the partially-folded state increases with increasing denaturant, two changes were 
observed in the HSQC spectrum. 1) At low (<4 M) and high (>6 M) urea, fast chemical 
exchange dominates the equilibrium and results in chemical shift perturbations in the 
native baseline and upon the population of RRM2 intermediate state. 2) At concentrations 
between 4-6 M urea, in the transition region of the equilibrium unfolding reaction, slow 
exchange dominates with the presence of two chemical shifts for all residues. The 
unfolding exchange for several residues is shown as black arrows between the two states 
starting from the native state (Fig. 3.6, red) and concluding at the intermediate state (Fig. 
3.6, blue). Addition of urea under native favoring conditions (0 – 4 M urea, Fig. 3.6A) 
with little population of the intermediate state revealed that all residues within RRM2 
behave differently (Fig. 3.6, left insets) depending on their location within the native 
structure. For example, V193 (located in β1) and I257 (β5) showed marked decreases in 
intensity at lower urea (~2.0 M, yellow) than the other residues shown, including E204 
(α1), M218 (β2) and I250 (β4), which persist until ~4.5 M urea (green). Additionally, the 
magnitude of the chemical shift perturbation varies widely for all residues (Fig. 3.7) with 
no clear trend across the domain. These results supports the evidence obtained by CD245, 
near-UV CD, and Tyr FL that RRM2 may populate an ensemble of native conformations 
for potential functional purposes.  
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Figure 3.7. A. Equilibrium Unfolding profiles and chemical shift perturbations (B) 
for V193 (closed circles), E204 (closed squares), M218 (closed diamonds), I250 (open 
circles) and I257 (open squares). The five representative residues unfold by a two-state 
mechanism (N D U) with linear chemical shift perturbations in the native baseline before 
complete loss of intensity at higher denaturant concentrations. 
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At concentrations greater than 4.5M of urea, where the RRM2 intermediate state 
dominates the RRM2 unfolding equilibrium (Fig. 3.3A), the crosspeaks of the RRM2 
native state (Fig. 3.6, red) collapses in the amide hydrogen dimension (Fig. 3.6, blue) 
revealing an unfolded-like RRM2 intermediate state. However, the crosspeaks of this 
HSQC spectrum does not resemble those of a random coil (245, 253, 254) and suggests 
the presence of residual secondary structure at high denaturant when the RRM2 
intermediate is significantly populated. Furthermore, as the urea concentration and 
intermediate population increase, these crosspeaks experience additional chemical shift 
perturbations and changes in peak intensity as shown in the right insets of Figure 3.6, in a 
similar manner as the native baseline. These results suggest that both the RRM2 native 
and intermediate states may adopt multiple conformations, some of which may play an 
essential role in TDP-43 function or serve to template misfolding and aggregation. 
Using the cross peak intensities, the population of the native state at each urea 
concentration was plotted as a function of urea to determine the thermodynamics of each 
residue across the domain to identify regions of RRM2 that may resist denaturation in the 
intermediate state (Table 3.3). For example, the equilibrium unfolding profiles for V193, 
E204, M218, I250 and I257 show slight differences in the transition midpoint between 
the residues (Fig 3.7). I257, in the immediate C-terminus, has the lowest Cm of these 
residues (2.93 ± 0.16 M) compared to V193 (3.66 ± 0.55 M), E204 (4.01 ± 0.32 M), 
M218 (3.74 ± 0.26 M) or I250 (3.89 ± 0.31 M), suggesting the residues in the immediate 
C-terminus of RRM2 (residues 253-261; Cm = 3.34 ± 0.45 M) may be more susceptible to 
unfolding that the remainder of RRM2 (Table 3.1, 3.82 ± 0.54 M). Residues in the N-
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terminus (L188-K192), T199, T203, V220, G245 and E261 have complex intensity 
changes as a result of interference from other cross peaks in the native and intermediate 
states (Table 3.3, *,#). Despite complications in quantification from these few residues, 
all residues within RRM2 undergo a single cooperative transition that was modeled to a 
two-state unfolding mechanism (N D I/U) to obtain thermodynamics for each residue in 
RRM2 (Table 3.3) and revealed that no particular region persists in the RRM2 
intermediate state. These results were not surprising due to the relatively small size of 
this domain (76 amino acids), as even small perturbations in one region could drastically 
affect the environment of all residues within RRM2. However, the average Cm of the 
exchange between the RRM2 native and unfolded states (Cm: 3.82 ± 1.95 M) is lower 
than the midpoints obtained through near-UV, FL and SAXS (Table 3.1) measurements. 
Taken together, these results suggest that the unfolding equilibrium of RRM2 may 
consist of an ensemble of conformations in both the native and intermediate states that 
can appear spectroscopically similar. 
 
Secondary structure in the intermediate comprises the N-terminal half of RRM2 
Although multiple methods reveal the RRM2 intermediate state lacks any native 
tertiary contacts, far-UV CD suggests the presence residual secondary structure within 
the domain, whose propensity may not require the formation of tertiary structure. Using 
the amide and backbone chemical shifts of the RRM2 native and intermediate states,  
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several secondary structure propensity algorithms were employed, including TALOS+ 
(246), CSI 2.0 (247) and those developed by Marsh et al. (245) to identify residues that 
maintain a propensity to form secondary structure relative to random coil state. In the 
case of the native state of RRM2 (Fig. 3.8A, solid line), seven discreet regions deviate 
from random coil behavior as predicted from the NMR structure (Fig. 3.8B), DSSP, 
TALOS+ and CSI 2.0: two with a propensity for α-helices (Fig. 3.8A, red, α1: 204-211, 
α2: 237-244) and five for β-strand (Fig. 3.8A, blue, β1: 190-195, β2: 216-222, β3: 229-
234, β4: 246-250, β5: 254-260). The addition of urea to populate the RRM2 intermediate 
state (Fig. 3.8A, dotted line) resulted in maintained secondary structure propensity in the 
N-terminal half of RRM2 with residues in β1 and α1 maintaining secondary structure in a 
similar manner as the RRM2 native state (Fig. 3.8B). However, as shown by Tyr FL, 
near-UV and SAXS, little tertiary structure remains in the RRM2 intermediate state and 
thus these elements may not exist in a native-like conformation. The residues between 
220 and 235, which comprise β2 and β3 in the RRM2 native state, continue to have β-
strand propensity albeit comprised of residues not normally found in β2 and β3. These 
results suggest that β2 and β3 may adopt alternative conformations in the RRM2 
intermediate state that could serve as a potential source of aggregation. Molecular 
dynamic simulations may elucidate the particular conformations of the residual secondary 
structure elements of the RRM2 intermediate state. 
The most striking feature of the secondary structure propensity of the RRM2 
intermediate state is the elimination of the propensity in the C-terminal α2, β4 and β5 
region. These results suggest that this region is largely disordered in the RRM2  
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Figure 3.8: Residual structure localizes to the first βαβ motif of the RRM2 
intermediate state. A. Secondary structure propensity of the RRM2 native (solid) and 
intermediate (dotted) states from the 1H, 15N, Cα and Cβ chemical shifts with positive and 
negative values represent α-helical and β-strand propensity, respectively. The RRM2 
intermediate at 6.5 M urea retains native-like secondary structure propensity in β1, α1 
and the β2-β3 region. However, the C-terminal α2, β4 and β5 regions have a vastly 
reduced propensity compared to the native state, suggesting a disordering of the C-
terminal half of RRM2 in the intermediate state. This region contains the TDP-43 NES 
sequence (A, yellow) and suggests the RRM2 intermediate may expose this sequence for 
cytoplasmic transport. B. NMR structure mapping the region of residual structure in the 
RRM2 intermediate state to β1 and α1 (blue: β-strands, red: α-helices) and non-native 
secondary structure propensity in the β2-β3 region (B, cyan) with the remainder of 
RRM2 being disordered (gray). The lack of tertiary contacts in the intermediate state 
suggests these residual secondary structure elements may adopt non-native 
conformations. 
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intermediate state and likely exposes the embedded NES sequence, comprising I239-I250 
in α2 and β4 (Fig. 3.8A, yellow), to solvent for recognition in cytoplasmic transport. 
Thus, the population of the RRM2 intermediates results in the formation of an unfolded-
like higher energy that could play a role in normal TDP-43 function, via the exposure of 
the NES sequence in the C-terminal half of RRM2, or in TDP-43 misfolding through 
aggregation mediated by the residual structure and aggregation prone sequences in 
RRM2. Increased populations of the RRM2 intermediate during stress or upon cleavage 
(235) may disrupt normal TDP-43 function via enhanced cytoplasmic transport and 
increased TDP-43 misfolding leading to neurodegeneration. 
 
RRM1 and RNA stabilize the native state of RRM2 
As had been shown previously (235), interactions with RRM1 and RNA stabilize 
the native state of RRM2 against the population of the intermediate state. Indeed, the 
NMR structure of the tethered RRM domains (tRRMs, pdb: 4bs2) reveals that the β4 and 
β5 region of RRM2 provide hydrophobic contacts with β2 and β3 of RRM1. SAXS 
electron density envelops of the apo-tRRMs (Fig. 3.9A) reveals unoccupied electron 
density that suggests that the native state of the tRRMs is inherently dynamic, but mutual 
interactions with nearby RRM1 would influence the folding of RRM2. Furthermore, the 
interaction of RNA with tRRMs limits the unoccupied electron density (Fig. 3.9B), 
suggesting RNA significantly stabilizes the RRM1-RRM2 interactions and reduces the 
population of the RRM2 intermediate state. Indeed, Rg measurements reveal a slight  
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Figure 3.9: RRM1 and RNA may serve as protective factors against the population 
of the RRM2 intermediate state. A-B. ab initio modeling of the RNA-bound NMR 
structure of the tRRMs (pdb: 4bs2) into the electron density envelopes for tRRMs (B) and 
tRRMs-(UG)6 (C). The RNA was removed for tRRMs modeling, while the RNA 
sequence used in this study, (UG)6 differs slightly from the published structure. The 
RRMs of TDP-43 bind to RNA in a unique manner (72) where residues of the NES are 
involved in interdomain interactions with RRM1. The unoccupied electron density in the 
apo-tRRMs (B) suggests dynamics between the two RRMs and possibly multiple 
conformations that are limited upon addition of the RNA scaffold (C). These results 
suggest that RRM1 and RNA would limit the access of the RRM2 intermediate state and 
the NES signal. C. Kratky plots of the tRRMs in the absence (solid line) and presence 
(dotted line) of RNA (UG6). Neither the maximum at q = 0.1 nor the overall shape of the 
Kratky plot change significantly upon the addition of RNA. Indeed, RNA induces only a 
slight compaction in the Rg (tRRMs: 23.1 ± 0.1 Å, tRRMs + (UG)6: 22.1 ± 0.1 Å). 
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compaction of the tRRM domains (tRRMs: 23.1 ± 0.1 Å, tRRMs + (UG)6: 22.1 ± 0.1 Å)  
with little change in the Kratky plots between the apo- (tRRMs, Fig. 3.9C, solid line) and 
RNA-bound (Fig. 3.9C, dotted line) states. These results support the existence of 
significant interactions between RRM1 and RRM2 in the absence of RNA that are further 
enhanced upon addition of an RNA scaffold. These results suggest that the presence of 
RRM1 and RNA would severely limit the access of the RRM2 intermediate state and 
exposure of the NES sequences and suggests a protective role for RRM1 and RNA in the 
population of the RRM2 intermediate state. 
 
Discussion 
 Here, the structural characteristics of the intermediate state of RRM2 of the RNA-
binding protein, TDP-43, were investigated using a combination of low and residue-level 
resolution biophysical techniques. The RRM2 intermediate state lacks the native tertiary 
structure and globularity as observed through near-UV, Tyr FL and SAXS (Figs. 3.1 and 
3.4) but contains secondary propensity by far-UV CD (Fig. 3.1A and 3.1B) located in the 
N-terminus of RRM2 via NMR (Fig. 3.8A). The lower average stability of the C-terminal 
residues of RRM2 (Table 3.3) in addition to the disordered propensity of α2, β4 and β5 
(Fig. 3.8) could result in the exposure of the normally buried NES (225) and aggregation 
prone peptides (151, 152). These results suggest that the RRM2 intermediate state may 
provide a residual structure platform in the N-terminal half of RRM2 for proper refolding 
of the domain post-cytoplasmic transport or misfolding and aggregation with other TDP-
43 molecules and similar proteins including hnRNP A1 and A2/B1 (82, 83, 255, 256).  
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The unfolded-like nature of the RRM2 intermediate state is reminiscent of 
intrinsically disordered proteins, which can possess significant, albeit somewhat transient, 
secondary structure, but lack the tertiary contacts required for the formation of a stable 
three-dimensional structure (257). Indeed, evidence from near-UV CD, Tyr FL and 
SAXS reveals a loss of tertiary structure and globularity of RRM2 upon the population of 
the intermediate state (Figs. 3.1 and 3.3) with only the propensity to form secondary 
structure in the N-terminal portion of RRM2 (Fig. 3.9). Multiple disordered proteins can 
undergo large conformational changes under certain conditions (187, 258, 259), usually 
when involved in protein-protein (250) or protein-nucleic acid interactions (252, 260). 
Indeed, several normally disordered sequences, such as Aβ (261–263) and α-synuclein 
(264, 265), can adopt misfolded conformations resulting in their aggregation as observed 
in neurodegeneration (42, 262, 264, 266–272). Like other intrinsically disordered proteins 
implicated in disease (257, 259), the RRM2 intermediate may adopt an ensemble of 
partially-folded structures (Fig. 3.4B) rather than a unique conformation. One or more of 
these conformations may yield an opportunity for RRM2 and TDP-43 misfolding, 
particularly with aggregation prone sequences located near in sequence, such as β3 and 
β5 in RRM2 (152), oxidized or crosslinked RRM1 (205, 217, 273), or the Q/N-rich 
regions of the prion-like C-terminal domain (85, 150, 237, 274). Intriguingly, multiple 
studies have highlighted the importance of fragments of TDP-43 containing RRM2 and 
the C-terminus in aggregation and toxicity in cellular models, where each domain alone 
did not induce these phenotypes (138–141). These results suggest that the RRM2 
intermediate state could serve as a decision point for partitioning between TDP-43 intra-
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molecular folding vs. inter-molecular aggregation. The population of the intermediate 
state, loss of RNA-binding or protein-protein interactions and C-terminal ALS-mutations 
could shift this partitioning towards misfolding and aggregation. The partially-folded 
state in RRM2 could alternatively serve as a stepping stone to limit the conformational 
search to achieve the native functional state of RRM2 and TDP-43.  However, as 
misfolding and aggregation are intricately linked to the folding energy landscape (25), the 
residual structure (Fig. 3.9) and possible conformational flexibility in the tertiary 
structure and globularity (Figs. 3.1, 3.3 and 3.4), of the RRM2 intermediate state may 
provide template structures to aid in TDP-43 misfolding and aggregation. 
Alternatively, the RRM2 intermediate could serve a crucial functional role in 
nucleocytoplasmic transport of TDP-43. In the NMR structure of RRM2, the NES region 
(residues I239 - I250, (225)) is sequestered in the native structure with the four critical 
hydrophobic residues (I239, L243, L248 and I250 (224)) contributing to α2 and β4. 
These particular residues lack significant secondary structure propensity in the RRM2 
intermediate state unlike the N-terminal, β1, α1, β2 and β3 region (Fig. 3.8A, yellow). 
The exposure and disordered nature of this region could potentially serve as a signal for 
recognition by exportin to the cytoplasm (275). Normally, interactions with RRM1 and 
RNA stabilize the native state of RRM2 would limit the population of the intermediate 
state (Fig. 3.9) and access to the NES sequence (235). L131 in RRM1 and I249 in RRM2 
and the NES sequence interact upon tethering of the RRM domains and would directly 
stabilize the sequestration of the NES sequence. However, cleavage of TDP-43, as has 
been observed in patient samples at multiple cleavage sites (30, 49, 139, 276), can result 
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in the degradation of the N-terminal region, including RRM1 and the NLS sequence, 
resulting in a loss of a bulk of the RNA binding provided mainly through RRM1 (73, 
235) and an inability to localize to nucleus (225). This mechanism may result in the 
accumulation of C-terminal fragments of RRM2 and the C-terminus, which have been 
shown to be toxic and highly aggregation prone (138–141). While the role of cleavage in 
disease pathogenesis is highly controversial (79, 183, 232, 233), thermodynamics on a 
fragment of RRM2 revealed increased populations of this intermediate state (235), 
suggesting a possible mechanism for its cytoplasmic localization through the enhanced 
exposure of the NES sequence, upon the isolation of RRM2 from RRM1 and RNA in 
cleavage fragments. 
The residual structure and exposure of the NES of the RRM2 intermediate state 
could provide opportunities for interplay between the functional and aggregation 
interactions. Under normal cellular conditions, the formation of interactions with RRM1 
and RNA result in the stabilization of the native folded state of RRM2 with the burial of 
the NES residues within the hydrophobic core of the domain and a population of the 
RRM2 intermediate state of less than <0.1% (235). Normally, a majority of TDP-43 is 
localized within the nucleus, with a small fraction present in the cytoplasm (228), perhaps 
a result of exposure of the NES in this small fraction of functional TDP-43 molecules. In 
this case, the reversible refolding of the RRM2 intermediate state to the native folded 
structure would allow for the sequestration of the NES and maintenance of functional 
TDP-43. However, stress or cleavage of TDP-43, with the removal of RRM1 and RNA, 
could enhance the transport of full-length or fragmented TDP-43 to the cytoplasm and aid 
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in the formation of stress granules (37, 277–279) or other cellular structures, such as 
liquid like assemblies (280–284), that can convert to non-functional TDP-43 complexes 
with time or repeated stress. Additionally, the residual secondary structure elements 
lacking any defined structure could serve as template for further misfolding and 
aggregation with other misfolded RRM2 domains or enhance pathogenic conformations 
with RRM1, the disordered C-terminus, or other prion-like proteins such as hnRNP A1. 
In either case, the non-functional complexes or aggregates would limit the functional 
pool of TDP-43 and destabilize tightly regulated RNA processes, such as splicing (78), 
microRNA biogenesis (87) and TDP-43’s own autoregulation (80), leading to cellular 
toxicity and neurodegeneration. Targeting the RRM2 intermediate state with 
conformational or sequence-specific antibodies or small molecule compounds could 
inhibit the population of this potentially pathogenic conformation and limit the TDP-43 
misfolding and aggregation observed in a host of neurodegenerative diseases.  
In recent years, effort has focused on stabilizing the native conformations of 
disease-related proteins (39, 96, 118, 122, 285–287) through the binding of small 
molecule compounds to reduce the population of the potentially aggregation-prone non-
native conformations and inhibit toxicity (288–290). Along similar lines, antibody 
therapeutics and biomarkers specifically targeting these conformations would provide 
critical tools for disease diagnosis and progression (291–293). Indeed, antibodies are used 
in a range of research diagnostics: the C4F6 antibody selectively targets misfolded human 
superoxide dismutase I (SOD1) in ALS (294, 295), while Herceptin is used in the 
treatment of breast cancer (296) to prevent dimerization of Her-2 and downstream 
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signaling (297). Recently, a panel of antibodies have been raised against TDP-43 (298) 
with the identification of multiple antibodies specific for pathological conformations of 
TDP-43 observed in patient tissues. One antibody specifically targets RRM2 but it is 
unclear how this pathological conformation correlates to the partially folded state 
observed on its folding energy landscape. The RRM2 intermediate state, in the context of 
the full-length protein under cellular conditions, could serve as a critical target for 
antibody and biomarker development for use in the diagnosis and treatment of TDP-43-
mediated neurodegenerative disease. 
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Chapter IV – An RRM intermediate links the ALS RNA-binding proteins, TDP-43, 
FUS/TLS and hnRNP A1 
 
 
 
The work presented in this chapter was a collaboration between Jill Zitzewitz, myself and 
several undergraduate students, Elizabeth (Liz) DiLoreto, Lidiette Angeles and Muska 
Hassan. Liz DiLoreto, Lidiette Angeles and Muska Hassan cloned and purified the RRM 
domains of matrin-3, hnRNP A1 and FUS/TLS, respectively. Liz DiLoreto, Lidiette 
Angeles, Muska Hassan and I collected and analyzed the data. Liz DiLoreto, Lidiette 
Angeles, Muska Hassan, Jill Zitzewitz and I were involved in data interpretation. Jill 
Zitzewitz and I wrote the chapter. 
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Abstract 
 Missense mutations in the RNA-binding proteins, TDP-43, FUS/TLS, matrin-3 
and hnRNP A1, have been associated the neurodegenerative disease, amyotrophic lateral 
sclerosis. Each of these proteins contains at least one RNA-recognition motif (RRM) that 
may contribute to a common mechanism in RNA-binding protein-related 
neurodegeneration. Folding of the RRM domains of TDP-43 revealed a highly populated 
intermediate state on the folding free-energy landscape of RRM2 that may normally play 
functional or misfolding roles. Here, the folding energy landscapes of the RRM domains 
of FUS/TLS, matrin-3 and hnRNP A1 were investigated to map higher energy species 
that may lead to non-functional pools of RNA-binding proteins. The isolated RRM 
domains of matrin-3 and the first RRM of hnRNP A1 (A1RRM1) display behavior 
characteristic of two-state folding and unfolding. However, the RRM domain and 
FUS/TLS and the second RRM domain of hnRNP A1 (A1RRM2) have breaks in the 
cooperativity via circular dichroism and intrinsic fluorescence suggestive of a partially 
folded state in these systems. While each of the isolated domains has a relatively weak 
affinity for RNA, tethering the matrin-3 and hnRNP A1 domains results in an increased 
binding affinity and, in the case of matrin-3, cooperativity. These results indicate that the 
RNA-binding proteins, TDP-43, FUS/TLS and hnRNP A1, populate RRM partially-
folded states that may contribute to protein function or misfolding in conjunction with the 
adjacent prion-like domain.  
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Introduction 
 Amyotrophic Lateral Sclerosis (ALS) is a rapid, debilitating disease that primarily 
affects upper and lower motor neurons (44). Death occurs within 3-5 years after disease 
onset mostly a result of pulmonary distress (299). The hallmark feature of ALS and other 
neurodegenerative diseases is the accumulation of proteinaceous cytoplasmic inclusions 
in patient tissues (30, 49). Furthermore, mutations, first in superoxide dismutase 1 
(SOD1) (300) and subsequently in a host of other genes, have been identified in the 
pathogenesis of ALS (163, 301). These genes are diverse, ranging from variants in 
structural and RNA-binding proteins, such as profilin (52) and Tar DNA-binding protein 
of 43 kDa (TDP-43) (57), respectively, to GGCCCC-repeat expansions in c9orf72 (54, 
55). Although mechanistic insights into how these genes exert their toxic effects remains 
elusive, several hypotheses have been proposed: 1) a loss of normal function (183, 302), 
2) a toxic gain of function (303) or 3) some combination of either mechanism (135, 304). 
In the case of SOD1, evidence suggests small oligomers or the aggregates themselves 
(172–174) may induce toxicity as mutations have varying affects on SOD1 function with 
some retaining wild-type-like activity (158, 159). Conversely, mounting evidence 
suggests that aggregation of TDP-43 reduces the normal functional pool of this protein 
and subsequently disrupts its various RNA processing functions (183).  
 Since the discovery of TDP-43 as a major contributor to neurodegeneration (49), 
mutations in set of the RNA-binding proteins, fused in sarcoma/translocated in sarcoma 
(FUS/TLS) (51), matrin-3 (305), and heteronuclear ribonucleoprotein A1 (hnRNP A1)  
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Figure 4.1: Domain Architectures and RRM Structures of the ALS-linked RNA-
binding proteins. A. Domain architectures of TDP-43, FUS/TLS, Matrin-3 and hnRNP 
A1. Although these RNA-binding proteins have different domain arrangements, one 
similarity between these polypeptides is the presence of one or two RNA-recognition 
motif (RRM, blue) domains adjacent to predicted regions of disorder including glycine 
(Gly)-rich (orange) and glutamine-glycine-serine-tyrosine (QGSY)-rich (red) regions 
where mutations (*) have been identified in neurodegeneration. Other domains include 
zinc fingers (ZnF, green) and arginine-glycine-glycine (RGG)-rich repeats (light green), 
adjacent to disordered glycine (Gly)-rich (orange) and glutamine-glycine-serine-tyrosine 
(QGSY)-rich regions (red). Strong nuclear localization sequences (NLS, purple) result in 
nuclear retention with additional nuclear export sequences (NES, yellow) embedded in 
RRM2 of TDP-43 and the RRM domain of FUS/TLS for potential cytoplasmic functions. 
TDP-43 also possess a well-folded N-terminal domain (NTD, light red) with a similar 
topology to axin 1 (75). B-F. NMR structures of the FUS RRM (pdb: 2la6), RRM1 
(mRRM1, pdb: 1x4d) and RRM2 (mRRM2, pdb: 1x4f) of matrin-3 and RRM1 
(A1RRM1) and RRM2 (A1RRM2) of hnRNP A1 (pdb: 1up1). Each RRM has the 
classical β-α-β-repeat topology common for this motif. Intrinsic fluorescent probes on 
each RRM are shown as sticks with tyrosine residues in yellow and tryptophan residues 
in green. 
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(306), have been associated with ALS pathology (Fig. 4.1). All of these proteins are 
ubiquitously expressed with substantial nuclear localization (307–311) and participate in 
a wide range of RNA-binding processes, including splicing and microRNA biogenesis 
(TDP-43) (81, 87, 312–314), transcriptional regulation (FUS/TLS) (315–317), telomere 
maintenance (hnRNP A1) (318–321) and nuclear RNA scaffolding (matrin-3) (322, 323). 
Additionally, each protein has been shown to have high affinity for discreet RNA 
sequences (73, 235, 319, 324–326). Although functionally unique, the domain 
architectures are similar between this set of four ALS-RNA binding proteins (Fig. 4.1A). 
Each protein consists of two or more RNA-binding domains (RBD), one or more nuclear 
localization sequences (NLS), and in some cases, a nuclear export sequence (NES).  In 
the case of FUS/TLS and matrin-3, the RBD consists of RNA recognition motif (RRM) 
domains paired with CCCC-type Zinc fingers (ZnF) (44, 305). TDP-43 and hnRNP A1 
each contain two RRM domains, RRM1 and RRM2 (44, 306). These domains have the 
classical βαβ-repeat topology (Fig. 4.1B-F) with minor differences in structure. They all 
have differences in loop length (FUS/TLS, matrin-3) and insertion of an extra β-strand 
(TDP-43). Although the RRM domain is a common motif (189, 327), it is interesting that 
four RNA-binding proteins, containing this domain, have been associated with ALS and 
suggests a common mechanism may drive the toxicity observed in ALS patients. 
 Recent evidence has shown that RRM2 of TDP-43 is required for cellular and in 
vivo toxicity and aggregation (138–141), in combination with the disordered C-terminus, 
where a vast majority of ALS-linked mutations cluster (44, 57). Furthermore, a similar 
finding has been observed for FUS/TLS where the single RRM domain in combination 
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with the preceding glycine-rich region being critical determinants for toxicity (328). 
These data suggest that pathological conformations adopted by the RRM domain may 
enhance disease phenotypes in these proteins. Biophysical studies on the RRM domains 
of TDP-43 have shown that RRM2 populates a partially-folded state at equilibrium (235), 
binds weakly to RNA in isolation from RRM1 (73, 235) and possess predicted 
aggregation-prone sequences (151, 152). Furthermore, cleavage within the domain as 
observed in patients (142, 144, 145), dramatically increases the population of the RRM2 
intermediate in TDP-43. However, it is unclear whether the RRM intermediate is a 
common link between a subset of ALS-linked proteins. 
 Here, we use the denaturant, guanidine hydrochloride (Gdn-HCl), to sample 
higher energy conformations to probe the equilibrium unfolding landscapes of the RRM 
domains of FUS/TLS, matrin-3 and hnRNP A1. The FUS/TLS RRM (FUS RRM) and 
RRM2 of hnRNP A1 (A1RRM2) populate a stable equilibrium intermediate state under 
native conditions, in a similar manner as RRM2 of TDP-43. However, like RRM1 of 
TDP-43, both matrin-3 RRM domains exhibit two-state behavior without the population 
of partially-folded states. The commonality of the RRM intermediate in ALS-linked 
RNA-binding proteins containing prion-like domains, TDP-43, FUS/TLS and hnRNP A1, 
suggests that crosstalk between structured and disordered regions may aid in misfolding 
and toxicity in neurodegeneration. However, neither RRM domain of matrin-3 populates 
an equilibrium intermediate and may cause ALS through an alternative mechanism. 
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Material and Methods 
Protein Purification 
 DNA sequences encoding the FUS/TLS RRM (FUS RRM: amino acids 285-370), 
isolated and tethered matrin-3 RRMs (mRRM1: 398-473, mRRM2: 496-571, mtRRMs: 
398-571) and hnRNP A1 RRMs (A1RRM1: 14-91, A1RRM2: 105-182, A1tRRMs: 14-
182) were purchased from GeneScript, Inc. with an N-terminal hexahistidine tag (His6) 
and a PreScission Protease cleavage site (LEVLFQGP) for purification purposes. Using 
the engineered NcoI and BamHI sites at the 5’ and 3’ ends, respectively, each construct 
was cloned into pET-3d for expression in BL21 DE3 E. coli induced by 1 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) for 18 hours at 20°C.  
 The cells were resuspended in lysis buffer (20 mM NaPi, pH 7.8, 300 mM NaCl 
and 30 mM Imidazole, 1 µg mL-1 DNAse and protease inhibitors (Roche) followed by 
lysis by sonication. If proteins were present in the insoluble fraction, the lysis was 
performed in lysis buffer supplemented with 6 M urea. Following centrifugation, cell 
lysates were applied to equilibrated His60 Nickel resin (Clonetech) and incubated 
overnight at 4°C. Bound proteins were eluted using elution buffer (20 mM NaPi pH 7.8, 
300 mM Imidazole) into either 5X volume of PreScission Protease cleavage buffer (20 
mM Tris, 1 mM DTT) for natively prepared proteins or 10X volume of buffer for urea 
lysates to refold the RRM domains. Due to the differences in isoelectric point between 
each RRM, the matrin-3 RRMs were cleaved at pH 6.5 for subsequent purification by SP 
sepharose (GE Healthcare) ion exchange chromatography, while the FUS and hnRNP A1 
RRMs were cleaved at pH 8.8 for purification on a Q sepharose column (GE healthcare). 
 133 
Superdex 75 size exclusion chromatography (GE Healthcare) was used to remove minor 
contaminants prior to dialysis into the working buffer (10 mM KPi, pH 7.2, 150 mM KCl, 
1 mM β-mercaptoethanol (BME)). The purity of all protein samples were >99% as 
determined by SDS-PAGE and mass spectrometry (UMass Medical School). 
 
Size Exclusion Chromatography 
 Size exclusion chromatography was performed as previously described (235) in 
working buffer at 4°C with protein concentrations between 0.5 to 4.0 mg mL-1 for each 
construct in the absence of nucleic acid to determine the oligomeric state of each RRM 
construct. 
 
Equilibrium Unfolding Experiments 
 All CD experiments were performed using a Jasco-810 spectrophotometer 
equipped with temperature control. Native state scans of each protein in the absence of 
denaturant were acquired between 200-260 nm in a 0.1 mm cuvette (Hellma) at 20°C. A 
total of 10 scans were averaged and buffer subtracted to obtain the final spectra. 
Wavelength scans for the equilibrium unfolding experiments were acquired in 0.5 mm 
cuvette (Hellma) from 220-260 nm with increasing concentrations of Gdn-HCl. Tyrosine 
(Tyr) and tryptophan (Trp) FL spectra were obtained using T-format Spex-3 fluorometer 
equipped with temperature control. Tyr-containing RRM domains (mRRM1, A1RRM2) 
were excited at 274 nm, and emission spectra were collected between 280 and 400 nm. 
Trp-containing RRMs (FUS RRM, mRRM2, mtRRMs, A1RRM1, A1tRRMs) were 
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excited at 295 nm to reduce Tyr contributes in these domains, and emission spectra 
between 300 and 450 nm were collected. Protein concentrations ranged from 4 to 30 µM 
at increasing denaturant concentrations varied from 0 to 8 M Gdn-HCl. Final Gdn-HCl 
concentrations were measured using an ABBE refractometer, and all buffers were buffer 
subtracted for data analysis.  Each data set was modeled to a two-state or three-state 
equilibrium unfolding mechanism as previously described (235). For domains revealing 
equilibrium intermediates, the population of these partially folded states was calculated 
using the partition function as determined previously (235). 
 
Electromobility Gel Shift Assays (EMSA) 
 RNA-binding assays were performed in a similar manner as described previously 
(235). Briefly, 50 µl reactions containing 3 nM of 6-carboxyfluorescien (FAM)-labeled 
RNA was incubated with increasing protein concentrations to a maximum of 2 µM 
protein. The RNA sequences used for these experiments are as follows with the RNA-
binding consensus sequences underlined: FUS/TLS (325): 5’-gugggugggugg-3’, matrin-3 
(326): 5’-cuucucacuacugcacuugacuaguc-3’ and hnRNP A1 (319): 5’-
uaugauagggacuuagggug-3’. After incubation for 2 hours at room temperature, samples 
were loaded onto an 8% acrylamide slab gel and run for 75 minutes at 4°C. Imaging was 
performed on a Typhoon FLA-9000 with 473 nm excitation and a 520 nm bandpass 
cutoff filter. The percent bound was determined as described previously and modeled to 
the Hill equation for RRM domains with >100 nM affinity to their cognate RNA (198). 
For high affinity recognition, the quadratic modified model was used (198). 
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Results 
Each RRM domain is well-folded with significant secondary structure 
Each isolated and tethered RRM system was expressed and purified to 
concentrations >2 mg mL-1. The FUS RRM (Fig. 4.2, cyan), mRRM1 (Fig. 4.2, green) 
and the tethered matrin-3 RRM domains (mtRRMs, Fig. 4.2, red) are monomeric by size 
exclusion chromatography, except for mRRM2, which shows a tendency to dimerize at 
high protein concentrations (Fig 4.2, blue). All RRM adopt the similar βαβ-repeat 
topology by NMR or X-ray crystallography, typical of RRM domains. However, the CD 
spectrum of the isolated and tethered RRM domains (Fig. 3) reveals differences in the 
overall shape of the spectra between the RRM domains, but all RRMs are well-folded 
with >-6000 MRE signal suggesting the presence of significant secondary structure. The 
FUS RRM has a distinct CD spectrum minimum at 208 nm with a shoulder at 222 nm 
(Fig. 4.3A, cyan), which resembles the second RRM of TDP-43 (tdpRRM2) (235). The 
CD spectra of the matrin-3 RRM domains differ from the FUS RRM with significant 
contributions from minima localized at 208 and 222 nm. Both mRRM1 (Fig. 4.3B, green) 
and mRRM2 (Fig. 4.3B, blue) contain significant mean residue ellipticity (MRE) signal 
with values greater than -8000 deg cm-1 dmol-1 but the overall shape of the spectra differs 
between the two domains (Fig. 4.3B). The increased 222/208 nm ratio of mRRM1 
compared to mRRM2 suggesting that mRRM1 possesses significantly greater 
contributions from α-helical elements than mRRM2. Indeed, the overall shape of the CD  
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Figure 4.2: Size exclusion chromatography profiles of the ALS-linked RNA binding 
proteins, FUS/TLS and matrin-3. All RRM domains examined were monomeric by 
size exclusion chromatography, except for mRRM2 (blue), which displayed a population 
of dimeric species under running conditions. Loading concentrations for all proteins was 
~1 – 1.5 mg mL-1. 
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Figure 4.3: All RRM domains are well-folded with significant secondary structure 
and unfold completely in 7 M Gdn-HCl. A. CD spectrum of the FUS RRM (cyan) 
displays a prominent 208 minimum with a shoulder at 220 nm. B. CD spectra of the 
matrin-3 RRM domains. RRM1 (mRRM1, green) and RRM2 (mRRM2, blue) of matrin-3 
have different shapes with significant differences in signal near 208 nm. Tethering the 
two RRM domains of matrin-3 (mtRRMs, red) increase the amplitude of the CD spectra 
compared to the sum of the isolated domains (mtRRM1 + mtRRM2, dotted red) 
suggesting that tethering stabilizes the secondary structure of the matrin-3 RRM domains. 
C. CD spectra of the hnRNP A1 RRM domains. RRM1 (A1RRM1, orange) and RRM2 
(A1RRM2, purple) of hnRNP A1 have dissimilar CD spectra with minima at 208 nm and 
differences in the amplitude of the shoulder at 222 nm. Tethering the RRM domains of 
hnRNPA1 (A1tRRMs, brown) has a decreased 208 nm signal compared to the sum of the 
two isolated domains (A1RRM1 + A1RRM2) suggesting that tethering affects the 
secondary structure of the two domains. At 7 M Gdn-HCl (black), all RRM domains 
show a similar loss of secondary structure (black). All CD spectra were obtained at 3 – 10 
µM in the experimental buffer. 
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spectrum for mRRM1 and mRRM1 closely resembles the spectrum of the first RRM of 
TDP-43 (tdpRRM1) and tdpRRM2, respectively (235). However, in the case of mRRM2, 
the amplitude of the shoulder between 220 and 230 nm (Fig. 4.3B, blue) is smaller than 
observed for tdpRRM2 and the FUS RRM. Tethering mRRM1 and mRRM2 through the 
short linker region (Fig. 4.3B, red) results in a CD spectrum with a slightly increased 
amplitude compared to the average of the isolated domains (mRRM1 + mRRM2, red 
dotted) suggesting that secondary structure elements in mtRRMs may be stabilized upon 
tethering, possibly through interdomain interactions. This small increase in secondary 
structure could also arise through the formation of a helix in the linker region that has 
been observed in other tethered RRM structures, including hnRNP A1 (329). The CD 
spectrum of A1RRM1 (Fig. 4.3C, orange) closely resembles the obtained spectrum of 
mRRM1 (Fig. 4.3B, green) with prominent minima at 208 and 222 nm. However, the CD 
spectrum of A1RRM2 does not resemble any of the other RRMs examined in this study, 
or the CD spectra of TDP-43 (235). A1RRM2 (Fig. 4.3C, purple) has a prominent 210 
nm minimum with shoulder between 220 and 230 nm that is ~50% the MRE signal of the 
210 nm peak, unlike those observed in the FUS RRM (Fig. 4.3A, cyan) and mRRM2 
(Fig. 4.3B, blue). This difference may arise from different packing of the β-sheet or more 
contributions from α-helix (204). Tethering the hnRNP A1 RRM domains displays 
reduced MRE signal than either of the isolated A1RRM domains (Fig. 4.3C, black) and 
resembles the tethered RRM domains of TDP-43 (tdptRRMs). These results suggest that 
tethering affects the secondary structure of the isolated domains that may occur through 
interdomain interactions as observed in X-ray crystal structure (330). The loss of this 
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secondary structure can serve as a probe to monitor the equilibrium unfolding pathway of 
these RRM domains. The addition of the denaturant, Gdn-HCl, drastically reduces 
secondary structure formation (Fig. 4.3, black) to result in the population of the unfolded 
state.  
 
The FUS RRM populates an intermediate state 
In order to map the folding free-energy landscapes of the RRM domains of the 
ALS-linked RNA-binding, CD and intrinsic FL was used to probe changes in secondary 
and tertiary structure, respectively, as the denaturant, Gdn-HCl, was added to sample the 
unfolded state. In addition to the changes in secondary structure of the FUS RRM, the FL 
of the single Trp residue on α2 (Trp353) was probed for global changes in structure with 
increasing denaturant. As shown in Fig. 4.4A, the CD equilibrium unfolding profile (Fig. 
4.4A, closed circles) displays a three state equilibrium unfolding pathway (N D I D U) 
with the population of an intermediate state at 2.4 M Gdn-HCl (Fig. 4.4A, red arrow). 
Each transition contributes ~2 kcal mol-1 of stability for a total free-energy of unfolding 
of 4.61 ± 0.19 kcal mol-1 (Table 4.1). The residuals of a two-state model of the CD (Fig. 
4.4B, solid) compared to a three-state model (Fig. 4.4B, solid line) of the FUS RRM 
equilibrium unfolding profile by support the presence of a stable equilibrium intermediate 
state. Furthermore, the steep positive native baseline of the CD equilibrium profile is 
suggestive of dynamics in the native secondary structure in the FUS RRM. Indeed, the 
Trp FL spectra as a function of denaturant (Fig. 4.4, open circles) reveals a single 
transition with a midpoint of 0.96 ± 0.04M, which is not coincident with either the N D I  
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Figure 4.4: The FUS RRM populates an intermediate state. A. The CD (closed 
circles) and Trp FL (open circles) equilibrium unfolding profile of the FUS RRM were 
modeled to a three-state (N D I D U) and two-state (N D U) unfolding mechanism, 
respectively. The unfolding of the FUS RRM displays a break in the cooperativity at 2.4 
M Gdn-HCl (red arrow) suggestive of the population of an intermediate state. B. 
Residuals of a two-state model (dotted line) compared to a three-state model (solid line) 
of the FUS RRM equilibrium unfolding profile by CD. C. Fraction apparent plots of 
equilibrium unfolding profiles of the FUS RRM reveal non-coincident CD (closed 
circles) and Trp FL (open circles) transitions, supporting the possible presence of 
multiple intermediate states in the FUS RRM. 
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(1.48 ± 0.02 M) or I D U (3.79 ± 0.11M) transitions observed by CD. This transition 
occurs at denaturant concentrations in the steep native baseline by CD, suggesting the 
instability of the secondary structure may arise from changes localized around α2 near the 
Trp reside. At concentrations greater than 1.8 M Gdn-HCl, the Trp FL intensity becomes 
insensitive to changes in structure suggesting that Trp353 is exposed to solvent at these 
concentrations. The non-coincident transitions observed by CD and Trp FL equilibrium 
unfolding profiles of the FUS RRM (Fig. 4.4B) suggests that this domain may unfold 
through the population of multiple stable partially-folded states (Table 4.1). 
 
The isolated RRM domains of matrin-3 unfold in a two-state manner 
The addition of Gdn-HCl to mRRM1 revealed a characteristic equilibrium profile 
of a two-state (N D U) unfolding mechanism by CD and Tyr FL intensity of the three 
Tyr residues in mRRM1 (Fig. 4.5A, open and closed circles). The coincidence of the CD 
and Tyr FL midpoints (1.79 ± 0.02 M) supports a two-state model without the population 
of other states beside the native and unfolded states. Globally modeling to a two-state 
unfolding pathway results in a highly cooperative m-value (1.93 ± 0.03 kcal mol-1 M-1), 
near the predicted value for this domain (195), and a folding free-energy in the absence of 
denaturant of 3.46 ± 0.07 kcal mol-1. However, the mRRM1 construct used in this study 
lacks the ICC sequence (331), unlike mRRM2, and may result in decreased 
thermodynamic stability due the missing ICC-RRM interactions. 
         Denaturation of mRRM2 monitoring secondary structure changes (Fig. 4.5B, closed 
squares) revealed a similar equilibrium unfolding profile observed for mRRM1 at the  
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Figure 4.5: The RRM domains of matrin-3 unfold in a two-state mechanism. A. The 
unfolding profiles of mRRM1 displays coincident CD (closed circles) and Tyr FL (open 
circles) transitions model to a two-state (N D U) mechanism. B. mRRM2 similarly does 
not populate a partially folded state by CD (closed squares). Trp FL (open squares) is 
insensitive to the unfolding of mRRM2 until high denaturant concentrations (>3 M Gdn-
HCl), suggesting the Trp may undergo FL quenching by sequence local sulfur-containing 
residues (332). C. Tethering the matrin-3 RRM domains (mtRRMs) results in a single 
cooperative transition by CD (closed diamonds) at higher denaturant than each isolated 
domain. In a similar manner as mRRM2, the Trp FL (open diamonds) is insensitive to the 
unfolding of mtRRMs. 
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same protein concentration (Fig. 4.5A) with the population of the native and unfolded 
states. Fluorescence of the single Trp in mRRM2 (Fig. 4.4B, open squares) revealed that 
the Trp is insensitive to tertiary structure changes in mRRM2 at Gdn-HCl concentrations 
in the CD native baseline and transition regions (0 – 3 M Gdn-HCl). This insensitivity 
may arise through local and conformational quenching by the sequence local sulfur-
containing residues, cysteine and methionine, which have been shown to quench Trp FL 
(332, 333). At concentrations >3 M Gdn-HCl, the Trp FL intensity increases due to 
changing conditions of the solvent. Modeling of the CD equilibrium unfolding profile of 
mRRM2 to a two-state state mechanism (N D U) revealed a concentration dependence to 
the thermodynamics of mRRM2 unfolding (Table 4.2). These results further suggest that 
mRRM2 can self-associate in isolation from mRRM1 to form dimers as was shown by 
size exclusion chromatography (Fig. 4.2, blue). Gdn-HCl titrations at a series of protein 
concentrations (Fig. 4.6A and 4.6B) revealed that the midpoint increased from 1.80 ± 
0.04 M to 2.30 ± 0.03 M Gdn-HCl, with similar changes in the proposed m-values (3 µM: 
1.77 ± 0.05 kcal mol-1 M-1; 12 µM: 2.31 ± 0.03 kcal mol-1 M-1, Table 4.2), suggesting a 
burial of surface area at increased concentrations. CD spectra of mRRM2 at increasing 
concentrations (Fig. 4.6C) did not reveal any significant changes in secondary structure 
changes at concentrations ranging from 4 to 16 uM, suggesting that the mRRM2 
monomer and dimer are indistinguishable by this technique. As the population of the 
dimeric mRRM2 is small by size exclusion chromatography (Fig. 4.2, blue), the 
monomer is likely the predominate species at equilibrium during these experiments. 
Thus, the stability of the mRRM2 monomer is less than or equal to the stability obtained  
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Figure 4.6: Concentration dependent unfolding of mRRM2. A-B. Equilibrium 
unfolding profiles of the CD signal (B) and fraction apparent unfolded (C) of 3 µM 
(circles), 6 µM (squares) and 12 µM (diamonds) mRRM2 as a function of denaturant 
modeled to a two state mechanism (N D U) reveals shifted midpoints to higher 
denaturant concentrations and increased m-values with increasing total mRRM2 
concentration. A global fit to a N2 D 2M D 2U equilibrium revealed an increased 
stability as a direct result of the population of mRRM2 dimers. C. CD spectra of 
increasing concentrations of mRRM2 suggest the monomer and dimer of mRRM2 are 
indistinguishable. 
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at 3 µM (3.19 ± 0.12 kcal mol-1). However, equilibrium unfolding data at nanomolar 
concentrations would provide key insights into the dimerization of mRRM2.   
The dimerization of the small fraction of mRRM2 (Fig. 4.2B) would contribute 
significantly stability to native state of mRRM2. The differences in the native baselines at 
different mRRM2 protein concentrations (Fig. 4.6A and 4.6B) may provide insights into 
the mRRM2 monomer-dimer equilibrium. Global modeling of equilibrium unfolding 
profiles at all mRRM2 protein concentrations to a N2 D 2M D 2U unfolding mechanism 
resulted in a larger total m-value than obtained for mRRM1 (3.03 ± 0.06 kcal mol-1 M-1 
vs 1.93 ± 0.03 kcal mol-1 M-1, Table 4.1) suggesting there is significant burial of surface 
area upon mRRM2 dimerization. This dimerizaton provides substantial thermodynamic 
stability and results in a total free-energy in the absence of denaturant of 8.82 ± 0.15 kcal 
mol-1. Other techniques, such as anisotropy or ultracentrifugation, may provide insights 
into the dimerization status under similar conditions used in this study. 
 
Tethering the matrin-3 RRM domains results in stabilization and coincident RRM 
unfolding  
The equilibrium unfolding profile of mtRRMs by CD (Fig. 4.5C, closed 
diamonds) revealed a single cooperative transition with a higher midpoint (2.30 ± 0.02 
M) than either isolated domain at the same concentration. However, the ICC sequence in 
the isolated mRRM1 domain is absent, unlike in the tethered mtRRMs domain. This 
sequence may contribute additional thermodynamic stability in the isolated domain and 
shift the midpoint towards higher denaturant. The FL of the mtRRMs single Trp residue  
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Figure 4.7: Tethering stabilizes the matrin-3 RRM domains against denaturation. 
Fraction apparent plots of the mRRM1 CD (solid green line) and Tyr FL (dashed green 
line), mRRM2 (solid blue line) and mtRRMs (solid red line) equilibrium unfolding 
profiles. The near-coincident midpoints of mRRM1 CD and Tyr FL suggest a two-state 
unfolding mechanism for mRRM1. The shifted midpoint of mtRRMs (red) compared to 
mRRM1 (green) and mRRM2 (blue) alone suggest tethering stabilizes the two domains. 
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(Fig. 4.5C, open diamonds), which is present in mRRM2, behaves almost identically to 
the independent domain, suggesting that tethering does not impact the unfolding of this 
region. Size exclusion chromatography as well as equilibrium unfolding experiments at a 
series of protein concentrations indicate that mtRRMs is monomeric and lacks the protein 
concentration dependence observed in mRRM2 (Fig. 4.6). These observations coupled 
with the shifted midpoint suggest that interactions with mRRM1, whose local 
concentration exceeds mRRM2 of a different polypeptide chain, may impair or occlude 
mRRM2 dimerization. As a result, mtRRMs likely unfolds in a two state manner (N D 
U). Interestingly, the total free-energy of folding in the absence of denaturant (4.54 ± 
0.03 kcal mol-1) and the m-value (1.98 ± 0.01 kcal mol-1 M-1) from the N D U unfolding 
model are similar to those observed for mRRM1 (Table 4.1). The m-value for the 
mtRRMs is much lower than expected for a protein of ~200 amino acids (4.57 kcal mol-1 
M-1) and resembles the average m-value obtained from mRRM1 and mRRM2. These 
results suggest that the two RRM domains of matrin-3 may unfold coincidently when 
tethered (Table 4.1, Fig. 4.7). These results suggest the matrin-3 RRMs do not populate 
intermediate states on the equilibrium unfolding pathways, unlike FUS/TLS (Fig. 4.4) 
and TDP-43 (235). 
 
A1RRM2 populates an intermediate state like the FUS RRM and RRM2 of TDP-43 
 The unfolding profiles of A1RRM1 were well defined by a single transition by 
both CD and Trp FL (Fig. 4.8A) with coincident midpoints (1.34 ± 0.02 M). Thus, the  
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Figure 4.8: The hnRNP A1 RRM domains display complex equilibrium unfolding 
pathways. A. CD (open circles) and Trp FL (closed circles) unfolding profiles of 
A1RRM1 fit a two state (N D U) mechanism. B. A1RRM2 populates a state intermediate 
state (red arrow) by both CD (closed squares) and Tyr FL (open squares) and fits to a 
three state unfolding mechanism (N D I D U). C. Tethering the hnRNP A1 RRM 
domains (A1tRRMs) stabilizes A1RRM1 and increases the cooperativity of the CD 
(closed diamonds) and Trp FL (open diamonds) equilibrium profiles. Modeling to a three 
state (N D I D U) mechanism suggests that the A1tRRMs intermediate state (red arrow) 
may consist of the A1RRM1 unfolded and A1RRM2 intermediate states. 
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CD and Trp FL were globally modeled to a two-state transition (N D U) to obtain an m-
value of 2.74 ± 0.05 kcal mol-1 M-1 and free-energy in the absence of denaturant of 3.66 ± 
0.04 kcal mol-1 (Table 4.1). These results suggest that A1RRM1 populates only two 
species during the unfolding process, the native and unfolded states, with no stable 
intermediate, similar to RRM1 of TDP-43 (235). 
 The equilibrium unfolding profile of A1RRM2 occurs at low denaturant by both 
CD (Fig. 8B, closed squares) and Tyr FL intensity at 300 nm (Fig. 4.8B, open squares) 
with a break in cooperativity at 1.4 M Gdn-HCl by both techniques (Fig. 4.8B, red 
arrow). Unlike the case of RRM2 of TDP-43 with the Tyr FL loosely monitoring the N D 
I transition and being insensitive to the I D U transition (235), the Tyr FL of A1RRM2 is 
coincident to both the N D I and I D U transitions observed by CD. At high denaturant 
concentrations (>5 M Gdn-HCl) in the unfolded baseline, there is little change in the 
MRE signal suggestive of no change in secondary structure. However, the slope of the 
Tyr FL unfolded baseline is steeper than m-value of the I D U transition (Fig. 4.8B, open 
squares) and resembles the Trp FL observed in mRRM2 and mtRRMs (Fig. 4.5B and 
4.5C). This similarity suggests that local sequence or residual tertiary packing quenching 
of the three Tyr residues may occur in the I D U transition that that is relieved at higher 
denaturant concentrations upon population of the unfolded state. The total m-value and 
free-energy of unfolding are comparable to those obtained from A1RRM1 with an m-
value of 2.84 ± 0.05 kcal mol-1 M-1 and free-energy of unfolding of 3.86 ± 0.09 kcal mol-1 
(Table 4.1). The major difference between the unfolding profiles of A1RRM1 and 
A1RRM2, other than the presence of an intermediate state in A1RRM2, lies in the  
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Figure 4.9: Tethering stabilizes the RRM domains of hnRNP A1. A. Fraction 
apparent plots of the hnRNP A1 RRM equilibrium unfolding profiles monitored by CD. 
Tethering the RRM domains of hnRNPA1 (A1tRRMs, brown) increases the stability of 
the native state, potentially through interactions between the domains, which results in 
increased cooperativity of the first transition (N D I) with coincident unfolding of 
A1RRM1 and A1RRM2. The A1tRRMs intermediate (brown) overlays the I D U 
transition observed for A1RRM2 (purple) suggesting the A1RRM2 intermediate is 
maintained when tethered to A1RRM1. B. Fraction apparent plots of the FL emission 
from the single Trp in A1RRM1 in the isolated (A1RRM1 FL, orange) and tethered 
(A1tRRMs FL, brown) domains. Tethering A1RRM1 and A1RRM2 results in an 
increased cooperativity of A1RRM1 unfolding, similar to the cooperativity observed by 
CD (B, black), further supporting interaction between the domains that result in 
stabilization against denaturation.  
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midpoint of the N D U transition of A1RRM1 (1.34 ± 0.02 M) and the N D I transition 
of A1RRM2 (1.03 ± 0.05 M) (Table 4.1). These results suggest that the RRM domains of 
hnRNP A1 are similar to those of TDP-43, where RRM2 populates an intermediate state, 
unlike RRM1 (235). 
   
Tethering the A1tRRMs increase the cooperativity and quenches the A1RRM1 
tryptophan 
Unlike the matrin-3 RRM domains, which appear to unfold independently of each 
another, tethering the RRM domains of hnRNP A1 (A1tRRMs) influences both the CD 
and Trp FL native states. Interestingly, the Trp FL from the single Trp in A1RRM1 in the 
A1tRRMs is significantly quenched compared to the native state of the isolated A1RRM1 
suggesting A1RRM2 may favor conformations located near the Trp of A1RRM1. The 
CD unfolding profile of A1tRRMs (Fig. 4.8C, closed diamonds) retains the break in 
cooperativity observed in A1RRM2 and was modeled to a three-state equilibrium 
unfolding profile (N D I D U). The increase in the m-value of the N D I transition of 
A1tRRMs (3.21 ± 0.07 kcal mol-1 M-1) compared to the first transition of the isolated 
domains (Table 4.1), suggest that both A1RRM1 and A1RRM2 unfold at similar urea 
concentrations upon tethering.  
The A1tRRMs Trp FL profile (Fig. 4.8C, open diamonds) reveals similar 
midpoints and m-values to A1RRM1 alone (Cm: 1.15 ± 0.03 M, m-value: 2.70 ± 0.02 
kcal mol-1 M-1) (Fig. 4.9A). These results suggest that tethering the RRM domains of 
hnRNP A1 does not significantly affect the tertiary structure of A1RRM1 and continues 
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to unfold in a two-state manner in the presence of A1RRM2. However, in comparison to 
the isolated A1RRM2, the midpoint of the N D I transition of A1tRRMs is shifted 
towards higher denaturant (Fig. 4.9B) suggesting tethering the A1RRM domains 
stabilizes A1RRM2 (Table 1). Indeed, NMR studies on this construct have proposed 
inter-domain interactions that are critical for the correct orientation of the hnRNP A1 
RRM domains for RNA recognition (330). The coincident Trp FL and N D I transition 
by CD for A1tRRMs suggest that A1RRM1 and A1RRM2 populate their unfolded and 
intermediate states, respectively, at the break in cooperativity at ~2 M Gdn-HCl (Fig. 
4.8C, red arrow). A fraction apparent unfolded plot of the three hnRNP A1 constructs 
(Fig. 4.8B) reveals overlapping profiles between the I D U transitions of A1tRRMs and 
A1RRM2, supporting the A1RRM2 intermediate as the same intermediate observed in 
A1tRRMs. These results suggest that tethering the two hnRNP A1 RRM domains 
provides a significant stabilization of the native state of A1RRM2. 
 
The FUS RRM and A1RRM2 significantly populate their intermediates under native 
conditions 
 Using the thermodynamic parameters derived from the three-state equilibrium 
models, the population of the intermediate state at any given concentration of Gdn-HCl 
was determined as shown previously (Fig. 4.10). The FUS RRM (Fig. 4.10, cyan) and 
A1RRM2 (Fig. 4.10, purple) intermediates comprises >70% of the population at their 
maximum populations of Gdn-HCl, similar to RRM2 of TDP-43 (Fig. 4.10, black). 
Furthermore, these domains sample this conformation 2.3% and 1.7% of time at  
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Figure 4.10. The FUS RRM and A1RRM2 significantly populate their respective 
intermediates under native conditions. Population of the intermediate state as a 
function of denaturant derived from the thermodynamic parameters obtained from the 
three-state (N D I D U) model of the unfolding of the FUS RRM (cyan), A1RRM2 
(purple) and A1tRRMs (brown). The FUS RRM and isolated A1RRM2 domains 
significantly populate their respective intermediate states under native conditions, in a 
similar as RRM2 of TDP-43 (black). 
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equilibrium under native conditions and may enhance misfolding of their respective 
proteins (Table 4.3). RRM2 of TDP-43 samples its intermediate <1% under native 
conditions (Table 4.3), but is enhanced by temperature or cleavage (235). In the case of 
hnRNP A1 and TDP-43, tethering their respective RRM1 domains dramatically reduces 
the population of this partially-folded state, potentially through stabilizing interactions 
between the RRM domains, that prevent the access to a potentially pathogenic 
conformation. While FUS/TLS contains a single RRM domain, the other nearby RBDs, 
such as the RGG-boxes and ZnF, may contribute to the stability of the FUS RRM. 
 
Tethering enhances the RNA-binding affinity of matrin-3 and hnRNP A1  
All of the proteins involved in this study have been associated with multiple roles 
in RNA regulation, including splicing, transcription and nuclear mRNA retention. Thus, 
the ability of these RRM domains to bind to RNA likely plays an important role in 
stabilizing these RRM domains against the population of non-native conformations. 
Through the use of the electromobility gel shift assay (EMSA), the binding affinity was 
measured of each isolated and tethered RRM domain constructs for sequences, previously 
identified from RNA immunoprecipation (RIP), crosslinksing (FUS) or enrichment in 3’-
UTRs upon knockdown. The FUS RRM bound weakly to its consensus sequence (Fig. 
4.11, Table 4.4), supporting the evidence that a bulk of the RNA binding activity may be 
supplied from the adjacent RGG-motifs and ZnF (Fig. 4.1A) (227, 325), in a similar 
manner as RRM1 in TDP-43 (73, 235). For the isolated RRM domains of matrin-3 and 
hnRNP A1, mRRM2 and A1RRM1 bind with a greater affinity (mRRM2: 3980 ± 360  
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Figure 4.11: The tethered matrin-3 RRM domains bind RNA in a highly cooperative 
manner. A. EMSA assay of the FUS RRM, mtRRMs and A1tRRMs to their respective 
RNA sequences, shown below the EMSA assay. Assay was performed by titration of 
increasing protein concentration to a fixed concentration of fluorescently-labeled RNA. 
B. Quantification of the EMSA assay using the Hill equation. The FUS RRM (cyan) has 
weak RNA binding (>8 µM) while the tethered matrin-3 (red) and hnRNP A1 (brown) 
RRM domains display nM apparent binding affinities. 
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nM, A1RRM1: 1840 ± 1200 nM) than their counterparts (Fig. 4.11, Table 4.4). However, 
evidence has suggested that multiple RRM domains in tandem enhances affinity 
significantly compared to a single motif (334). Indeed, tethering the RRM domains of 
matrin-3 and hnRNP A1 result in an increase of RNA-binding affinity by more than 2 
orders of magnitude compared to the isolated domains (Table 4.4). Interestingly, the Hill 
coefficient of the mtRRMs is larger (2.9 ± 0.4) than those obtained for the other domains 
(1.1 ± 0.1) suggesting the tethering of the matrin-3 RRM increases the cooperativity of 
the interaction with RNA (Table 4.4). These results suggest that the isolated RRMs bind 
relatively weakly to known RNA targets, while tethering the matrin-3 and hnRNP A1 
RRM domains enhances this affinity. Thus, RNA will contribute folding and misfolding 
energy landscapes of the ALS-linked RNA-binding species and modulate the population 
of partially-folded and unfolded species. 
 
Discussion 
 Single point mutations, deletions and RNA repeat expansions have been identified 
in numerous genes as contributors to the neurodegenerative disease, ALS (53). These 
genes encode for proteins with drastically different domain architectures and structures, 
however, the functional roles of these genes are widely variable (30, 49, 51, 52, 54, 55, 
300, 305, 306, 335–343). Cytoplasmic inclusions of the RNA-binding protein, TDP-43, 
have been observed in large proportions of ALS and FTLD patients (30, 49, 53), 
regardless of the presence of mutations. Since 2006 (30, 49), mutations in other RNA-
binding proteins, including FUS/TLS (51) and its homologs EWSR1 (338) and TAF15 
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(51), matrin-3 (305) and hnRNP A1 and A2/B1 (306) have also been identified as 
causative of neurodegeneration. Biophysical experiments on the RRM domains of TDP-
43 revealed the RRM2 domain populates an equilibrium intermediate state on its free-
energy landscape (235) that may serve either a productive or non-productive role in 
normal TDP-43 function. As all of the RNA-binding proteins associated with ALS 
contain at least one RRM domain, we investigated whether the RRM domains of 
FUS/TLS, matrin-3 and hnRNP A1 populate complex unfolding pathways in a similar 
manner as TDP-43. Indeed, intermediate states were identified for the FUS RRM and the 
RRM2 domain of hnRNP A1, but not in either RRM domain of matrin-3. These results 
suggest that the common feature between the subset of ALS proteins with glycine-rich 
domains is an RRM domain, which populates an intermediate state, located directly 
adjacent to a prion-like domain. 
 Inclusions of TDP-43 and ALS variants of FUS/TLS and hnRNP A1 accumulate 
in the cytoplasm of affected neurons in ALS patients (30, 44, 49, 306). Numerous studies 
on the aggregation and toxicity determinants of TDP-43 and FUS/TLS have implicated a 
role for a combination of RRM domains and prion-like sequences in the propagation of 
neurodegeneration phenotypes, as both the RRM domains or the prion-like regions alone 
do not confer toxicity (138–141, 328). Prion-like domains (PLD) normally mediate 
protein-protein interactions during transcription, splicing, microRNA biogenesis, stress 
granule formation and other RNA processes (82, 83, 87, 237, 312, 344, 345). However, 
recent findings on FUS/TLS and hnRNP A1 indicate the prion-like domains are sufficient 
to reversibly phase transition into liquid-like RNP granules (280–284). Several studies 
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have observed that prolonged exposure of full-length FUS/TLS and hnRNP A1 to the 
phase transition stimulus, such as temperature, protein or RNA concentration or ionic 
strength, results in the conversion of these liquid-like droplets to fibrillar-like aggregates 
(280, 282, 284). These aggregates are potentially a direct result of the increased local 
concentration of the proteins within these droplets, where small populations of misfolded 
conformations could lead to irreversible assemblies. Indeed, ALS-inducing mutations in 
the prion-like domains of these proteins have been shown to increase the formation of 
these irreversible structures (284), suggesting these substitutions may bias the dynamics 
of the PLD to favor pathological conformations. Interestingly, ALS-mutations only seem 
to enhance the conversion to fibrillar-like species, as the WT FUS/TLS and hnRNP A1 
sequences are sufficient for the formation of these species (280–284).  
In TDP-43, FUS/TLS and hnRNP A1, the prion-like domain is directly adjacent 
to an RRM domain that has been shown to populate partially folded states on their 
equilibrium unfolding profiles. Extrapolating to native conditions revealed that RRM2 of 
TDP-43, the FUS RRM and A1RRM2 populate their respective intermediate states >1% 
of the time at equilibrium (Table 4.3). While low in frequency, assimilation into liquid-
like droplets would greatly increase the local concentration of these partially-folded states 
and enhance their probability of templating misfolded conformations. These non-native 
states could interact with and stabilize the fibrillar-like structures of the prion-like 
domains through exposed hydrophobic surfaces in the RRM domains. These 
intermediates states, particularly in the FUS RRM and RRM2 of TDP-43, may serve a 
functional role in nucleocytoplasmic transport through the exposure of a leucine-rich 
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NES sequence (224) in these domains (Fig. 4.1A). Both FUS/TLS and TDP-43 have 
cytoplasmic functions (44, 233) and the population of this partially-folded state may 
serve as a prerequisite for transport. Interestingly, tethering the RRM domains of TDP-43 
(235) and hnRNP A1 (A1tRRMs) reduces the population of their respective RRM2 
intermediate species to less than 0.1% (Fig. 4.8C, Table 4.3). There has yet to be 
evidence of hnRNP A1 cleavage in neurodegeneration that would result in the removal of 
A1RRM1, unlike TDP-43 where C-terminal fragments containing only RRM2 and the C-
terminus accumulate in patient samples (49). The absence of cleavage events would 
further reduce the population of the A1RRM2 intermediate and mitigate another avenue 
for potential toxic conformations in hnRNP A1. 
Furthermore, RNA-binding would further stabilize the RRM domains against 
unfolding and misfolding. In each protein, the isolated RRM domains bind with apparent 
binding affinities in the 5 – 15 µM range (Fig. 4.11, Table 4.4). These results differ from 
those obtained for TDP-43 where RRM1 binds with nM affinity (73, 81, 235) and is 
sufficient for proper TDP-43 function (RRM2 is dispensible) (228, 229). Tethering the 
RRM domains of matrin-3 and hnRNP A1 enhanced the affinity by an order of 
magnitude but the Hill-coefficient of >1 for mtRRMs suggests the multiple mtRRMs can 
bind the same RNA (Table 4.4). This observation was not observed for hnRNP A1 or 
TDP-43. However, this suggestion is reminiscent of the formation of the liquid-like 
droplets by FUS/TLS and hnRNP A1 where RNA facilitated the phase transition by 
allowing the binding of multiple RNA-binding proteins per RNA molecule (282). 
Therefore, the RNA-binding capabilities of these proteins would play a critical role in 
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preventing misfolding. Interestingly, the RNA binding activity of TDP-43 is required for 
neuronal toxicity (346) suggesting RNA may serve a dual purpose in stabilizing the RRM 
domains, while simultaneously providing a scaffold for the assembly of RNP granules. 
Other members of the FUS/TLS and hnRNP A1 families have been implicated as 
potential causes of neurodegeneration and include the EWSR1, TAF15 and hnRNP 
A2/B1 proteins (306, 337, 338). The RRM domains of these family members show an 
85% similarity between the RRM domains of TAF15, EWSR and the FUS RRM, while 
RRM1 and RRM2 of hnRNP A2/B1 are 92% and 94% similar compared to A1RRM1 
and A1RRM2 (347). This high sequence homology may suggest similar unfolding energy 
landscapes between the RRM domains of these family members. The TAF15 and 
EWSR1 RRM domains may show a dynamic native state with a highly populated 
intermediate state in a similar manner as the FUS RRM (Fig. 4.4). RRM1 and RRM2 of 
hnRNP A2/B1 may exhibit two-state and three-state behavior, like their hnRNP A1 
counterparts (Fig. 4.8). Together, these results suggest that TDP-43 and the FUS/TLS and 
hnRNP A1 families may exert toxicity through partially-folded states in their RRM 
domains in combination with misfolded conformations in their PLDs. 
Matrin-3 is unique compared the other three RRM-containing proteins, including 
its domain architecture (Fig. 4.1), with two C2H2-type zinc fingers flanking the tandem 
RRM domains and no discernible PLD (348, 349). While the other proteins are linked to 
various aspects of mRNA processing (44, 78, 320, 350–353), matrin-3 is known to bind 
to matrix and scaffold attachment regions (M/SAR) (354) and function in DNA damage 
response (355), the retention of hyper-edited RNA (322, 356) and euchromatin 
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organization (357). This protein is known to self-associate into interconnecting fibrils for 
normal function (307), but the mechanism through which this oligomerization is achieved 
is not well understood. ALS-inducing mutations do not affect the nuclear localization of 
matrin-3 or form cytoplasmic aggregates (358). Interestingly, each of the RRM domains 
of matrin-3 (mRRM1 and mRRM2) unfolds through a simple two-state mechanism (N D 
U) without significantly populating stable equilibrium intermediates (Fig. 4.5). These 
results are unlike those obtained for TDP-43 (235), FUS/TLS (Fig. 4.4) and hnRNP A1 
(Fig. 4.8), where one RRM domain populates an intermediate state: RRM2 in TDP-43, 
the FUS RRM and A1RRM2. Therefore, neurodegeneration may occur through an 
alternative mechanism for matrin-3 rather than potential RRM-PLD aggregation-induced 
impairment of normal function. Indeed, the matrin-3 RRM domains contain an additional 
structural element in the form of a C-terminal interacting coil (ICC) motif that suggests 
matrin-3 has evolved differently than other RNA-binding proteins containing classical 
βαβ-repeat RRM domains (331). 
In a vast majority of ALS cases, the WT sequence of TDP-43 is sufficient for 
aggregate formation and disease pathogenesis (53). Mutations in TDP-43 have an array 
of effects on normal protein function and aggregation propensity (35, 57, 80, 83, 153, 
359–361). However, contributions from WT FUS/TLS and hnRNP A1 in aggregation and 
toxicity have yet to be found in patient samples. Why does the WT TDP-43 sequence, but 
not the FUS/TLS and hnRNP A1 sequences, initiate neurodegeneration? Could WT TDP-
43 be recruited by another nucleating species? The answer may arise through differences 
in the RRM domains as all three proteins contain PLDs that are required for normal  
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Figure 4.12: ILV contact maps of the RRM domains of FUS/TLS, matrin-3 and 
hnRNPA1. A-E. Contacts between isoleucine (I), leucine (L) and valine (V) residues 
(221, 222, 362) mapped to their secondary structure elements (left) and NMR structures 
(right) for FUS RRM (A, pdb: 2la6), mRRM1 (B, pdb: 1x4d), mRRM2 (C, pdb:1x4f), 
A1RRM1 and A1RRM2 (D-E, pdb: 1up1). Each domain consists of a single cluster 
(blue) that spans all regions of the RRM domain topology. The FUS RRM also contains a 
nuclear export sequence (NES, yellow), whose 4 hydrophobic residues contribute to the 
overall formation of the native state cluster (A). mRRM2 contains a single contact (L598-
V551) outside of the major cluster that may assist in docking α2 to the β-sheet of this 
domain. 
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protein function. The hydrophobic clusters of isoleucine, leucine and valine (ILV) 
residues, for each isolated RRM domain from TDP-43 (235), FUS RRM, matrin-3 and 
hnRNP A1 is shown in Figure 4.12. Previous work indicates that clusters of ILV residues 
play critical roles in the formation of cores of stability and stabilize partially-folded states 
(219, 221, 222, 362). In the case of the RRM domains, these partially-folded states may 
serve to minimize the conformational search to the native state or expose hydrophobic 
surfaces during misfolding events. Interestingly, the ILV clusters of the intermediate 
containing RRM domains (TDP-43 RRM2, FUS RRM and A1RRM2) reveal a larger 
number of contacts (Fig. 4.12, blue dashed lines) than ILV residues (Table 4.5). These 
results suggest that these highly networked clusters may serve to stabilize the formation 
of the RRM intermediate states (235) and provide a stable platform for templating 
misfolding and aggregation. The stabilities of the FUS RRM and A1RRM2 intermediates 
(2.44 kcal mol-1 and 1.48 kcal mol-1, respectively) suggests these domains may lack 
sufficient stability for misfolding and aggregation like their TDP-43 counterpart. Overall, 
the highly networked ILV cluster of the RRM2 of TDP-43 may provide insights into the 
role the WT TDP-43 sequence plays in normal function and neurodegeneration. 
The thermodynamic study on the equilibrium unfolding and RNA-binding of the 
RRM domains of FUS/TLS, matrin-3 and hnRNP A1, in combination with those obtained 
for TDP-43 (235) suggest a common mechanism for the initiation and propagation of 
neurodegeneration. In the cases of TDP-43, FUS/TLS and hnRNP A1, non-native or 
aberrant interactions between the intermediate-containing RRM domains and the adjacent 
PLD may result in a pool of misfolded proteins. These non-functional species would 
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reduce the concentration of functional RNA-binding proteins and subsequently lead to 
neurotoxicity and cell death. 
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Chapter V – Thermodynamic and Functional Consequences of the RRM2 
Intermediate State in TDP-43 via ILV Cluster Mutagenesis 
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Abstract 
 TDP-43 is a ubiquitously expressed nuclear RNA-binding protein with roles in 
multiple layers of RNA processing. In the neurodegenerative diseases, amyotrophic 
lateral sclerosis and frontotemporal dementia, TDP-43 is mislocalized to cytoplasm in the 
form of insoluble inclusions. The identification of missense mutations suggest a causative 
role for this RNA-binding protein in neurodegeneration. Thermodynamic studies on 
TDP-43 revealed an intermediate state in RRM2 that may have implications for the 
function and misfolding of TDP-43. Here, alanine mutagenesis of the isoleucine, leucine 
and valine (ILV) cluster identified several variants, which increase the population of the 
RRM2 intermediate in vitro in the isolated domain. All mutants examined were 
destabilized compared to the wild-type RRM2 domain and, in some cases, disrupted the 
RNA-binding capability of RRM1. Several mutants, inserted into full-length TDP-43 
tagged with EGFP or mCherry, display altered cellular localization in stable HEK 293 
cells compared to wild-type, a phenomenon also observed for ALS-inducing mutants and 
a TDP-43 C-terminal fragment identified from patient tissues. Initial fluorescence 
correlation spectroscopy studies in vitro using purified TDP-43 – GFP fusions revealed a 
larger inherent aggregation propensity for a TDP-43 C-terminal fragment compared to 
the full – length protein. These results indicate that enhanced populations of the RRM2 
intermediate state of TDP-43 may show similar cellular phenotypes as ALS-inducing 
mutations. These ILV mutants may serve as potential biomarkers for the development of 
antibodies or small molecule therapies targeting this non-native conformation in TDP-43 
in neurodegeneration. 
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Introduction 
 A majority of Amyotrophic Lateral Sclerosis (ALS) cases and proportions of 
other neurodegenerative diseases, including frontotemporal lobar dementia (FTLD), 
Parkinson’s and Alzheimer’s Disease, have been attributed to the RNA-binding protein, 
TAR DNA-binding protein of 43 kDa (TDP-43) (30, 49, 53, 363–366). The cross-
spectrum applicability of TDP-43 to multiple neurodegenerative diseases may implicate a 
common mechanism for TDP-43-mediated disease toxicity (30, 49). Over 95% of all 
ALS cases have reported the accumulation of mislocalized hyperphosphorylated and 
ubiquitinated TDP-43 inclusions in disease patient tissue samples (53). However, only 
small percentages of inheritable ALS (familial ALS, fALS) and sporadic ALS (sALS) 
result from dominant mutations in the TARDBP gene (57). Misfolded conformations of 
the wild-type protein may serve as platforms for the propagation of toxicity through both 
loss-of-function and gain-of-function phenotypes (79, 181, 183). ALS-mutations in TDP-
43 may shift the equilibrium to further enhance the populations of these misfolded states 
that lead to neurodegeneration, as has been shown for misfolding systems including, 
superoxide dismutase I (SOD1) (103, 106), transthyretin (TTR) (88, 90) and β-
microglobulin (93) among others (11, 38, 39, 41, 42).  
 TDP-43 is a ubiquitously expressed nuclear RNA-binding protein (Fig. 5.1A) 
with involvement in numerous aspects of RNA biology including pre-mRNA splicing, 
microRNA biogenesis and mRNA translational regulation (44, 78, 79). TDP-43 
selectively targets UG-rich sequences through its two RNA-recognition motifs (Fig. 
5.1A, RRM1 and RRM2) with high affinity (72–74, 235), while its N-terminal domain 
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(NTD) is well-folded in an axin 1-like topology (75) and mediates protein 
oligomerization (76, 77). The disordered prion-like C-terminus (Fig. 5.1A, orange) is 
critical for interactions with other splicing factors, the microRNA machinery and its own 
regulation (78, 80, 82, 83, 86, 87, 255, 367, 368). ALS-mutations cluster within the C-
terminus (http://alsod.iop.kcl.ac.uk) with only two mutations located elsewhere in the 
sequence: A90V in the nuclear localization sequence (Fig. 5.1A, purple) and D169G in 
RRM1 (48). ALS-inducing mutations have varying and opposing effects on the 
functional aspects of TDP-43 including altered half-life (153, 359–361), aggregation and 
fragmentation propensity (35, 57, 369) and splicing capabilities (84, 154). However, 
TDP-43 mutants can have wild-type (WT) splicing activities and interactions with 
hnRNP A1 and A2/B1 (82). Furthermore, the C-terminus has been identified as a prion-
like domain with multiple glutamine/asparagine (Q/N)-rich segments that are both critical 
for protein-protein interactions as well as TDP-43 self-association (84, 85, 274, 370–
372). Indeed, evidence from multiple cell culture and animal models suggests that the C-
terminus and the RRM domains are critical for increased toxicity (138–141). Intriguingly, 
the expression of the C-terminus alone does not display this phenotype but tethering 
either the intact or a disease-related fragment of RRM2 drastically increases the 
aggregation propensity and toxic effects of TDP-43. These results suggest interplay 
between the disordered C-terminus and the structured RRM domains of TDP-43 may 
play a critical role in mediating the dysfunction of TDP-43 in neurodegeneration. 
Equilibrium unfolding studies on the RRM domains of TDP-43 revealed a highly 
populated folding intermediate in the second RRM (RRM2) that may play a role in 
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normal TDP-43 function or misfolding and aggregation observed in disease (235). A 
majority of ALS patients with cytoplasmic TDP-43 inclusions lack mutations in the 
TARDBP gene, and the wild-type protein is sufficient for disease pathogenesis (53). 
These results suggest that the RRM2 intermediate state may play a role in mediating 
misfolding and disease, in addition to its normal functions. Insights into the structure of 
the RRM2 intermediate revealed that the C-terminal half of RRM2, containing the NES, 
lacks definitive secondary structure suggesting this region is exposed in the intermediate 
state (Chapter III). However, the functional and dysfunctional consequences of 
populating the RRM2 intermediate state are not well understood. This partially-folded 
state may serve a functional role through exposure of a nuclear export sequence (NES) 
(Fig. 1A, yellow, 239-IAQSLCGEDLII-250) for recognition in cytoplasmic transport 
(224). Indeed, alanine mutagenesis of the key hydrophobic residues in this segment 
resulted in a lack of cytoplasmic TDP-43 and the accumulation of nuclear aggregates 
containing both mutant and endogenous TDP-43 (225). Furthermore, this state may serve 
to template misfolding through exposed hydrophobic surfaces and aggregation prone 
sequences, such as β3 and β5 (152), that could interact with the prion-like C-terminus 
(151, 152, 373), RRM1 (205, 206, 217, 273, 374), truncated RRM2 (151, 214) or other 
proteins (82, 83, 86) to propagate aggregation observed in neurodegenerative disease. 
Here, alanine mutations in the isoleucine, leucine and valine (ILV) cluster of the 
isolated RRM2 domain were used as a tool to enhance the population of the intermediate 
state and identify effects on TDP-43 folding and function. All RRM2 mutants examined 
were classified into two classes: two-state mutations (Group I) and those, which retain the 
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RRM2 intermediate (Group II). These mutants have the possibility to disrupt the RNA-
binding capabilities of the isolated RRM domains, and show similar localization to ALS 
disease variants in the full-length protein. A C-terminal fragment of TDP-43 (residues 
208-414)(49) was shown as inherently more aggregation prone than the full-length 
protein, likely a result of loss of the N-terminus of TDP-43, including the NTD and 
RRM1, and the exposure of hydrophobic surfaces upon the removal of β1 in RRM2 
(Chapter II) that may drive aggregation in combination with the glycine-rich C-terminus. 
These results suggest that the intermediate state in RRM2 may alter the conformations of 
TDP-43 to enhance the aggregation of propensity of the full-length TDP-43 and impact 
the normal function of this protein leading to eventual neurodegeneration. 
 
Materials and Methods 
Construct Construction  
 Mutations in the hydrophobic isoleucine, leucine and valine (ILV) clusters of the 
isolated (Fig. 5.1B) and tethered RRM2 domain were guided by an in-house software 
(http://biotools.umassmed.edu/ccss/ccssv2/basic.cgi) (221, 222, 362) that calculates the 
contact surface area between residue side chains. ILV to alanine (A) mutations were 
inserted into the WT isolated (residues 193 – 261) and the RRM1 tethered (tRRMs: 
residues 97 – 261) RRM2 domain in a modified pGEX-6p1 vector (235) using the 
QuickChange method (Stratagene) and verified through Sanger Sequencing (Genewiz). 
The following mutations were inserted into the isolated RRM2 domain as mapped to the 
NMR structure (pdb: 1wf0): V195A (Fig. 5.1B, red), V217A (Fig. 5.1B, orange), V220A 
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(Fig. 5.1B, dark green), V232A (Fig. 5.1B, green), I239A (Fig. 5.1B, cyan), L243A (Fig. 
5.1B, blue), L248A (Fig. 5.1B, dark blue), I250A (Fig. 5.1B, pink), I253A (Fig. 5.1B, 
purple) and I257A (Fig. 5.1B, brown). The following complementary mutations were 
inserted into RRM2 in the context of the RRM1-RRM2 tethered domain with the natural 
amino acid linker: V195A, V232A and I257A. All constructs have an N-terminal 
hexahistidine (His6) tag with a PreScission protease cleavage site (LEVLFQ/GP) to aid in 
protein isolation. 
 Constructs containing the full-length TDP-43 sequence (residues 1 – 414), a C-
terminal fragment (residues 208-414) and enhanced green fluorescent protein (EGFP) 
were cloned into a modified pGS-21a vector (222) with N-terminal His6 and PreScission 
protease cleavage sequences. The full-length and C-terminal TDP-43 sequences were 
cloned with a C-terminal EGFP fluorescent tag. All EGFP constructs contain the A206K 
mutation to limit its dimerization capabilities (375).  
 
Protein Purification 
 All mutant RRM2 and tRRMs proteins were transformed into BL21 DE3 PlysS E. 
coli for protein expression after induction at 30°C (RRM2) or 20°C (tRRMs) by 1 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 16-20 hours. Purified protein was 
isolated as previously described (235) using metal-affinity chromatography followed by 
PreScission protease digestion and Q sepharose ion exchange chromatography. All 
proteins purity was >95 % as indicated by SDS-PAGE. Protein concentration was 
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measured by A280 absorbance (192), using an extinction coefficient of 15,470 M-1 cm-1 for 
tRRMs and 1490 M-1 cm-1 for RRM2 mutant constructs.   
 Fluorescently-tagged WT and C-terminal TDP-43 constructs were transformed 
into BL21 DE3 E. coli and expressed using 1 mM IPTG at 20°C for 16-20 hours. The 
recombinant proteins were isolated from the insoluble fraction by the addition of 6 M 
urea to the lysis buffer for purification by metal affinity chromatography (235). Proteins 
were refolded into working buffer (10 mM KPi pH 7.2, 150 mM KCl, 1 mM BME) prior 
to experimentation. Protein concentration was determined by the EGFP absorbance at 
488 nm using the extinction coefficient of 61,000 M-1 cm-1. 
 
Equilibrium Unfolding Experiments 
The native-state circular dichroism (CD) spectrum of each mutant in the isolated 
RRM2 construct was collected from 200-280 nm on a Jasco-810 spectropolarimeter with 
a thermoelectric temperature control system in a 0.1 cm cuvette (Hellma). Guanidine 
hydrochloride (Gdn-HCl)-induced denaturation spectra were collected from 260-215 nm 
at a scan rate of 50 nm min-1 and a response time of 8 s for each isolated RRM2 mutant. 
Samples were prepared as previously described (235). All Gdn-HCl concentrations were 
measured using an ABBE Refractometer, and all CD measurements were baseline 
corrected for buffer contributions. Each CD spectra was normalized for protein 
concentration and number of amino acids and reported as mean residue ellipticity (MRE) 
(193). Steady-state fluorescence (FL) measurements were performed on a Spex 
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Fluorolog-3 equipped with a wavelength electronics temperature controller for the 
isolated RRM2 constructs as previously described (235).  
 Denaturation experiments by CD and FL were performed in triplicate for each 
mutant. The equilibrium folding data were analyzed using an appropriate equilibrium 
folding model with the in-house data analysis software Savuka (194) as shown 
previously. Each data set was subjected to a global analysis, where the baselines were 
local parameters and the free-energy of folding in the absence of denaturant (ΔG°H2O) and 
the m-value were globally linked between data sets. 
 
Nucleic Acid Binding Experiments 
 Electromobility Gel Shift Assays (EMSA) were used to determine the effect of 
ILV mutations on the apparent RNA binding affinity in the context of RRM1 using the 
tRRMs construct and a UGUGUGUGUGUG (UG)6 RNA sequence as previously 
described (235). In short, increasing concentrations of WT or mutant tRRMs proteins (up 
to 2 µM) were incubated with 3 nM FAM-labeled UG6 in reaction buffer for 2 hours at 
room temperature. The bound and unbound species were separated using an 8% 
polyacrylamide gel, quantified using the Multi Gauge Software (Fujifilm) and modeled to 
the quadratic RNA-binding equation (198). The apparent RNA binding affinities (Kd,app) 
were converted to thermodynamic stability (ΔG° = -RT ln (Kd,app)) and compared to the 
WT tRRMs binding affinity to obtain the effect of the mutation on the RNA binding 
capabilities of the tRRMs construct in terms of ΔΔG°. 
 
 190 
Fluorescence Correlation Spectroscopy of full-length and fragmented TDP-43 in vitro 
FCS measurements of full-length TDP-43, a C-terminal fragment and EGFP were 
acquired using a custom FCS setup (Single Molecule Facility, UMass Medical School). A 
96-well glass bottom plate (Greiner) containing 5 nM refolded EGFP-tagged proteins was 
excited using a 488 nm laser at 0.5 mW power through a 60X, 1.2 N.A. water immersion 
objective lens (Olympus UPlanSApo). The in-house custom FCS setup is equipped with a 
plate reader for accurate coverslip/plate and objective positioning and a pinhole to define 
the confocal volume. In-house software is used to position the confocal volume 20-30 µm 
above the coverslip during the course of the FCS experiment. The size of the confocal 
volume was determined using 1 nM Alexa 488. The EGFP fluorescence is passed through 
a 525 ± 20 nm bandpass filter prior to detection of the fluorescence fluctuations using the 
sing an idQuantique id100-50 single-photon avalanche photodiode (SPAD) and SPC-150 
counting card (Becker & Hickl). The FCS autocorrelation function, G(τ), was calculated 
using the Burst Analyzer software (Becker & Hickl) or the in-house software, Savuka 
(194), and fit to a double autocorrelation model (376). 
 
Stable Cell Line Creation 
 Stable cell lines for the inducible expression of full-length TDP-43 and its 
variants and fragments were created using Flp-In™ HEK-293 cells (Thermo Scientific). 
The cells were transfected using lipofectamine 2000 (Thermo Scientific) according to the 
manufacturers’ instructions with the pOG44 and pcDNA5/FRT vectors (Thermo 
Scientific). The pcDNA5/FRT vector contains the full-length or fragmented TDP-43 gene 
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with N-terminal FLAG, C-terminal myc and either a monomeric (A206K) enhanced 
green fluorescent protein (EGFP) or mCherry fluorescent tags. HEK-293 cells with 
successful incorporation of the TDP-43 gene were selected by the addition of 100 µg mL-
1 hygromycin B to the Dulbecco’s Modified Eagles growth Medium (DMEM) 
supplemented with 10% FBS. TDP-43 protein expression was initiated by the addition of 
1 µg mL-1 tetracycline (Sigma-Aldrich) and observed through confocal microscopy using 
a Leica TCS SP5 Confocal Scanning microscope at UMass Medical School. The nucleus 
was observed through DAPI nuclear staining using a 405 nm laser with EGFP or 
mCherry expression monitored through a 488 nm or a 540 nm laser with the appropriate 
emission filters. 
 
Results 
Mutation of the ILV cluster drastically alters the secondary structure of RRM2 
 In the equilibrium unfolding experiments, the isolated RRM2 domain of TDP-43 
significantly populates an intermediate or partially-unfolded state prior to complete 
unfolding at >7 M Gdn-HCl (235). However, the role of this intermediate in the normal 
localization and function of this RNA-binding protein is unknown. Previously, RRM2 
was shown to have a large central cluster of the hydrophobic residues, isoleucine, leucine 
and valine (ILV) in the core of this small, 80-amino acid (β-α-β)-repeat domain. 
Hydrogen exchange data on other repeat proteins including the TIM barrel (219–221) and 
CheY protein families (222, 362) suggest that large clusters of ILV residues form earliest  
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Figure 5.1: Domain Architecture and RRM2 Mutants of TDP-43. A. TDP-43 is a 
nuclear 414 amino acid RNA-binding protein consisting of two RNA-recognition motifs 
(RRM1, green and RRM2, blue), a well-folded N-terminal axin 1-like domain (NTD, red) 
and a disordered C-terminus (glycine-rich region, orange). A nuclear localization 
sequence (NLS, purple) and nuclear export sequence (NES, yellow) suggest both nuclear 
and cytoplasmic functions. ALS-inducing mutations predominately cluster in the glycine-
rich region (asterisks,*). The C-terminal mutations listed, G298C, A315T, Q331K and 
M337V, were used in stable line creation. B. Isoleucine, leucine and valine (ILV) 
residues that comprise the highly networks hydrophobic core mapped onto the RRM2 
NMR structure (pdb: 1wf0) with appropriate residue labels. C. CD spectra of the RRM2 
mutants from 200-260 nm all show reduced secondary structure compared to the WT 
sequence (black) suggesting destabilization upon disruption of the ILV cluster. The 
RRM2 unfolded and SVD reconstructed intermediate states are shown as black dashed 
and dotted line, respectively. 
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during the folding reaction with the greatest protection and contribute to the formation of 
on- and off-pathway intermediates in these systems. The ILV cluster of RRM2 spans 16 
residues with 19 contacts that span all secondary structure elements and buries 645 Å2 
surface area (235)(Chapter IV). Single alanine substitutions at these residues will provide 
insights into each residues’ contribution to the stability and formation of the RRM2 
intermediate state.  
A native CD spectrum of each mutant, normalized for protein concentration, 
immediately indicates the effect of a single alanine on the secondary structure of RRM2. 
All mutations drastically reduce the MRE signal to <70% of the native RRM2 CD 
spectrum (Fig. 5.1C, blue). The overall shape of the WT RRM2 spectrum, with a 
minimum at 210 nm and a shoulder at 230 nm, is maintained by several mutations 
including V195A (Fig. 5.1, red), V220A (Fig. 5.1, dark green), I253A (Fig. 5.1, purple) 
and I257A (Fig. 5.1, black), albeit with a wide range of reduced amplitudes (between 16-
70% of the WT RRM2 MRE signal). Furthermore, while these mutants have a similar 
shape, each has decreased ellipticity in the 230 nm region compared to the WT RRM2. 
This increased amplitude is likely due to disruption of the RRM2 β-sheet due to the 
alanine substitution while leaving the alpha-helical face intact. Other mutations show a 
more drastic effect, particularly I250A in the NES, which has a single 218 nm minimum 
and lacks the 230 nm shoulder (Fig. 5.1, pink), and V232A, which has little to no 
secondary structure (Fig. 5.1, brown). These two mutations seem to affect the overall 
secondary structure of the domain rather than merely a reduction of the WT MRE signal.  
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Figure 5.2: CD Spectra of RRM2 ILV Mutants reveal significant loss of secondary 
structure upon alanine substitution. CD spectra of V195A (A), V217A (B), V220A 
(C), L248A (E), I253A (G) and I257A (H) closely resemble the WT RRM2 spectrum 
with a minimum at 210 nm and a shoulder between 220 and 230 nm. V232A (D) and 
I250A (F) have drastically different features with a loss of the 210 nm minimum and the 
appearance of a minimum at 218 nm, suggesting a severe perturbation of the α-helices 
and larger contributions from the β-sheet, that may resemble the RRM2 intermediate 
state. 
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The CD spectrum of each mutant is shown individually in Figure 5.2. These results 
suggest that mutation of the hydrophobic core to alanine can have varying effects on the 
secondary structure of the isolated RRM2 domain that may result in increased 
populations of the RRM2 intermediate or unfolded states and may even yield RRM2 
misfolded conformations. Indeed, several of the mutations examined resemble the 
reconstructed CD spectrum of the WT RRM2 intermediate (Fig. 5.1C, dotted line), 
suggesting that the native states of these mutations may resemble the RRM2 
intermediate. 
 
Alanine mutations enhance the population of the RRM2 intermediate state 
 The intriguing effect of the mutations on the secondary structure of RRM2 
suggests the population of partially-folded and unfolded states are potentially enhanced 
by the removal of a single contact in the hydrophobic cluster. The equilibrium unfolding 
profiles (Fig. 5.3) were obtained by monitoring the secondary and tertiary structures at 
increasing concentrations of denaturant using CD and Tyr FL. The resulting equilibrium 
unfolding profiles by CD of I239A (Fig. 5.3E), L243A (Fig. 5.3F), L248A (Fig. 5.3G), 
I250A (Fig. 5.3H), I253A (Fig. 5.3I) and I257A (Fig. 5.3J) were modeled to a two-state 
mechanism (N D U) with the absence of the RRM2 intermediate state and are referred to 
as Group I mutations. Fraction apparent plots of the Group I mutations (Fig. 5.4A) reveal 
similar midpoints for most of the mutants, except L243A (Fig. 5.4A, dark blue) and 
I253A (Fig. 5.4A, purple), suggesting a similar destabilization between these mutants. 
Each mutant is extremely destabilized compared to the WT (Table 5.1) with an average  
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Figure 5.3: Equilibrium unfolding profiles of the RRM2 ILV Mutants by CD and 
Tyr FL. V195A (A), V217A (B) and V220A (C) retain the RRM2 intermediate while 
I239A (E), L243A (F), L248A (G), I250A (H), I253A (I) and I257A (J) result in two-
state equilibrium unfolding profiles by CD (closed circles). The mutations have varying 
effects on the Tyr FL (open circles): V217A (B), V220A (C), I239A (E), L248A (G) 
show a guanidine dependence while V195A (A), L243A (E), I253A (I) and I257A (J) 
lack significant changes in Tyr FL between the native and unfolded states. The Tyr FL 
profile of I250A (H) shows a sharp decrease in Tyr FL even at the lowest denaturant 
concentrations suggesting the native state of this variant is highly dynamic, which is 
further suggested by the steep native baseline by CD. V232A (D) is unique as the alanine 
mutation is severely destabilizing, with little change in CD and Tyr FL upon denaturation 
and suggests that V232 plays an integral role in the formation of both the RRM2 native 
and intermediate states. 
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stability of ~2 kcal mol-1 (Table 5.1) compared to the 7.42 ± 0.27 kcal mol-1 contributed 
from the N D I and I D U transitions observed for WT. Furthermore, a majority of these 
mutations show a lack of denaturant dependence of the Tyr FL (Fig. 5.3), unlike WT 
RRM2 whose Tyr FL unfolding partially correlates to the N D I transition of WT RRM2 
with the Tyr FL becoming insensitive to the I D U transition. These results suggest that 
these mutants may lack the WT native tertiary structure as observed by the FL of Tyr214 
and form a new “native” state, which may resemble the WT RRM2 intermediate state. 
 While some mutants result in a two-state unfolding profile, others, including 
V195A (Fig. 3A), V217A (Fig. 5.3B) and V220A (Fig. 5.3C), retain an equilibrium 
unfolding profile with the population of the RRM2 intermediate and are referred to as 
Group II mutations. The V220A mutation most closely resembles the unfolding transition 
observed for the WT with destabilization of both the N D I and I D U transitions by 1.48 
± 0.16 kcal mol-1 and 1.91 ± 0.18 kcal mol-1, respectively. Similarly, the midpoint of the 
Tyr FL (1.89 ± 0.04 M) coincides with the N D I transition by CD. Each transition of the 
unfolding profile of V195A and V217A are further destabilized compared to V220A but 
still provides ~1.8 kcal mol-1 from each transition (Table 5.2). In the case of V232A, 
there is relatively little secondary structure and the Tyr FL profile lacks any denaturant 
dependence. The equilibrium unfolding profile depicts a three-state transition but the 
MRE signal change between the states is small (<500 MRE), which suggests that this 
residue may be critical for maintaining structure in the WT RRM2. The fraction apparent 
unfolded plots of the Group II mutations, in comparison to WT (Fig. 5.4B), reveal shifted 
midpoints towards lower denaturant concentrations suggesting an increase in the  
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Figure 5.4: Fraction apparent plots of the CD equilibrium unfolding profiles of the 
RRM2 mutations. Group II mutations (A) are destabilized relative to the WT (black) but 
retain a three-state equilibrium unfolding profile (N D I D U) with the population of an 
intermediate state. Group I mutants (B) were modeled to a two-state transition (N D U) 
and lack the RRM2 intermediate.  
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Figure 5.5: Alanine mutations alter the folding energy landscape of RRM2. A. 
Selected fraction apparent unfolding profiles of the two classes of ILV mutations 
compared to the WT sequence (black). Group I mutations (dark blue) result in a two-state 
(N D U) equilibrium unfolding profile, while Group II (light blue) retain the RRM2 
intermediate, albeit with destabilized N D I and I D U transitions. B-C. ILV residues, 
shown as spheres, mapped onto the NMR structure (B) and the topology map (C) of 
RRM2. Group I mutations (dark blue) cluster in the C-terminal half of RRM2, while 
Group II mutations (light blue) localize to the N-terminus. The two-state nature of the 
Group I mutations suggest that these residues may play a critical role in the formation of 
the native RRM2 structure. I239 is part of the NES but does not contribute to the ILV 
cluster in RRM2. The effect of the mutations in grey on the RRM2 equilibrium unfolding 
pathway has yet to be determined. 
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population of the intermediate state. From their thermodynamic parameters obtained 
through a three-state model, the Group II mutations increase the population of the RRM2 
intermediate state from <1% in the WT to between 2-5% depending on the mutation 
(Table 5.3).  
Mapping the NMR structure with the unfolding equilibrium profile models (Fig. 
5.5A) reveals clustering of severely destabilizing Group I mutations (Fig. 5.5B and 5.5C) 
on the C-terminal α2-β4-β5 region (dark blue), while the Group II mutants localize to the 
N-terminus (light blue). Previous NMR structural studies highlight the α2-β2-β3 elements 
as key region of residual structure into the RRM2 intermediate (Chapter III); therefore, 
V193A and L207A would likely retain its intermediate state, while V255A would likely 
resemble the two-state mutants.  Together, these results suggest that mutation in the C-
terminus may play an important role in the formation of the RRM2 native state. Mutation 
in this region simplify the unfolding equilibrium profiles compared to the WT sequence 
and dramatically destabilize RRM2, result in loss of Tyr FL sensitivity and likely result 
in a “native” state that may resemble the RRM2 intermediate. As RRM2 contains a NES 
in α2-β4, these residues would likely need to unfold for export recognition further 
supporting these residues role in stabilizing the native state of RRM2. Structural insights 
using NMR may provide insights into the structures these RRM2 mutants adopt under 
native conditions, especially whether they resemble the RRM2 intermediate state 
(Chapter III). 
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Enhancement of the RRM2 intermediate decreases the affinity for RNA 
 In the full-length protein, RRM2 is tethered to RRM1 through a 15-amino acid 
linker to recognize RNA in an atypical fashion for a tandem RRM system (72), where the 
two RRM domains stabilize each other against denaturation through mutual interactions 
(235). Thus, the population of partially-folded or unfolded states by RRM2 may influence 
or disrupt the RNA-binding activity of RRM1. Using EMSA assays (Fig. 5.6A), the 
apparent binding affinity of three RRM2 mutants, V195A, V232A and I257A, was 
investigated in the context of RRM1 (tRRMs). The WT tRRMs binds to a (UG)6 RNA 
with an apparent dissociation constant (Kd,app) of 4.6 ± 0.7 nM (Fig. 5.6B, black, Table 
5.4). The two Group I mutations, V195A and I257A, which show reduced secondary 
structure and unfold in a two-state manner, have Kd,app of 7.0 ± 0.6 nM and 7.6 ± 0.8 nM, 
respectively (Fig. 5.6B, Table 5.4). This decrease in affinity results in a ΔΔG° between 
the mutant and WT tRRMs of less than 0.5 kcal mol-1 (Table 5.4). These results suggest 
that these mutants do not significantly destabilize the RNA binding affinity of the 
tRRMs. The little effect on the RNA binding of these mutants may arise through the 
stabilizing interaction between RRM1 and RRM2, which is thought to occur through 
interactions between β4 in RRM2 and β2 in RRM1 and may contribute to stabilizing the 
“native” states of these RRM2 mutants. Interestingly, the V232A mutation, which has 
very little secondary structure (Fig. 5.1C, green), drastically decreases the RNA binding 
affinity by a ΔΔG° of 3.15 ± 0.23 kcal mol-1 compared to WT (Table 5.4). These results 
suggest that mutations in RRM2 can have varying affects on the RNA binding activity of 
the tRRMs with either having WT-like or severely weakened RNA binding capabilities. 
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Figure 5.6: Enhancement of the RRM2 intermediate decreases the affinity of TDP-
43 for RNA. A. Electromobility gel shift assays (EMSA) of increasing concentrations of 
purified RRM2 ILV mutants in the context of RRM1 (tRRMs) to a fixed concentration of 
fluorescently-tagged (UG)6 RNA. V195A and I257A mutants show little effect on the 
RNA-binding capability of tRRMs suggesting either the presence of RRM1 or RNA may 
stabilize and fold RRM2. V232A, on the other hand, drastically reduced the affinity for 
the UG-rich RNA. B. Quantification of the EMSA assays reveals similar RNA-binding 
curves between the WT, V195A and I257A mutants with a greater than three orders of 
magnitude weaker binding affinity for V232A. 
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RRM2 and ALS-linked mutant have similarly altered subcellular localization  
To investigate the role of the RRM2 intermediate state on the localization of 
TDP-43 under cellular conditions, a library of stable HEK-293 cells was created using 
EGFP- or mCherry-tagged full-length TDP-43 constructs containing RRM2 intermediate- 
inducing or ALS mutations. After tetracycline induction for 24 hours, the cells were fixed 
and mounted for confocal imaging to observe changes in localization of mutant TDP-43 
compared to the WT protein. Co-cultures of WT TDP-43 with either EGFP (green) or 
mCherry (red) fluorescent tags (Fig. 5.7A) predominantly localize to the nucleus as 
shown by co-staining with DAPI (Fig. 5.7B). The mutant TDP-43 proteins with either 
ALS (A315T, Fig. 5.7C and 5.7D) or RRM2 intermediate (I257A, Fig. 5.7E and 5.7F)-
inducing mutations display one of two cellular phenotypes: 1) Nuclear puncta (Fig. 5.7C 
and 5.7D and Fig. 5.8B and 5.8C) or 2) Diffuse cytoplasmic expression (Fig. 5.8D-F). 
The nuclear puncta observed for the RRM2 mutants, V220A, V232A, and I257A, closely 
resemble the puncta seen in the ALS-inducing mutant, A315T, among others (data not 
shown). In some instances, as in the case with the dividing V220A TDP-43 HEK-293 
cells (Fig. 5.8B), the nuclear puncta become cytoplasmic. It is unclear whether these 
puncta remain cytoplasmic or return to the nucleus upon the completion of cell division 
and can be examined through other assays. While these mutant TDP-43 variants are 
localized in puncta within the nucleus, these results are in contrast to the diffuse nuclear 
expression observed for WT TDP-43 (Fig. 5.7A and 5.7B). 
While a majority of the mutations tested in this study formed nuclear puncta, two 
mutants, I250A (Fig. 5.8D) and Q331K (Fig. 5.8E), are nuclear depleted and are  
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Figure 5.7: Intermediate and ALS-inducing mutations show similar phenotypes in 
HEK-293 cells. Confocal images of cocultured stable HEK-293 cells expressing 
mCherry and EGFP-tagged full-length TDP-43 after expression with 10 µg mL-1 
tetracycline for 24 hours. Cocultures of mCherry-tagged (red) WT TDP-43 (A-F) with 
EGFP-tagged (green) WT (A), A315T (C) or I257A (E) full-length TDP-43. Images in B, 
D and F are the same as those shown in A, C, and E with the addition of DAPI staining 
for identification of the nucleus. A315T and I257A variants of TDP-43 localize to the 
nucleus in a similar manner to the WT protein. However, whereas the WT protein is 
diffuse throughout the nucleus, the mutant variants form nuclear puncta. 
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Figure 5.8: Confocal images of stable HEK-293 cells expressing EGFP-tagged 
intermediate-enhancing or ALS-inducing mutants in full-length TDP-43 after 24 
hours induction with 10 µg mL-1 tetracycline. All images have DAPI staining for 
identification of the nucleus. V220A (B) and V232A (C) variants have nuclear localized 
TDP-43 in a similar manner to the WT. However, the mutant proteins tend to form 
nuclear inclusions rather than the diffuse EGFP fluorescence observed for the WT. Other 
TDP-43 mutants including I250A (D), Q331K (E) and a C-terminal fragment (F) are 
depleted from the nucleus and accumulate in the cytoplasm with a diffuse EGFP 
fluorescence pattern. In the cases of Q331K (E) and the C-terminal fragment (F), 
cytoplasmic inclusions are observed (yellow asterisks). 
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localized within the cytoplasm with a few occurrences of larger puncta formation (yellow 
stars). The expression pattern of I250A and Q331K is similar to a TDP-43 C-terminal 
fragment spanning residues 208-414 (Fig. 5.8F). This fragments lacks the N-terminus, 
RRM1 and β1 and α2 of RRM2. A previous study on the folding of this RRM2 fragment 
(RRM2c: residues 208-261) revealed an enhanced intermediate population that may 
increase exposure of the embedded NES and serve to retain TDP-43 in the cytoplasm 
(235). Taken together, these results suggest that RRM2 intermediate-inducing mutations 
can result in similar localization patterns in cells as two ALS mutations, A315T and 
Q331K (Figs. 5.7 and 5.8). Could the population of the RRM2 intermediate state coupled 
with cytoplasmic localization serve as a potential hazard that leads to TDP-43 misfolding 
and aggregation?  Further studies are required to understand how the formation of nuclear 
puncta and cytoplasmic localization of the RRM2 intermediate and ALS-inducing 
mutations affect the normal functions of TDP-43 and whether these RRM2 intermediate 
mutations can induce neurodegeneration in animal models. 
 
Fragments of TDP-43 are inherently more aggregation prone than the full-length 
protein 
 An FCS-based assay was developed to monitor solution and cellular TDP-43 to 
understand the role that RRM2 intermediate and ALS-inducing mutations may alter the 
dynamics, oligomeric state and the behavior of fluorescently-tagged full-length TDP-43 
in solution and in cells. As a preliminary investigation into the size of the different TDP-
43 conformations, the full length TDP-43 protein (residues 1 – 414) was compared to a  
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Figure 5.9: Fragments of TDP-43 form larger species than the intact protein. A. 
Autocorrelation curves of EGFP alone (green) and EGFP-tagged full-length (red) or a C-
terminal fragment (blue) of TDP-43. All autocorrelation functions were obtained from 
samples containing 5 nM total protein concentration. The increased amplitude of the 
autocorrelation function for the C-terminal fragment of TDP-43 suggests a decrease in 
the number particles in the confocal volume compared to EGFP alone or the intact 
protein B. Normalized autocorrelation curves of those shown in A. reveal a shift toward 
larger diffusion times for the fragment despite the removal of the N-terminal 207 amino 
acids of TDP-43. These results suggest that the fragment has a higher tendency to self-
associate thereby decreasing the number of particles and increasing the diffusion time 
compared to the full-length protein. 
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C-terminal fragment comprising a portion of RRM2 and the disordered C-terminus 
(residues 208 -414); each with a C-terminal EGFP for fluorescence detection. At 5 nM 
total protein concentration, the two TDP-43 constructs have markedly different 
autocorrelation functions (Fig. 5.9A). Indeed, the inverse of the G(0) values reveal an 
average of 7.6 ± 0.7 particles in the confocal volume during the acquisition of the 
fluorescence fluctuations for full-length TDP-43 but this value decreases to 2.9 ± 1.0 
particles for the C-terminal fragment. This differs from monomeric EGFP, which has a 
similar number of particles in the confocal volume as the full-length TDP-43 (Table 5.5). 
Normalization of the autocorrelation curves reveals a shift towards larger diffusion times 
for the C-terminal fragment than full-length TDP-43. Indeed, modeling the 
autocorrelation curves of both constructs to two diffusion times reveals that both TDP-43 
constructs contain larger species than EGFP alone (Fig. 5.9B, green, τdiff = 3.4 ± 0.3 ms) 
with the C-terminal fragments having a larger diffusion component (Fig. 5.9B, blue) than 
the full-length protein (Fig. 5.9B, red)(Table 5.5). Together, these results suggest that, 
even at 5 nM total protein concentration and the removal of the N-terminal 207 residues, 
the C-terminal fragment of TDP-43 has a higher tendency to form larger species than the 
full-length protein. This construct is identical to the C-terminal fragment used for 
confocal microscopy and contains only a fragment of RRM2 (RRM2c), which has been 
shown to enhance the population of the RRM2 intermediate. These results suggest that 
the removal of RRM1, which normally would prevent access to the intermediate through 
mutual stabilization, through protease cleavage (138, 141, 151, 184, 214, 235) may 
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enhance TDP-43 misfolding, oligomerization and aggregation through the increased 
population of the RRM2 intermediate state in TDP-43 C-terminal fragments. 
 
Discussion 
 Intermediates on the protein folding energy landscape have long been thought as 
stepping stones towards the formation of the native three-dimensional structure of a 
protein (15–19). However, in some cases, these partially-folded species have been 
investigated as potentially pathogenic conformations that lead to a host of human diseases 
(377–379), including neurodegenerative diseases (39). One ALS-linked protein in 
particular, the homodimeric enzyme superoxide dismutase I (SOD1), has been shown to 
favor the monomeric and unfolded states upon amino acid substitution (103, 106), that 
could serve as targets for therapeutic development. Cytoplasmic inclusions of the RNA-
binding protein, TDP-43, are present in a majority of not only ALS patients (53), but 
those suffering from FTLD (30, 49), Parkinson’s (366) and Alzheimer’s diseases (364, 
365) as well, and suggests that pathological conformations of TDP-43 may play a 
common role throughout this spectrum of neurodegeneration. Folding studies of the RRM 
domains of TDP-43 have identified an intermediate state in RRM2, that is absent in 
RRM1 (235). Structural studies using NMR (Chapter III) provides a possible role for this 
partially folded state in RRM2: exposure of an embedded NES sequence in RRM2 (224) 
for recognition and cytoplasmic transport via the nuclear export machinery (275). 
However, whether the RRM2 intermediate state plays a role in the normal function of 
TDP-43 (via nucleocytoplasmic transport) or instead mediates the formation of 
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dysfunctional, misfolded complexes and aggregation or both is not well understood. 
Alanine mutagenesis of the single, highly networked cluster of ILV residues within 
RRM2 resulted in several candidate RRM2 mutants with increased populations of the 
intermediate state (Table 5.3). Two mutants examined yielded little to no impact on the 
RNA-binding capability of TDP-43 (Fig. 5.6, Table 5.4), a majority of which is provided 
by RRM1, and had similar cellular localization in HEK-293 as the ALS-variants, A315T 
and Q331K (Figs. 5.7D and 5.8E). FCS experiments further propose a protective role 
against aggregation for RRM1, as its removal in C-terminal fragments results in the 
formation of larger order species than observed for the full-length protein (Fig. 5.9). 
These data suggest that the RRM2 ILV to alanine mutants may serve as a critical tool to 
delineate the contributions of the RRM2 intermediate in normal and abnormal TDP-43 
functions as well as substrates for the development of conformation-specific antibodies 
for potential diagnostic and therapeutic purposes for patients with neurodegenerative 
disease. 
 The BASiC hypothesis, pioneered by the Matthews group, has linked ILV clusters 
with protection against hydrogen exchange and the formation of kinetic folding 
intermediates in the αβ-repeat proteins (220–222, 362). Indeed, RRM2 of TDP-43 
possesses a large network of ILV residues that may contribute to the formation of its 
intermediate state and overall increased stability compared with RRM1 (Fig. 5.1A and 
5.5B) (235). In addition, RRM2 contains two aromatic clusters, an interior cluster, 
located peripherally to the ILV cluster, and an exterior cluster, which forms base-stacking 
interaction with DNA and RNA.  The internal aromatic cluster may serve to protect the 
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ILV residues against contact with solvent (362) and further enhance the stability of 
RRM2, as has been shown in other systems including BPT1 (380).  
Alanine mutagenesis has been used for decades to investigate the contributions of 
individual side chains to the thermodynamic stability of domains without major 
alterations to the backbone φ and ψ angles afforded by glycine and proline (381–383). In 
the case of ILV mutations, the insertion of a single alanine could disrupt the hydrophobic 
connectivity and van der Waals interactions (362, 384, 385) that contribute to the overall 
stability of RRM2. As observed in Figures 5.1 and 5.2, eight different ILV to A 
mutations resulted in a gradient of reduced secondary structure of RRM2 suggesting 
significant destabilization of the overall fold of RRM2. Furthermore, none of the alanine 
mutants examine had a WT-like stability (Tables 5.1 and 5.2) and, depending on location, 
eliminated the three-state equilibrium unfolding profile observed for WT RRM2 (Fig. 
5.4A). While not unexpected, the severity of some mutants (i.e. V232A) on the unfolding 
landscape of RRM2 revealed the importance of the ILV residues contribution to the 
stability of RRM2.  
Whereas larger proteins, such as the TIM barrel family (>200 amino acids), may 
tolerate mutants through slight rearrangements of the larger hydrophobic core (221, 386), 
the smaller RRM domains (~70 amino acids) may lack sufficient hydrophobic residues 
and stability to accommodate the absence of the nonpolar side chain. The severely 
destabilizing mutants (Group I) cluster around the C-terminus of RRM2 and the NES 
region (239-250) (Fig. 4.5) and suggest that these variants may exist in a conformation, 
which exposes the NES sequence to solvent under native conditions. The Group II 
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mutations, on the other hand, retain the three-state equilibrium unfolding mechanism 
observed for WT (Fig. 5.4B), are destabilized and increase the population of the RRM2 
intermediate state under native conditions (Table 5.3). However, further experimentation 
using structural techniques would provide critical insights into the native states of these 
RRM2 mutants, particularly of those with simplified two-state unfolding profiles (Group 
I), as these variants may potentially exist as the intermediate state under native 
conditions. 
 Mutations associated with neurodegeneration have localized within the disordered 
regions of the essential RNA-binding proteins, TDP-43, FUS/TLS (48), matrin-3 (305) 
and hnRNP A1/B2 (306). In the case of TDP-43 and hnRNP A1/B2, these mutations are 
thought to disrupt protein-protein interactions (48, 306) and increase the 
amyloidogenicity of particular stretches of sequences (152, 218), while a significant 
portion of FUS/TLS ALS variants reside in the nuclear localization sequence and disrupt 
FUS/TLS nuclear transport with the presence of cytoplasmic inclusions (226, 387–389). 
To date, only one disease-linked mutation has been identified in the folded domains 
(NTD, RRM1 and RRM2) of TDP-43: D169G in RRM1 (http://alsod.iop.kcl.ac.uk), 
suggesting that these highly conserved domains (75, 78) may not tolerate amino acid 
substitution as efficiently as other, less conserved regions of the protein, such as the 
disordered C-terminal glycine-rich domain (390). Interestingly, two of the RRM2 ILV 
mutations did not perturb the RNA-binding capability of the tRRM construct towards an 
UG-rich RNA sequence (Fig. 5.6). These results suggest that RRM1 is sufficient for 
RNA-binding or that the interdomain interactions between RRM1 and RRM2 possibly 
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provide sufficient stability to properly fold RRM2 for RNA recognition. The most 
destabilizing variant, V232A (Fig. 5.6, green), resulted in a three-order of magnitude 
weaker apparent binding affinity and suggests this weakly folded RRM2 variant 
interferes with the RNA-binding ability of RRM1. The D169G mutation located within 
RRM1 (AA: 101-181) has an increased resistance to thermal denaturation and recognizes 
RNA with a slightly increased apparent affinity than WT (73, 276, 391). These results 
suggest that the mutation to glycine may benefit RRM1 through enhanced dynamics near 
the site of insertion that potentially aids in RNA recognition (74). In addition, the D169G 
and K263E mutations (276, 391), as well as many other ALS-linked mutants located in 
the glycine-rich region, including A315T and M337V, have shown increased half-life 
compared to the WT sequence (359–361, 392). However, no mutations that directly 
impact the hydrophobic core of the RRM domains of the ALS-linked RNA-binding 
proteins or shift the population of the RRM2 intermediate state have been identified. 
These data could suggest that the devastating effects of the ILV mutations on the 
structure of RRM2 (Figs. 5.1-5.5) could impact the normal function and regulation of 
TDP-43 in a cellular environment (Fig. 5.6, V232A) and potentially cause embryonic 
lethality. Therefore, the RRM2 ILV mutants could serve as tools to modulate the 
population of this partially-folded state and develop novel antibodies and biomarkers, 
which would provide key insights in connecting the functions and cellular consequences 
of populating the RRM2 intermediate with its relationship with neurodegeneration. 
 The ALS-mutations present in the C-terminal disordered glycine-rich domain of 
TDP-43 function and aggregation have shown varied effects on splicing activity, 
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localization and interaction with other hnRNP proteins, particularly hnRNP A1/B2 (82, 
84, 154). The identification of the RRM2 intermediate state (27) suggested that this 
partially-folded state may guide the folding and misfolding of TDP-43. Previous studies 
have identified that a fragment of RRM2 is sufficient to initiate aggregation (151), 
potentially as a result of exposure of aggregation prone sequences in β3 and β5 (152). 
Multiple studies have shown that C-terminal fragments of TDP-43 contain all or part of 
RRM2 are intrinsically more aggregation prone and confer toxicity in cell culture models, 
unlike its full-length counterpart (138–141). Interestingly, the disordered C-terminus 
alone cannot exert toxicity even with the presence of multiple Q/N-rich regions (83–85), 
observed in prion-like proteins (274, 370), and amyloidogenic peptides, which form 
fibrils in isolation (152, 218). Other studies have suggested that non-native disulfide bond 
formation in RRM1, in addition to methylation and ubiquitination, as well as the NTD 
(76, 77) could play a role in mediating TDP-43 aggregation (205, 393, 394).  
Using FCS to monitor the dynamics of purified EGFP-tagged full-length (amino 
acids: 1-414) and a C-terminal fragment (amino acids: 208-414) at low nM 
concentrations, the C-terminal fragment was shown to possess an inherent increased 
tendency to self-associate in vitro compared to the full-length protein (Fig. 9, Table 5), a 
finding similarly observed in cell culture models (138, 140). These results suggest that 
RRM1, possibly with the addition of RNA (190), may play a protective role in mitigating 
aggregation through mutual interactions with RRM2 that reduce the population of the 
RRM2 intermediate state. However, the relevance of the RRM2 intermediate state and its 
role in the TDP-43 function and misfolding have yet to be examined. In some cell culture 
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models, mutant forms of TDP-43 have an increased toxicity compared to the WT protein. 
Expression of A315T and Q331K TDP-43 resulted in the formation nuclear puncta, have 
an increased fragment and associate with stress granules and FUS/TLS (48, 57, 153, 155, 
373, 395). In this study, stable expression of fluorescent-tagged WT and mutant TDP-43 
in HEK-293 cells were used to probe how RRM2 ILV mutants affect the localization of 
TDP-43 under cellular conditions. Expression of WT TDP-43 results in the dominantly 
diffuse nuclear localization (Fig. 5.7A and 5.7B) that is widely reported. However, the 
incorporation of an ALS or RRM2 ILV mutation resulted in two different phenotypes: 1) 
A315T (Fig. 5.7C and 5.7D), V220A (Fig. 5.8B), V232A (Fig. 5.8C) and I257A (Fig. 
5.7E and 5.7F) form nuclear puncta with little expression in the cytoplasm and 2) I250A 
(Fig. 5.8D), Q331K (Fig. 5.8E) and a C-terminal fragment (208-414) (Fig. 5.8F) become 
mislocalized to the cytoplasm with little nuclear expression. The Group II mutations, 
V220A and V232A, remain nuclear while the Group I mutant, I250A, has a cytoplasmic 
localization as hypothesized from the structure of the RRM2 intermediate state (Chapter 
III) and thermodynamics of these variants. Further structural insights into these mutations 
using NMR may provide insights into the structure of the I257A variant and its nuclear 
localization. These results suggest that RRM2 intermediate and ALS-inducing mutations 
result in similar phenotypes with the formation of potentially non-functional aggregates 
that eventually lead to cell death through either direct (gain-of-function) or indirect (loss-
of-function) mechanisms. Further studies will examine how the population of RRM2 
intermediate state connects to the functional aspects of normal function and 
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nucleocytoplasmic trafficking of TDP-43 and whether the RRM2 intermediate serves as a 
major contributor to aggregation and toxicity in a host of neurodegenerative diseases.  
Since the discovery of TDP-43 as a major contributor to neurodegeneration, 
multiple groups have proposed possible mechanisms through which TDP-43 initiates 
neuronal death. The most common pertain to three mechanisms (48): 1) a loss-of-
function mechanism (181, 183), where the accumulation of cytoplasmic TDP-43 
aggregates disrupts autoregulation (80), depletes the functional pool of this RNA-binding 
protein and results in the dysregulation of a host of RNA processes (44, 78) leading to 
cell death, 2) a gain-of-function mechanism where misfolded or aggregates of TDP-43 
themselves are the toxic species (396, 397) or 3) some combination of both loss- and 
gain-of-function mechanisms (79, 232). In the case of another ALS-related protein, 
SOD1, evidence suggests that this protein exerts its toxicity in a gain-of-function 
mechanism as most mutations retain enzymatic activity (158, 159), mutations are 
disperse throughout the sequence (166) and mouse SOD1 knockout models are viable 
with only slight neurological defects (398). Ample evidence supports a loss-of-function 
mechanism for TDP-43-mediated neurodegeneration (183), as the role of inclusions as a 
prerequisite for toxicity is highly controversial (79), with multiple groups supporting both 
sides of the spectrum. In either case, smaller species, such as oligomers, have not been 
investigated for their role in toxicity. Indeed, other proteins systems, such as Aβ (269), 
Huntingtin (399, 400) and α-synuclein (272), are thought to exert toxicity through 
oligomeric intermediates, prior to the formation of amyloid plaques or amorphous 
aggregates. An understanding of the earliest TDP-43 misfolding events using 
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fluorescence cross-correlation spectroscopy (FCCS), including contributions from the 
RRM2 intermediate state population to the formation of dimers, tetramers and higher 
orders species, would fill a critical gap in the mechanism through which TDP-43 exerts 
its toxicity. These soluble species could potentially serve as targets for therapeutic 
intervention prior to assembly into insoluble larger-order TDP-43 misfolded structures 
that may directly or indirectly, through loss of normal TDP-43 function, impact cellular 
homeostasis. 
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Chapter VI – An Unfolded, Reduced Monomeric Nucleus Leads to SOD1 
Aggregation 
 
 
 
 
The work presented in this chapter contains preliminary data for a grant investigating the 
role of sequence biases in the unfolded state as a possible nucleation event during SOD1 
folding and aggregation. This work was a collaborative effort between Osman Bilsel, Jill 
Zitzewitz, Bob Matthews, Noah Cohen, Sagar Kathuria, Erendira Avendano-Vazquez 
and myself. Jill Zitzewitz and I purified WT SOD1 and the A4V and G93A ALS-mutants 
and collected the thioflavin T fluorescence aggregation kinetics with Osman Bilsel in the 
single molecule facility in the Biochemistry and Molecular Pharmacology Department at 
UMass Medical School. Erendira Avendano-Vazquez created the stable HEK-293 cell 
line and obtained confocal images. Sagar Kathuria and I performed the trypsin protease 
digestion experiments. Jill Zitzewitz, Osman Bilsel, Bob Matthews, Noah Cohen and I 
contributed to the interpretation of the data. I wrote the chapter with guidance from Jill 
Zitzewitz and Osman Bilsel. 
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Abstract 
 Missense mutations in the enzyme, superoxide dismutase I (SOD1) result in the 
neurodegenerative disease, amyotrophic lateral sclerosis, with the accumulation of SOD1 
aggregates in the cytoplasm of affected neurons. SOD1 is thought to exert its toxicity 
through a gain-of-function mechanism with oligomers and larger order species serving as 
the likely toxic species. However, the exact mechanism and critical nuclei, which initiate 
the aggregation reaction, are poorly understood. Here, the aggregation reaction of wild-
type  SOD1 and two ALS-variants, A4V and G93A, were examined using a thioflavin T 
fluorescence (ThT FL) binding assay in the absence of agitation. Aggregation initiated 
through the addition of reducing agent results in sigmoidal ThT FL kinetic traces, whose 
characteristic lag phase was dependent of the stability of the disulfide reduced SOD1 
monomer. Further analysis using the Ferrone-Wetzel aggregation model suggests that 
SOD1 aggregation likely proceeds through a reduced unfolded monomeric nucleus. Live 
cell fluorescence correlation spectroscopy experiments in HEK-293 indicated similar 
SOD1 aggregation mechanisms in solution and cells. Protease digestion revealed 
decreased protease resistance in the higher order SOD1 species, further implicating the 
SOD1 unfolded state as a key species in SOD1 aggregation. Therapeutics directly 
targeting the unfolded forms of SOD1 may inhibit aggregation and delay disease onset 
and neuronal cell death.  
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Introduction 
 A large percentage of all of the familial or genetically-linked cases of the 
neurodegenerative disease, Amyotrophic Lateral Sclerosis (fALS), are a direct result 
from mutations in, copper, zinc Superoxide Dismutase I (SOD1) (53, 163, 300). 
Mutations result in the redistribution of the protein into cytoplasmic inclusions in the 
cytoplasm of motor neurons, eventually leading to cell death (39, 401). Furthermore, 
recent evidence has suggested that post-translational modification of WT SOD1 by 
cysteine or tryptophan oxidation may confer toxicity through similar mechanisms as 
mutations (100). Several lines of evidence suggest that SOD1 aggregates or even small 
oligomers directly impact the survival of motor neurons through a toxic gain-of-function: 
1) Mutations have variable effects on SOD1 function (158, 159), 2) Mutations are present 
throughout the protein sequence rather than clustered in a specific region (166), and 3) 
SOD1 knockout (KO) mice do not develop ALS symptoms (398). However, the 
mechanism through which SOD1 confers its toxic effects on motor neurons is not well 
understood. 
 SOD1 is a homodimeric protein with each monomer containing 153 amino acids 
arranged in an 8-stranded greek-key β-barrel (166). Like all members of the SOD family, 
SOD1 is a radical scavenging enzyme catalyzing the dismutation of superoxide anions 
(O2-) to produce oxygen (O2) and hydrogen peroxide (H2O2) (59). Two large disordered 
loops, the zinc binding and electrostatic loops, are critical for the incorporation of three 
post-translational modifications during the course of the SOD1 maturation cycle (61–63):  
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Figure 6.1. The maturation pathway of SOD1 offers multiple species that could 
initiate aggregation. The nascent SOD1 polypeptide is synthesized off of the ribosome 
in the unfolded state in the absence of post-translational modifications. This fully 
unfolded SOD1 species folds slowly to monomer in a two-state mechanism. The copper 
chaperone for SOD1 (CCS) assists in the formation of the disulfide bond and insertion of 
metal ions (Cu and Zn) resulting in disulfide bonded, metallated SOD1 monomers. SOD1 
dimerization occurs rapidly upon formation of the disulfide bond to form the native, 
enzymatically-active SOD1 dimer. Each intermediate in the SOD1 maturation cycle, 
including the SOD1 unfolded state, could serve as a potential species to initiate 
misfolding and aggregation of SOD1 in ALS. 
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the coordination of zinc and copper ions for stability (64) and function (59), respectively, 
as well as a disulfide bond between C57 in the zinc binding loop and C146 on β8 (65, 
66). Loss of each of these modifications could potentially serve as potential misfolded 
species that could propagate aggregation (Fig. 6.1). Indeed, studies have proposed that 
aggregation may proceed through the loss of metal binding and disulfide bond shuffling 
(101, 109, 110, 402–404). Furthermore, ALS-mutations have a range of effects on the 
stability and function of SOD1 (158, 159). SOD1 folds through a monomer intermediate 
(2U D 2M D N2), which rapidly associates to form the native dimer (105, 106). The slow 
folding of the monomer and rapid subsequent association results in little to no 
populations of the monomer at micromolar concentrations. A common thread between 
SOD1 mutations lie in the folding energy surface of SOD1, where a decrease in the 
thermodynamic stability of the monomer folding (2U D 2M), the association reaction 
(2M D N2) or a combination of both (106). The A4V mutation, which is the most 
common in North America (405), predominantly affects the monomer-dimer equilibrium 
(106) while G93A, a mutation shown to recapitulate ALS phenotypes in a mouse model 
(398), preferentially affects the stability of the monomer folding reaction (106). 
Furthermore, reduction of the disulfide bond drastically destabilizes the dimeric form of 
SOD1 to favor monomers with mutations compounding the decreased stability to further 
shift away from the native state of SOD1 (65, 108, 109). The altered stability of the 
mutants results in increased populations of non-native conformations of SOD1 that may 
serve as progenitors to the self-association into aggregates. 
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 Numerous studies have undertaken efforts to connect folding and aggregation by 
identifying potential states that may serve to bridge these two energy landscapes (1, 11–
14, 20). Initial candidate states include unfolded or partially folded species on the folding 
energy landscape, which may allow for protein misfolding prior to acquisition of the 
native conformation (21–24). These species have been identified as candidate therapeutic 
targets in other misfolding diseases (88, 119). Indeed, multiple studies on SOD1 
misfolding have investigated the role of the disulfide bond, metal ion cofactors and 
mutations on the aggregation of this protein and its relevance to ALS (101, 109, 110, 
402–404). One possibility is that small conformational changes in the native SOD1 dimer 
can serve as the precursor to aggregation (406). On the other hand, urea-dependent 
aggregation of SOD1 revealed that aggregation leads from the population of the SOD1 
unfolded state (407). Furthermore, multiple groups (407, 408) have proposed that 
aggregate fragmentation contributes significantly towards the propagation of SOD1 
misfolding and may support a prion-like SOD1 misfolding model (409–411).  However, 
the ALS disease relevance of agitation and fragmentation in instigating misfolding of this 
highly stable protein under cellular conditions remains unknown (406, 407, 412–415). In 
addition, specific sequences in SOD1 may play a key role in the formation of the earliest 
aggregation events, small oligomers, which are thought to confer the most severe toxicity 
in cases such as Aβ and Huntington among others (172–174, 269, 272, 413, 416). 
Hydrogen exchange coupled to mass spectrometry (HX-MS) of SOD1 aggregates 
isolated from ALS patient samples revealed increased protection in between the N-
terminal residues 30 residues, residues between 90-120 in the β5-β6 region and the C-
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terminus of SOD1 (417), but whether these sequences mediate oligomer formation or 
become sequestered from solvent in larger aggregated species remains elusive. 
 In this study, we describe a novel non-agitation-based SOD1 aggregation method 
using lifetime detection of thioflavin T (ThT) binding in a plate reader format to identify 
the determinants for the misfolding of A4V, G93A and WT SOD1, under various 
conditions including oxidation status, solvent conditions and protein concentration. 
Fitting of the aggregation kinetics to standard models for aggregation suggests that the 
unfolded SOD1 monomer may serve as the critical nucleus for the initiation and 
propagation of SOD1 aggregation. Furthermore, this study proposes that fragmentation of 
pre-existing aggregates under quiescent conditions does not contribute significantly 
towards SOD1 aggregation, unlike agitation-based aggregation reactions. Fluorescence 
correlation spectroscopy (FCS) measurements in live HEK-293 cells using stably-
expressing fluorescently-tagged SOD1 constructs revealed similar elongation rates in 
solution studies, which suggests the aggregation kinetics observed in solution are similar 
to those observed in the cellular environment. Initial protease digestion experiments on 
these species reveal increased susceptibility of SOD1 oligomers and aggregates to 
digestion compared to the native SOD1 dimers, further supporting a role for the unfolded 
state in SOD1-mediated aggregation in ALS. 
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Materials and Methods 
SOD1 Protein Purification 
 SOD1 and its A4V and G93A mutant variants were expressed and purified as 
previously described in the AS-SOD1 background containing the C6A and C111S 
mutations to prevent disulfide shuffling during the purification (referred to as SOD1 
throughout this study) (106). The proteins were isolated from BL21 DE3 PlysS E. coli 
and demetallated using EDTA with 5 M Gdn-HCl to remove any residual zinc and copper 
cofactors (apo-SOD1). All SOD1 variants were >95% pure as determined by SDS-PAGE 
and mass spectrometry (Mass Spectrometry Facility, University of Massachusetts 
Medical School). 
 
SOD1 Aggregation 
The aggregation of SOD1 and its variants was monitored using thioflavin T 
fluorescence (ThT FL) in 96-well glass-bottomed plates (Greiner). Two stock plates at 
2X of the final concentrations were mixed in a 1:1 ratio using a liquid handler (Beckman 
Coulter) to a final volume of 200 µL in each well, where mixing served as time = 0 for 
the aggregation reaction. Plate 1 contained different SOD1 concentrations ranging from 8 
to 60 µM (4 to 30 µM final) and included wells without protein for controls. Plate 2 
contained 400 µM ThT and the aggregation initiator. For our experiments, multiple 
concentrations (between 0-28% v/v final concentration) of the fluorinated alcohol, 
trifluroethanol (TFE), or 1 mM of the reducing agent, tris(2-carboxyethyl)phosphine  
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Figure 6.2: Plate setup for ThT-binding SOD1 aggregation assays. Columns 
contained increasing protein concentrations from 0 to 30 µM protein with the first two 
columns (1, 2) serving as no protein controls. Wells 1-12 contained 0% TFE (v/v) with 
wells 13 – 24, 25 – 36 and 37 - 48 containing 16, 18, and 20% TFE (v/v), respectively. 
This setup was repeated for wells 49 -96 with the addition of 1 mM TCEP. All wells, 
except the first well of each row, contained 200 µM ThT. 
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(TCEP) served to initiate the aggregation reaction. A typical plate setup is shown in 
Figure 6.2 including protein only, ThT only and TFE/TCEP controls for each experiment.  
ThT was excited at 435 nm using the doubled output of a Ti:Sapphire laser. A 
custom plate reader setup, consisting of an xy-stage(Biopoint 2, Ludl) and epi-
illumination optics, was interfaced with time correlated single photon counting (TCSPC) 
using two photomultiplier tubes (PMH-100-6, Becker-Hickl) and counting cards (SPC-
150, Becker-Hickl). Magic angle detection using a Glan-Taylor polarizer was used to 
avoid bias from rotational dynamics of the fluorophores. A bandpass filter centered at 
525 nm (FF01-525/45) was used for wavelength selection of the ThT fluorescence. The 
ThT FL lifetime of each well of the 96-well plate was collected for 3 seconds with plate 
repeats occurring until the aggregation reaction had proceeded for >24 hours. Data 
collection of 3 sec/well resulted in >100 data points for each well over a time span of 24 
hours. The aggregation reaction was performed on the apo-WT, A4V and G93A SOD1 
proteins. All experiments were performed at room temperature (~21°C). 
 
Data Analysis 
 The integrated intensity of each ThT FL excited state decay was tagged with the 
data acquisition time and plate well number (Fig. 6.2) to follow the aggregation kinetic 
for each SOD1 variant and condition examined. These traces were fit to three established 
models of aggregation to extract mechanistic insights into the aggregation process of 
SOD1. 
1. Crystallization-like model (418) 
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ThT FL Intensity = scaling factor ∗ 1− !!! ∗ !"# !!∗! !! !! + offset       Eqn. 6.1 
where ka is representative of the elongation rate (min-1) and kb is a function of multiple 
terms including the population of each species present during the reaction and the lag 
phase of the aggregation reaction.  
2. Quadratic Elongation Model (419) ThT FL = A ∗ t! + c                    Eqn. 6.2 
where A is dependent on the elongation rate (k+), the rate of formation of the nucleating 
species (kn*), the total SOD1 protein concentration (c) and the size of the critical nucleus 
(n*) as shown by Equation 3.3. 
A = ½*k+2*kn*c !∗! !!                         Eqn. 6.3 
The size of the critical nucleus, n*, is provided by a plot of the log (A) vs. the log (c), 
which results in a linear regression with a slope = (!∗! ) + 1 and a y-intercept = log 
(½*k+2*kn*). 
3. Fragmentation model (420) 
This model fits the lag time (related to kb) as a function of protein concentration to a 
power function as shown in Equation 3.3,  𝑘! = 𝑎 ∗𝑀!!  Eqn. 6.4
where kb is the lag time, Mt is the total protein concentration, a is a constant and γ is the 
exponent of the power function. If fragmentation is a significant component of the 
aggregation mechanism, the exponent |γ| = 0.5. 
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Stable Cell Line Creation 
 Stable cell lines for the inducible expression of SOD1 and its variants were 
created using Flp-In™ HEK-293 cells (Thermo Scientific). The cells were transfected 
using lipofectamine 2000 (Thermo Scientific) according to the manufacturers instructions 
with the pOG44 and pcDNA5/FRT vectors. The pOG44 vector contains the Flp 
recombinase for insertion of the target gene sequence into the HEK-293 genome. The 
pcDNA5/FRT vector contains the WT, A4V or G93A SOD1 gene with N-terminal 
FLAG, C-terminal myc and either a monomeric (A206K) enhanced green fluorescent 
protein (EGFP) or mCherry fluorescent tags. For cellular-based experiments, the C6A 
and C111S mutations used in the in solution studies were not incorporated into the SOD1 
gene. HEK-293 cells with successful incorporation of the SOD1 gene were selected by 
the addition of 100 µg mL-1 hygromycin B to the Dulbecco’s Modified Eagles growth 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). SOD1 protein 
expression was initiated by the addition of 1 µg mL-1 tetracycline (Sigma-Aldrich) and 
observed through confocal microscopy using a Leica TCS SP5 Confocal Scanning 
microscope at UMass Medical School after fixing with 4% formaldehyde for 1 hour at 
room temperature. The nucleus was observed through DAPI nuclear staining using a 405 
nm laser with EGFP or mCherry expression monitored through a 488 nm or a 540 nm 
laser with the appropriate emission filters. 
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Fluorescence Correlation Spectroscopy (FCS) in live cells 
 Expression of SOD1 and its variants in HEK-293 was achieved by addition of 1 
µg mL-1 tetracycline (Sigma) to the growth media. For the FCS experiments, the growth 
media was changed to the FluoroBrite™ DMEM (Thermo Scientific) supplemented with 
10% FBS and 4 mM GlutaMAX (Thermo Scientific). As our home-built confocal setup 
does not support carbon dioxide (CO2) regulation, the addition of 25 mM HEPES pH 7.4 
maintained pH in the absence of 5% CO2 typically used during cell culture. The cells 
were induced for 24 hours on 4-quadrant coverslip-bottom plate (Greiner) prior to 
imaging. 
 The plate containing EGFP-tagged SOD1 was excited using a 488 nm laser at 0.5 
mW power through a 60X, 1.2 N.A. water immersion objective lens (Olympus 
UPlanSApo). The in-house custom FCS setup is equipped with a plate reader for accurate 
coverslip/plate and objective positioning and a pinhole to define the confocal volume. In-
house software is used to position the confocal volume 20-30 µm above the coverslip 
during the course of the FCS experiment. The size of the confocal volume was 
determined using 1 nM AlexaFluor 488 (A488), which has a known diffusion coefficient 
of 430 µm2 s-1 (421) and yielded a confocal volume of 2-3 fL. The EGFP fluorescence is 
passed through a 525 ± 45 nm bandpass filter (Semrock) prior to detection of the 
fluorescence fluctuations using an idQuantique id100-50 single-photon avalanche 
photodiode (SPAD) and SPC-150 counting card (Becker & Hickl). The FCS 
autocorrelation function, G(τ), was calculated using the Burst Analyzer software (Becker 
& Hickl) or the in-house software, Savuka (194), and fit to a one or two-component 
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autocorrelation model. In the case of A4V, the autocorrelation was simultaneously 
modeled to a crystalline-like model (Eqn. 1) to determine the aggregation parameters, ka 
and kb, in live cells. 
 
Native Gel Electrophoresis 
 Increasing concentrations of WT, A4V and G93A SOD1 were incubated with 
20% TFE or 1 mM TCEP to initiate aggregation and incubated at room temperature for 
24 hours to allow the reaction to proceed. After 24 hours, 40 µL samples were loaded 
onto a 10% polyacrylamide gel and separated with an applied voltage of 80 V for 3 hours 
at room temperature. Gels were stained with Coomassie Blue Stain to identify larger 
species during the course of the aggregation reaction. 
 
SOD1 proteolysis 
 The native SOD1 dimers, soluble oligomers and insoluble, visible aggregates 
were subjected to digestion with 1 µg mL-1 trypsin for two hours at room temperature. 
Soluble oligomers were formed through incubation with 1 mM TCEP for 48 hours 
followed by centrifugation for 5 minutes at 10,000 RPM, collection of the supernatant 
and confirmed through light scattering using a Zetasizer Nano Series (Malvern). Time 
points (0, 1, 5, 10, 30, 60, 120 minutes) were collected in 20 µL aliquots with subsequent 
trypsin quenching by the addition of reducing SDS-PAGE buffer. Samples were loaded 
onto 10-20% gradient acrylamide gels and separated with an applied voltage of 120 V for 
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2 hours. SOD1 and peptide fragments were resolved using silver staining to quantify low 
abundance SOD1 fragments (422). 
 
Results 
ThT increases in intensity upon binding SOD1 aggregates 
 A well established method for monitoring the aggregation reaction of various 
proteins involved in misfolding diseases, including SOD1, has been the binding of the 
small compound ThT (423). ThT is relatively non-fluorescent in solution (quantum yield 
~10-3) but, when bound to β-rich elements (424), dramatically increases in fluorescence 
intensity and serves as a useful probe for the formation of amyloid-like structures during 
protein misfolding (Fig. 6.3A). Interestingly, ThT has the unique property of having 
multiple fluorescent lifetimes, which largely depends on the conformation of the protein 
and the binding orientation of ThT. Indeed, in solution, ThT has very weak fluorescence 
with a very short lifetime (<0.5 ns) (Fig. 6.3A, red). Upon binding, the fluorescence 
increases with a corresponding increase in the fluorescence lifetime to >2-3 ns (Fig. 6.3A, 
green) due to changes in the local environment around ThT upon binding proteins and 
aggregates (425). Thus, ThT will serve as a useful probe for monitoring the aggregation 
of SOD1 and its variants upon the addition of aggregation-inducing conditions, such as 
TFE and TCEP. TFE has been shown to alter the quality of the solvent in such a way as 
to mimic cellular conditions surrounding membranes (426). Multiple studies have 
indicated that SOD1 has shown a tendency to aggregate in and around the mitochondrial 
and nuclear membranes (427–431). Furthermore, the loss of the disulfide bond and  
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Figure 6.3. Monitoring SOD1 aggregation through ThT binding. A. The FL lifetime 
decay increases upon sequestration into SOD1 aggregates. ThT in isolation has a relative 
low quantum yield with relativity little FL and a rapid lifetime decay (red). Upon binding 
to SOD1 aggregates, the FL quantum yield and intensity increase (green) and display 
much longer lifetimes compared to ThT alone (green). B. 96-well plate based aggregation 
assays monitoring ThT total intensity as a function of time. Aggregation occurs prior to 
first measurement in TFE containing plates (wells 12 – 48 and 61 - 96). Addition of only 
the reducing agent, TCEP (wells 49 – 61), shows delayed aggregation (>500 min) 
compared to the TFE-containing samples. 
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disulfide bond shuffling (101, 109, 158, 402, 403) has been thought to play a major role 
in mediating SOD1 misfolding in ALS. 
  
Reduction of the disulfide bond results in aggregation with a lag phase 
Using a ThT FL lifetime-based aggregation assay equipped with a plate reader, 
the aggregation of SOD1 can be monitored as a function of multiple variables including 
protein concentration, percentage of TFE (% v/v) or presence/absence of TCEP (Fig. 
6.3). An example of the ThT fluorescence (y-axis) as a function of well number (x-axis) 
over time (purple: time = 0, red: endpoint) is shown in Figure 6.3B. In the first 12 wells, 
G93A was incubated with ThT in the absence of TFE and TCEP and as a result, there 
was little observable increase in ThT FL (Fig. 6.3B, wells 1-12) over the course of the 
experiment. However, upon addition of TFE (wells 13-48), the ThT FL increases 
dramatically in a protein concentration-dependent manner (432). TCEP, in addition to 
TFE (wells 61-96), produces a similar effect with immediate aggregation occurring, even 
during the first few data acquisitions (Fig. 6.3B, purple). Interestingly, the wells where 
only 1 mM TCEP was added to the G93A SOD1, and not TFE, resulted in delayed 
aggregation compared to the reaction instigated by the presence of TFE (Fig. 6.3B, wells 
49-60, blue). Intriguingly, the final ThT FL intensities were highest in TCEP-only 
aggregation reactions (Fig. 6.3B, wells 49-60), followed by TFE in addition to TCEP 
(wells 61-96) and, finally, the TFE-only wells (wells 13-48). These results suggest that 
different conformations exist within the G93A aggregates between the different sets of 
conditions or ThT may favor preferential binding to reduced SOD1 aggregates compared  
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Figure 6.4. TCEP and TFE-induced aggregation display distinct aggregation 
kinetics. A, C, E. Aggregation in the presence of 1 mM TCEP of the WT (A), A4V (C) 
and G93A (E) SOD1 at protein concentrations between 4 – 28 µM. Addition of TCEP 
does not induce aggregation in the WT SOD1 but results in delayed aggregation in A4V 
and G93A variants of SOD1. B, D, F. Aggregation in the presence of 20% TFE (v/v) of 
the WT (B), A4V (D) and G93A (F) SOD1 at protein concentrations between 4 -28 µM. 
For each SOD1 variant, the aggregation occurs in a hyperbolic manner with no lag phase 
by ThT FL at concentrations > 10 µM and results in a loss of critical information 
regarding the nucleation of the aggregation reaction. 
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to TFE-induced aggregates. In addition, the disulfide bond may serve as a protective 
factor against aggregation, as shown by the decreased ThT FL intensities (Fig. 6.3B, 
wells 13-48) compared to the aggregation reactions in the presence of TCEP (Fig. 6.3B, 
wells 49-96).  
These differences between TCEP  (Fig. 6.4, left) and TFE (Fig 6.4, right)-induced 
aggregation were further examined when alternatively plotted as a function of time (Fig. 
6.4). In the case of TFE for all the variants tested (Fig. 6.4, right; WT: top, A4V: middle, 
G93A: bottom), aggregation was initiated immediately with a significant difference in 
ThT FL (20,000 counts) compared to the ThT only controls (<2,000 counts) at protein 
concentrations between 4 and 28 µM. The hyperbolic nature of the aggregation kinetics 
observed by TFE indicates a loss of key information about the earliest steps of SOD1 
aggregation. Thus, TFE will not be used further in this study. The TCEP-initiated 
kinetics, on the other hand, have discernable lag phases for the A4V and G93A SOD1 
variants (Fig. 6.4, middle and bottom left) with low ThT FL at short times (0 – 500 min) 
prior to a rapid elongation phase (Fig. 6.4C and 6.4E). These sigmoidal aggregation 
kinetics with distinct lag, elongation and plateau phases (in the case of G93A) monitor 
the entire aggregation kinetic mechanism including the possible misfolding of SOD1 and 
the nucleation step. Further analysis of the ThT FL lifetime decays will provide insights 
into the conformations of SOD1, including information regarding the populations of each 
species and whether one population is more aggregation-prone than another during the 
course of all stages of the aggregation reaction. Interestingly, only the mutant variants of 
SOD1 aggregated under reducing conditions and not the WT sequence (Fig. 6.4, top left)  
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Figure 6.5. Reduced SOD1 aggregation may occur through the population of the 
unfolded state. A-B. Kinetic traces of the aggregation of reduced A4V (A) and G93A 
(B) SOD1 at 5 protein concentrations: 6 µM (red), 10 µM (orange), 16 µM (green), 20 
µM (blue) and 24 µM (purple). Insets: Linear modeling of the protein concentration 
dependence of the elongation rate (ka) and nucleation/lag phase (kb). The elongation rate 
(ka) is protein concentration and mutation independent. As expected, the increasing kb 
with increasing protein concentration suggests shorter lag phases at higher concentrations 
of SOD1 variants. C) Kinetic traces of reduced G93A (circles), A4V (square) and WT 
(triangles) at 24 µM. Inset: kb dependence on the thermodynamic stability of WT 
(triangles), A4V (square) and G93A (circle) at room temperature. The lag phase shows a 
high correlation (R2 = 0.974) to the population of the unfolded state at room temperature. 
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suggesting that the ALS mutations may be sufficient for inducing an aggregation-prone 
conformation upon reduction of the disulfide bond. 
 
The lag phase depends on the stability of the reduced SOD1 variant 
 The aggregation kinetics of the reduced variants of SOD1 provides information 
on the lag and elongation phases of the association reaction. A crystallization-like model 
(418) quantifies the kinetics into two terms: ka, the elongation rate and kb, a group of 
terms that depends on the population and concentration of the aggregation-prone states 
and the lag phase, that can describe the entire sigmoid of the aggregation reaction. As 
shown in Figures 6.5A and 6.5B, the total ThT FL intensity increases with increasing 
protein concentration for A4V (Fig. 6.5A) and G93A (Fig. 6.5B). Furthermore, the lag 
phase decreases with higher protein concentrations of both variants. Using this model, the 
elongation rates, ka, are comparable between these two variants with an average value of  
0.008 min-1 (Fig. 6.5A and 6.5B, insets, Table 6.1) and are essentially protein 
concentration independent. However, the major difference between these two variants 
resides in the value of kb with G93A having a 4-fold larger kb than A4V (Fig. 6.5A and 
6.5B, Table 6.1) which is indicative of the shorter lag phase for G93A than A4V. These 
results suggest that the elongation rate (ka) of SOD1 aggregation is independent of the 
mutation but depends largely on the population of the nucleating species. Other studies 
have suggested that reduction of the disulfide results in the formation of monomeric 
SOD1, which has a markedly reduced thermodynamic stability compared to SOD1 dimer 
(65, 71, 433). Indeed, there is a strong correlation (R2 = 0.997) between the stability of 
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the mutant SOD1 and the kb values of G93A, A4V and WT SOD1 (Fig. 6.5C) at the same 
protein concentrations. Reduced G93A and A4V are 58% and 13% unfolded at room 
temperature while the WT protein is >99.9% folded (65). These findings correlate with 
the aggregation kinetics observed in Figure 6.5C, where G93A aggregates form the most 
rapidly and have the largest population of the unfolded state. These results suggest that 
populating the unfolded state may be a critical early event in the aggregation of SOD1. 
 
The nucleus of reduced SOD1 aggregation is an unfolded monomer 
 An alternative model derived by Ferrone and Wetzel (419) models the 
aggregation kinetics to a quadratic function to obtain information on the population and 
number of molecules in the critical nucleus for the propagation of SOD1 aggregation. As 
shown in Eqns. 2 and 3, the coefficient A is a function of the elongation rate (k+), the 
nucleation rate (kn*), the protein concentration (c) and the size of the critical nucleus (n*). 
As the starting species prior to the initiation of the aggregation reaction with TCEP is the 
dimeric form of SOD1, a monomer-dimer equilibrium exists at equilibrium during the 
aggregation. As a result, the protein concentration of unfolded molecules is dependent on 
the square root of the total protein concentration and, thus, a ½ term was incorporated 
into the exponent for the analysis of the SOD1 aggregation kinetic traces. The slope of 
the plot of log (A) vs. log (protein concentration) (Fig. 6.6A) provides a quantitative 
estimate measurement of the size of the critical nucleus (n*). The comparable slopes of 
the A4V and G93A log (A) vs. log (protein concentration) plots (Table 6.2; A4V: 1.50 ± 
0.15, G93A: 1.59 ± 0.14) result in critical nuclei of 1.00 ± 0.28 and 1.18 ± 0.28,  
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Figure 6.6: Aggregation of reduced SOD1 occurs by a non-fragmentation-based 
mechanism through a monomeric nucleus. A) Linear regression of A4V (open circles) 
and G93A (closed circles) of the log of the quadratic coefficient, A, vs. the log of the 
protein concentration. The critical nuclei were determined to be monomeric for both A4V 
and G93A. B-C. Power function of the A4V (B, open circles) and G93A (C, closed 
circles lag time (kb) vs. the protein concentration reveal greater exponents (A4V: |γ| = 
0.99 ± 0.16, G93A: |γ| = 1.55 ± 0.43) than expected for a fragmentation model (|γ| = 0.5) 
(434). 
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respectively (Table 6.2), which suggests the nucleus of the reduced SOD1 aggregation is 
likely monomeric for both variants. Furthermore, the y-intercept is a function of the 
elongation and nucleation rates, which appear, effectively, as a single combined 
parameter and are, therefore, not independently distinguishable in this model. Results 
from the crystalline-like model (Fig. 6.5, Table 6.1) revealed similar elongation rates 
between the A4V and G93A SOD1 variants. Thus, the intercept reduces to the nucleation 
rate, which depends on the populations of each species during the aggregation reaction. 
The ratio of the nucleation rates results in a ΔΔG° between A4V and G93A of 1.42 ± 
0.13 kcal mol-1 (Table 6.2), which is similar to the reduced monomer thermodynamic 
stability between these two mutants (1.21 ± 0.42 kcal mol-1) (65), further suggesting a 
role for the unfolded state in reduced SOD1 aggregation. Together, these results suggest 
that the critical nucleus for SOD1 aggregation is the unfolded monomeric SOD1. 
Fragmentation does not contribute to reduced SOD1 aggregation 
 A common feature of proposed SOD1 aggregation models includes fragmentation 
based propagation (420), where oligomers break off from larger species and serve as 
seeds to further enhance aggregation. This aggregation mechanism has been proposed for 
SOD1 by various groups (406, 407, 412–415) when using agitation to initiate the 
aggregation reaction. However, a plot of the lag time (kb) obtained using the 
crystallization-like model as a function of protein concentration (418, 420) was fit to a 
power function (Eqn. 6.4) revealed exponents (|γ|) of 0.99 ± 0.16 and 1.55 ± 0.43 for 
A4V and G93A (Table 6.3). These values are significantly different than an exponent of 
|γ| = 0.5 characteristic of fragmentation mechanisms and typically obtained when 
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aggregation is obtained by agitation (434). These steeper power functions suggest that the 
SOD1 aggregation is occurring at a much faster rate than would be expected if 
fragmentation were a key process during the reaction. Therefore, our studies reveal that 
fragmentation contributes less to the aggregation mechanism of reduced SOD1 compared 
to other proposed mechanisms for SOD1-mediated aggregation. However, it is not clear 
from our studies if fragmentation plays a role at longer time scales (>1500 min), whether 
ThT binding is insensitive to monitoring breakage of pre-existing aggregates or 
amorphous aggregates, monitoring only a small population of fibrils, or whether 
fragmentation occurs in disease models and ALS patients. Techniques measuring size 
distributions and their respective populations, such as FCS, would provide an alternative 
perspective into the aggregation reactions of SOD1 and its mutants. 
 
Mutant SOD1 is excluded from the nucleus and forms cytoplasmic puncta 
 Multiple studies have proposed small oligomeric forms as the potentially toxic 
species that initiates neurotoxicity in many misfolding systems (172–174, 269, 272, 416, 
435). In order to investigate the role of the population of the SOD1 unfolded state on the 
aggregation mechanisms of SOD1 in a cellular context, stable HEK-293 cell lines were 
created to monitor the aggregation reaction in live cells. These cells express EGFP- or 
mCherry-tagged SOD1 or one of the variants, A4V and G93A (Fig. 6.7), under the 
control of a tetracycline inducible promoter to allow initial control over the aggregation 
reaction. Co-culture of WT SOD1-EGFP (Fig. 6.8A and 6.8B, green) and A4V SOD1-
mCherry (Fig. 6.8A and 6.8B, red) followed by confocal microscopy of fixed cells 24  
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Figure 6.7: Fluorescently tagged SOD1 constructs. All constructs contain the human 
WT SOD1 sequence (black), with the only amino acid substitutions being the addition of 
the A4V and G93A ALS-mutations. The SOD1 sequence is preceded by an N-terminal 
FLAG tag (lavender) and followed by a myc-tag (tan) and either a monomeric EGFP 
(containing the A206K mutation)(green) or mCherry (red). The identity of the fluorescent 
tag did not affect the localization or distribution of the SOD1 proteins. 
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Figure 6.8: Mutant SOD1 forms cytoplasmic puncta and is depleted from the 
nucleus. A-B) Co-culture of stable HEK-293 cells with WT SOD1 – EGFP (green) and 
A4V SOD1 – mCherry (red) without (A) and with (B) nuclear DAPI staining (blue) of 
fixed cells 24 hours post-induction with tetracycline. C-D) Co-culture of stable HEK-293 
cells with WT SOD1 – mCherry (red) and G93A SOD1 – EGFP (green) without (C) and 
with (D) nuclear DAPI staining (blue). Identity of the fluorescent tag did not alter 
localization or distribution of the WT SOD1 protein. Both A4V and G93A mutant SOD1 
variants are depleted from the nucleus as shown by lack of DAPI fluorescence overlap 
and form cytoplasmic puncta. On average, G93A SOD1-containing HEK-293 cells 
contain more puncta than A4V SOD1 cells. 
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hours post-induction revealed a striking difference between the WT and mutant SOD1 
HEK-293 cells (Fig. 6.8A and 6.8B). While WT was diffuse throughout the cell staining, 
A4V SOD1 was depleted from the nucleus, as shown by DAPI staining (Fig. 6.8B, blue), 
and formed cytoplasmic puncta (Fig 6.8A, yellow arrows). A similar phenotype was 
observed with a co-culture of G93A SOD1 – EGFP and WT SOD1 – mCherry, with a 
greater number of cytoplasmic puncta and nuclear depletion (Fig. 6.8C and 6.8D). 
Similar results have been shown previously (60), where nuclear SOD1 depletion resulted 
in increased DNA damage due to oxidation. Swapping of the fluorescent protein on WT 
SOD1 did not affect its localization or distribution throughout the cell and suggests that 
the observations are not a result of the fluorescent tagging of the WT SOD1 or the A4V 
and G93A variants (Fig. 6.8A and 6.8C). Although lacking in quantification, the G93A 
SOD1 cells appear to contain a greater number of puncta than either A4V or WT (G93A 
> A4V > WT) (Fig. 6.8, compare A and C, yellow arrows) and is reminiscent of the 
stability correlation observed upon reduction of the disulfide bond to monitor aggregation 
(Fig. 6.5C, inset). These results suggest that the mutant SOD1 may form larger species, 
not present in the WT SOD1 cells, that are potentially not capable of freely diffusing 
through the nuclear pore, remain cytoplasmic and may contribute to toxic phenotypes 
associated with neurodegeneration. 
 
The SOD1 aggregation elongation rate is similar in live cells and in solution 
 Recently, multiple studies have proposed a role for small SOD1 oligomers as a 
key species in SOD1-mediated neurodegeneration in ALS (172–174). To investigate  
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Figure 6.9: WT SOD1 is dimeric in living cells while A4V SOD1 forms larger 
species. A. Confocal image of an A4V SOD1 expressing HEK-293 cell used for FCS 
measurements. B. FCS autocorrelation functions of stable HEK-293 cells expressing WT 
SOD1-EGFP (black) or A4V (blue and green). WT SOD1 containing HEK-293 cells 
diffuse with diffusion coefficients similar to those expected for the dimeric form of 
SOD1 (black). A4V SOD1 in HEK-293 cells, on the other hand, appear much larger with 
either aggregation (dark gray) or photobleaching (light gray) contributions during the 
collection of the fluorescence fluctuations. 
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whether oligomers are observed during the expression of exogenous SOD1, an FCS-
based approach was developed to monitor the SOD1 aggregation using live cell imaging. 
FCS is a powerful technique that can identify and monitor various species inside cells 
through changes in the fluctuations in the EGFP fluorescence during the course of the 
tetracycline induction. This technique will provide critical insights into the concentration, 
size distribution and brightness of multiples species during the association reaction (436). 
As a pilot experiment, EGFP-tagged WT and A4V SOD1 were expressed in HEK-293 by 
tetracycline induction and imaged using a custom-built FCS setup. A low-resolution 
image (128 pixels x 128 pixels) 37.5 µm x 37.5 µm region of an HEK-293 cell is shown 
in Figure 6.9A, with diffuse EGFP expression throughout the cell. However, upon 
acquisition of the fluorescence fluctuations of the WT and mutant SOD1 cells at a 
minimum of 5 different regions within the cells, differences were immediately evident 
between the two variants (Fig. 6.9B). Surprisingly, the number of particles in the 
confocal volume for the WT SOD1 protein (Fig. 6.9B, black, ~150 particles) suggests a 
cellular concentration of ~200 nM, far lower than typically reported cellular SOD1 
concentrations in the µM range (437, 438). However, the concentration of endogenous 
SOD1 in HEK-293 cells is not known. The autocorrelation functions derived from the 
WT SOD1 cells were highly uniform with diffusion coefficients similar to those for a 
predicted EGFP-SOD1 dimer (2450 ± 1730 µm s-1).  
HEK-293 cells expressing A4V SOD1 resulted in two types of autocorrelation 
functions (Fig. 6.9B): 1) increasing autocorrelation at long time scales (>1 sec) that never 
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reaches an autocorrelation of 1 (no correlation between particles) (Fig. 6.9B, dark gray) 
and 2) rapid decrease at long time scales (>1 sec) that results in autocorrelation functions  
below 1 (Fig. 6.9B, gray). These two extremes result from increasing and decreasing 
fluorescence intensity, respectively, over the course of the FCS data acquisition. These 
types of FCS are likely due to large species in the confocal volume that are continuing to 
aggregate on the time scale of the FCS measurement or photobleaching due to the slow 
motion through the confocal volume, respectively. These results suggested that the A4V 
SOD1 may aggregate in cells on a similar time scale as the solution aggregation studies. 
Modeling using a double diffusion coefficient model in addition to the crystalline-like 
model used in the solution studies reveals that the elongation rate, ka, is within a factor of 
2 between in solution and cells (6.11 ± 0.33 x10-3 min-1 vs. 2.85 ± 1.18 x10-3 min-1, Table 
6.3), while kb is >5000 fold larger in cells than in solution, likely as a result of cell 
growth at 37°C where the thermodynamic stability of SOD1 is reduced compared to 
room temperature. These results suggest that SOD1 may aggregate in cells via similar 
mechanisms as in solution through the population of the unfolded SOD1 monomer.  
 
Oligomeric and aggregated forms of SOD1 are more susceptible to proteolysis 
 The identification of particular sequences or structural biases in the unfolded state 
of SOD1 that favor aggregation would serve as putative target for small molecule 
stabilization or antibody recognition for disease diagnostics and therapeutics. A 
preliminary study using trypsin digestion was used to investigate changes in the digestion 
pattern for the SOD1 species: native dimer, soluble oligomers and insoluble aggregates.  
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Figure 6.10: Native PAGE of larger species of SOD1 conformations. 10% Native 
Acrylamide Gel of purified WT, A4V and G93A SOD1 after 24 hours incubation with 1 
mM TCEP or 20% TFE (v/v). The red arrow highlights the native dimer. Larger species 
are shown as discreet bands highlighted by yellow asterisks (*) and are present in all 
samples. Incubation with TFE induced larger species that did not enter the separating gel 
(top most asterisk).  
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Figure 6.11: SOD1 soluble oligomers and insoluble aggregates have increased 
susceptibility to protease digestion. Tryptic digest of the native dimer (left), oligomeric 
(middle) and aggregated (right) SOD1 show different digestion patterns (bands 0-5). The 
oligomeric and aggregated samples have rapid depletion of the intact SOD1 compared to 
the native dimer, which suggests an increased exposure of the trypsin digestion sites, 
likely through the SOD1 unfolded state.  
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Native PAGE (Fig. 6.10) of the aggregation reactions of A4V, G93A and WT SOD1 after 
24 hours incubation with TCEP and TFE revealed the formation of higher order species 
(Fig. 6.10, yellow stars) as was observed in the ThT binding assay (Fig. 6.3-6.4), upon 
reduction of the disulfide bond. The smaller, more homogeneous size distribution of the 
WT SOD1 oligomers (Fig. 6.10, lane 1), compared to the smear of conformations 
observed in A4V (Fig. 6.10, lanes 3-4) and G93A (Fig. 6.10, lanes 5-6), indicated that 
TCEP-treated WT SOD1 may serve as a model system for soluble oligomers after 
incubation for 48 hours as observed by light scattering methods (Brian C. Mackness, 
Sagar V. Kathuria, data not shown). Insoluble aggregates were isolated using 
centrifugation from >4 week old WT SOD1 protein preparations. Treatment of WT 
SOD1 dimer, soluble oligomers and insoluble aggregates with trypsin for increasing 
digestion times and separated by SDS-PAGE revealed the banding pattern shown in 
Figure 11. The native WT SOD1 dimer (Fig. 6.11A) is particularly resistant to digestion 
with a large percentage of the native ~16 kDa species remaining after 2 hours. After 1 
minute of digestion bands 2, 3 and 5 appear and during the course of the digestion, bands 
2 and 3 disappear completely with the simultaneous appearance of bands 1 and 4. Band 5 
continues to increase in intensity until 10 minutes of digestion upon which time the level 
of the band remains constant. This banding pattern is unique to the native WT SOD1 
dimer, as neither soluble oligomers nor insoluble aggregates display this pattern. Indeed, 
in both cases, the ~16 kDa species is rapidly depleted within 5 minutes of digestion with 
the dominant band 5 appearing. This is particularly true for the soluble oligomers (Fig. 
6.11B). However, in the case of insoluble oligomers (Fig. 6.11C), the ~16 kDa band 
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decreases slightly in molecular weight (Band 0) with further digestion of band 5 at longer 
time points to smaller peptides that were not observed on a 10-20% acrylamide gradient 
gel. These results suggest that oligomers and aggregates may be composed of unfolded 
polypeptide chains as these species would have a greater susceptibility to protease 
digestion. Furthermore, the oligomers serve as an intermediate stage between the native 
and aggregated states as they retain a resistant core against digestion while insoluble 
aggregates can be digested further into smaller protein fragments. HX or fast 
photochemical oxidation of proteins (FPOP) coupled with protease digestion and MS 
(439, 440) during the course of the aggregation reaction would provide critical markers 
for identifying buried sequences or regions in SOD1 oligomers and aggregates and how 
ALS-mutations affect potential seed sequences. 
 
Discussion 
 The pathological hallmark feature of ALS, as well as other neurodegenerative 
diseases including frontotemporal dementia, Alzheimer’s and Parkinson’s disease, is the 
accumulation of proteinaceous inclusions in the cytoplasm of affected motor neurons (30, 
39–43, 49, 166). Mutations in the catalytic enzyme, superoxide dismutase I (SOD1), have 
been shown to play a causative role in the neurodegenerative disease, ALS (50). Multiple 
studies have proposed that SOD1 exerts its toxic effects via a gain-of-function 
mechanism where the formation of oligomers and/or aggregates directly contributes to 
motor neuron toxicity (158, 159, 166, 398). However, the conformation(s) that initiate the 
formation of these higher order species and lead to toxicity and cell death is not well 
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understood. One possibility pertains to local conformational changes, such as loop 
dynamics and barrel orientation, in the native state of SOD1 that could serve as a driving 
force for non-native self-association and aggregation. A similar mechanism has been 
proposed for another ALS-related protein, profilin 1 (441, 442), where mutations result in 
the formation of a small cavity but otherwise do not significantly impact the overall 
structure of the protein (441). However, in this study, a ThT binding FL lifetime assay 
and protease resistance identified the unfolded reduced SOD1 monomer, rather than the 
native state, as a candidate species that initiates the aggregation process. The unfolded 
state may serve as a common link in the pathogenesis of neurodegenerative diseases, such 
as Huntington’s (polyQ) (443), Parkinson’s (α-synuclein) (444) and, now, ALS. 
Multiple groups have implicated a protective role for the disulfide bond and metal 
ions during aggregation (109, 120, 445). In this study, the disulfide-bonded SOD1 did not 
aggregate at any protein concentration tested, in the absence of TFE and TCEP, 
regardless of the presence of an ALS-mutation (Fig. 6.3B, wells 1-12). Reduction of the 
disulfide bond may serve as a key step in the formation of the SOD unfolded state in ALS 
patients. The removal of the disulfide bond drastically reduces the thermodynamic 
stability of the WT SOD1 dimer to result in the dissociation to the monomeric state (65, 
433). ALS-inducing mutations further destabilize SOD1 to the point where some variants 
are >50% unfolded under physiological conditions (65). Another proposed mechanism of 
SOD1 aggregation occurs through disulfide crosslinking of the four cysteine residues 
(412, 427, 446, 447). However, whether this mode of action serves to initiate aggregation 
under cellular conditions or occurs as a byproduct of the SOD1 association is not well 
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understood (403). In a similar manner as the disulfide bond, the metal ions, in particular 
the zinc ion, contributes significant stability to the native and unfolded states of SOD1 
(64). Structural characterization through NMR, X-ray crystallography and molecular 
dynamic simulations of the apo- and metal-bound states reveal that the metal ions result 
in a reduced dynamics of the disordered zinc and electrostatic loops (62, 109, 448–451) 
and inhibit potential pathological misfolded conformations. Interestingly, crosslinking 
experiments revealed the epitope of the C4F6 antibody, which specifically recognizes 
misfolded conformations of SOD1, was exposed in metal-deficient and mutant variants of 
SOD1 (295) suggesting metal ions inhibit access to potentially toxic conformations. 
Therefore, the complexity of the SOD1 maturation pathway (68) offers multiple potential 
opportunities for therapeutic intervention (Fig. 6.1), including monomer folding (169, 
452), dimer association (121, 122, 453), disulfide bond formation and metal ion 
incorportation (295). 
ALS mutations in SOD1 do not cluster within one or two particular regions in 
sequence or structure (58), as has been shown for other ALS-linked proteins, such as 
TDP-43 and FUS/TLS (48). These mutations lead to an overall destabilization of the 
native SOD1 dimer (102, 106), through loss of the disulfide bond (65), metal 
coordination (64, 454), the overall thermodynamic stability (65, 103, 105, 106) or a 
combination of these events to result in increased populations of non-native 
conformations, including variants with increased exposure of normally buried 
hydrophobic surface area (455). Indeed, a commonality between all of the ALS variants 
of SOD1 may lie in the unfolded state of the polypeptide chain, as SOD1 is the slowest 
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known two-state folder examined (105). The SOD1 unfolded state is present during 
several stages of the lifetime of the protein, particularly during translation off the 
ribosome, prior to disulfide bond formation and incorporation of metal ions (456), and 
potentially when transported through mitochondrial membranes (457, 458). Indeed, 
SOD1 has been shown to aggregate on the cytoplasmic face of the outer mitochondrial 
membrane and the intermembrane space leading to ALS-like phenotypes in cell culture 
and animal models (427, 430, 431, 459). Additionally, evidence suggests SOD1 
oligomers can insert into the mitochondrial membranes to form channels (460). 
Furthermore, DNA damage has been implicated as a contributor to SOD1-mediated ALS 
(461). In cell culture models (60), including those shown in Fig. 6.8, display nuclear 
exclusion of mutant SOD1 resulting in increased levels of DNA damage (60). The 
nuclear exclusion may arise from the increased propensity to self-associate and form 
higher order species that cannot readily diffuse through the nuclear pore (462). Therefore, 
the SOD1 unfolded state could lead to neuronal death through mitochondrial dysfunction, 
DNA damage or other mechanisms (461). 
Previous studies of SOD1 aggregation have implicated a role of aggregate 
fragmentation as a secondary nucleation mechanism for propagating elongation (407, 
408, 415, 463). In these models, smaller SOD1 fragments can serve as seeds to bypass 
the lag phase normally observed. In the context of in vitro studies, fragmentation likely 
arises as a result of agitation, which can result in shearing of the protein and the exposure 
of hydrophobic surfaces (464, 465). The monomeric variant of SOD1 unfolds in a 
classical two-state manner with the population of only the native and unfolded states 
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(105, 433). Agitation, therefore, may induce the formation of aggregation-prone 
conformations resembling neither the monomer nor unfolded states, which are potentially 
not relevant for in vivo SOD1 aggregation. These insights suggest that while 
fragmentation may play a prominent contribution in some studies of in vitro SOD1 
aggregation, other mechanisms likely occur in cell culture, animal models and ALS 
patients. Indeed, the non-agitation-based ThT binding assay described here (Fig. 6.6B) 
suggests that secondary nucleation events, such as fragmentation, do not contribute to the 
aggregation of SOD1 (Fig. 6B and 6C, Table 6.3) (434). Furthermore, the elongation 
rates observed in live HEK-293 cells by FCS (Fig. 6.9B, Table 6.1) were similar to those 
observed in vitro and suggest that fragmentation does not significantly contribute to 
aggregation in cell culture. Indeed, the applicability of fragmentation as a major source in 
SOD1 aggregation observed in vitro (407, 408, 463) to cell culture, animal models and 
ALS patients is not clear. One study has suggested that fragmentation of SOD1, as a 
result of vigorous agitation, has shown similar kinetics to what has been observed in a 
G93A mouse model (415). However, it is conceptually challenging to understand how the 
agitation-based aggregation methods used in vitro are applicable to living cells and motor 
neurons. 
Protein aggregation is a common phenotype observed in a host of human diseases 
(20), but the identity of the species responsible for toxicity and neuronal cell death has 
remained elusive. In the case of Aβ, α-synuclein and tau, multiple studies have proposed 
the concept of small, soluble toxic oligomers mediating neurodegeneration (269, 272, 
435) rather than their later stage fibrillar or amorphous counterparts. In the case of SOD1, 
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non-native conformations and soluble aggregates have been attributed to the cytotoxicity 
observed in cell culture and animal models (174, 466, 467). Our lab and others (65, 407) 
have further identified the SOD1 unfolded state as a critical determinant in the nucleation 
of reduced SOD1 self-association into potential higher order toxic species. These results 
suggest that the selective targeting of the unfolded state may provide therapeutic benefit 
to ALS patients. One mode of action has been to enhance the natural cellular quality 
control mechanisms that govern cellular homeostasis, such as the molecular chaperones 
(468). The upregulation of the heat shock proteins (HSPs), HSP110, HSP70 and HSP40, 
have been shown to target disordered aggregated proteins (469) and promote refolding to 
their native conformations resulting increased clearance of SOD1 aggregates (470) and 
restored vesicle transport (471). Alternatively, gene silencing could reduce mutant SOD1 
expression and alleviate aggregation (472–476). Indeed, viral delivery of small 
interfering RNA (siRNA) (472, 473) or expression of a short RNA (shRNA), which 
specifically targets the G93A allele, resulted in a delayed onset of ALS phenotypes in 
G93A mouse models (474). A recent approach, using the small molecule-based copper 
delivery system, Copper-ATSM, has shown promise in G93A SOD1 mice by reducing 
the population of copper-depleted SOD1 (477). Furthermore, leveraging the plethora of 
insights into the structure of SOD1 and many of the ALS-variants, a computational-based 
screen of small molecules identified several putative lead compounds, which bound at the 
A4V SOD1 dimeric interface and reduced aggregation in vitro (122). These 
multidisciplinary approaches to search for potential therapeutics, while targeted by 
different mechanisms and stages of SOD1 maturation (Fig. 6.1), all aim to limit the 
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oligomerization and aggregation of toxic SOD1 species that result in motor neuron death 
in neurodegenerative diseases. The targeting of the native SOD1 dimer using small 
molecules to preferentially stabilize the native state will be further explored in Chapter 
VII.  
The unfolded state of SOD1 as a potential nucleus for templating the formation of 
oligomers and aggregates, as shown via enhanced protease digestion in the larger SOD1 
species (Fig. 6.11), suggests that sequence-specific motifs in the primary sequence of 
SOD1 may play a role in aggregation. A FRET-based analysis of SOD1 peptides revealed 
a collapse in the C-terminus of SOD1 in the absence of denaturant and suggests that bias 
exists in the unfolded state of SOD1 (Osman Bilsel, Noah R. Cohen, C. Robert 
Matthews, unpublished). Indeed, this region of SOD1 was the most protected in SOD1 
aggregates obtained from ALS patients (417) and a hexa-residue sub region was 
sufficient to induce fibrillation of full-length SOD1 (111). Therefore, the C-terminal 
peptide may serve as a candidate conformation for the development of antibodies to 
prevent this region of SOD1 from forming a potential seed leading to further SOD1 
misfolding and aggregation. 
In conclusion, the monomeric unfolded state of SOD1 has been proposed as the 
critical nucleus in the aggregation of SOD1. Furthermore, fragmentation of existing 
oligomers and aggregates does not significantly contribute to the aggregation mechanism, 
as evidenced by the Dobson fragmentation model (434) and the comparison of the 
elongation rates in vitro and in cells. Protease digestion revealed decreased trypsin 
resistance in soluble oligomers and insoluble aggregates compared to the soluble native 
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SOD1 dimer, suggesting possible increased contributions from unfolded species. These 
results suggest that SOD1 aggregation may proceed from an unfolded monomeric 
nucleus, which can serve as a target for antibodies or small molecules for therapeutic 
developments in the diagnosis and treatment of SOD1-mediated neurodegeneration. 
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Chapter VII - Searching for ALS Therapeutics: A Time-Resolved FRET Assay and 
Small Molecule Screen Targeting Stabilization of the A4V SOD1 Native State Dimer 
 
 
 
The work presented in this chapter is the manuscript planned for submission to Nature 
Methods or Journal of Biomolecular Screening. This manuscript is a result of a 
collaborative effort between Meme Tran, Hong Cao, Bob Matthews, Jill Zitzewitz and 
Osman Bilsel. Jill Zitzewitz and Osman Bilsel designed the FRET assay. I purified and 
labeled A4V T88C SOD1 for the determination of the A4V dissociation constant, high 
throughput screens and secondary assays. The high throughput screen was prepared in the 
Small Molecule Screening Facility at UMass Medical School by Hong Cao. Meme Tran, 
Jill Zitzewitz, Osman Bilsel and I performed the screens in the Single Molecule 
Fluorescence Facility in the Biochemistry and Molecular Pharmacology Department in 
UMass Medical School. I also performed the secondary screens, analyzed the data and 
wrote the manuscript with Jill Zitzewitz and Osman Bilsel. Bob Matthews, Jill Zitzewitz, 
Osman Bilsel and I contributed to the interpretation of the data. 
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Abstract 
 Riluzole is the only FDA-approved therapeutic for the neurodegenerative disease, 
amyotrophic lateral sclerosis (ALS). Mutations in superoxide dismutase I (SOD1) 
account for 20% of all genetically linked ALS. A subset of the ALS variants destabilize 
the native SOD1 dimer to enhance the population of the unfolded and monomeric states, 
which have been proposed as candidate species in mediating SOD1 aggregation. 
Targeting SOD1 with small molecules, which preferentially bind to the native SOD1 
dimer, would provide therapeutic benefit by limiting the population of the SOD1 
unfolded and monomeric states. Here, a robust and highly sensitive time resolved Förster 
Resonance Energy Transfer (tr-FRET) assay was designed to directly probe the 
monomer-dimer equilibrium of the ALS variant, A4V. This in vitro assay is optimal for 
small molecule screening as tr-FRET does not limit the overall dynamics of SOD1 or 
assume a pre-determined small molecule binding pocket. High throughput screening 
(HTS) with the tr-FRET assay resulted in robust Z-scores of >0.85 using a center-of-mass 
(COM) analysis of the AlexaFluor 488 fluorescence (FL) lifetime decay. COM analysis 
provided a significant improvement over FL intensity alone as COM avoids 
complications associated with the fluorophore concentration and laser power dependence. 
The tr-FRET assay identified several putative compounds with micromolar EC50 values 
that resulted in enhanced populations of the FRET-competent A4V SOD1 dimer. The 
small molecule stabilizers of the native SOD1 dimer could serve as tools to link cellular 
toxicity with the population of partially-folded states, as well as scaffolds for ALS 
therapeutic development to specifically target SOD1 in ALS. 
 290 
Introduction 
 Riluzole is the only FDA-approved treatment for the neurodegenerative disease, 
Amyotrophic Lateral Sclerosis (ALS), with a modest effect on prolonging patient lifespan 
(478). This small molecule acts as an antagonist to multiple receptors (115, 479, 480) and 
does not specifically target proteins associated with ALS. Mutations in the ALS-linked 
protein, superoxide dismutase I (SOD1) account for ~20% of familial ALS (fALS) (53). 
These mutations reside throughout the protein sequence (166) and directly impact the 
thermodynamics of SOD1 (103, 106). SOD1 folds through a three-state mechanism (2U 
D 2M D N2) with slow monomer folding (105) preceding the rapid formation of very 
stable homodimers (106). Thermodynamic and kinetic analysis of a host of different 
SOD1 variants suggest that mutations destabilize the native SOD1 dimer resulting in 
increased populations of the SOD1 monomer and unfolded states (65, 106), which are 
candidate species for initiating SOD1 aggregation in ALS. Therefore, stabilizing the 
native SOD1 dimer using small molecules may decrease the population of these 
potentially pathogenic forms of SOD1 and provide therapeutic benefit to ALS patients. 
 Precedence for a native state stabilization assay is provided by Jeffrey Kelly and 
co-workers who proposed that the stabilization of the native state of transthyretin (TTR) 
may provide a possible mechanism to inhibit amyloid formation in nervous system and 
heart amyloidosis (95, 97). TTR is normally a tetrameric complex (481, 482) that acts as 
a carrier for thyroxine and Vitamin A binding protein in the blood and central nervous 
system (483). However, mutations in TTR promote the dissociation of this complex to 
favor the monomeric and unfolded forms (481, 482), which are critical species for the 
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formation of aggregates and amyloids in affected tissues (484). A prime candidate 
molecule for stabilizing the native structure of TTR was the natural TTR ligand, 
thyroxine (95, 97, 116). Indeed, the small molecule, Tafamidis, has shown promise in 
clinical trials with a slowing of neurodegeneration and maintenance of small and large 
nerve fibers (98). Furthermore, other small molecules, termed “pharmacological 
chaperones”, have been identified as treatments for Fabry disease, Gaucher disease and 
phenylketonuria (99). These results suggest that a stabilizer of the native state of SOD1 
could serve as a powerful diagnostic and treatment tool to modulate the folding energy 
landscape to prevent misfolding and aggregation in ALS. 
In a similar manner as TTR, directly stabilizing the native dimer of SOD1 would 
limit the formation of aggregation-prone partially-folded species, such as the monomer 
and unfolded state, that may play a critical role in ALS pathogenesis. Indeed, the 
introduction of an intermolecular disulfide bond at the dimeric interface of SOD1 (120) 
and chemical crosslinking at Cys111 (485) resulted in increased thermal stability and 
decreased aggregation propensity of mutant SOD1. These results support a hypothesis 
that the stabilization of the native state of SOD1 is a prime approach to inhibit the 
formation of misfolded and aggregated SOD1 (169). However, SOD1 does not possess 
any known ligand that could serve as an initial scaffold for small molecule development 
and optimization, unlike thyroxine with TTR. Therefore, screening could identify lead 
putative compounds that bind and stabilize SOD1, preventing the accumulation of 
potential toxic misfolded SOD1 conformations. A computational screen modeled small 
molecules in a presumed binding pocket at the dimer interface of the wild-type (WT) 
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SOD1 and identified 15 compounds that resulted in stabilization of SOD1 (122) and 
conflicting effects on in vitro aggregation (122, 123). These contradictory results 
emphasize the need for a complementary unbiased in vitro screen to identify small 
molecule stabilizers of the native SOD1 dimer.  
The demetallated A4V SOD1 variant served as a model system for the 
development of an in vitro small molecule screen as the dual perturbations of 
demetallation and the A4V mutation further enhance the population of the non-native 
conformations that have been proposed as candidate species for nucleating SOD1 
aggregation (61, 100, 106, 289, 486, 487). A4V destabilizes the native SOD1 dimer 
through the selective perturbation of the monomer association reaction (Fig. 7.1A, dashed 
lines) to yield enhanced populations of the monomer and unfolded states (Fig. 7.1B, 
dashed lines). These non-native conformations could serve as precursor states for 
mediating SOD1 aggregation (Fig. 7.1A, arrows) in ALS patients. Thus, small molecules 
that preferentially target the native conformation of SOD1 (Fig. 7.1, purple hexagon) 
would stabilize the SOD1 dimer (Fig. 7.1A, solid lines) and reduce the population of the 
monomer and unfolded states (Fig. 7.1B solid lines). These compounds could serve as the 
foundation for therapeutics specifically targeting the native SOD1 dimer to inhibit SOD1 
aggregation in ALS patients. 
Here, a time resolved Förster Resonance Energy Transfer (tr-FRET) assay 
coupled with fluorescence lifetime detection was designed to monitor the association 
reaction of A4V SOD1 (Fig. 7.1). In comparison to the computational screening, this in 
vitro assay does not assume a pre-determined ligand binding site on SOD1 and allows for  
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Figure 7.1: Rationale for screening for small molecule stabilizers of the native A4V 
SOD1 dimer. (A) The A4V variant (dashed blue line) predominately destabilizes the 
monomer-dimer equilibrium to increase unfolded (orange line) and monomer (yellow 
circle) SOD1 formation compared to WT (solid blue line). Small molecules (hexagon) 
can bind to SOD1 and shift the equilibrium to favor dimer formation (double yellow 
circles). Small molecules will reduce the population of the potentially aggregation prone 
unfolded and monomeric species (red arrows). (B) Relative population of each species 
for A4V SOD1 (dashed) and upon addition of small molecule (solid). The A4V variant 
(dashed bars) is expected to predominately shift the population from the native dimeric 
SOD1 species to favor the monomeric states (106). Small molecules (solid bars) will 
reduce the unfolded and monomeric species and favor dimer formation. 
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SOD1 dynamics that are typically absent in X-ray crystal structures (453, 488). This 
robust, high throughput assay can direct quantify subtle shifts in the monomer-dimer 
equilibrium at nanomolar (nM) concentrations as tr-FRET is concentration independent 
and depends solely on the monomer and dimer SOD1 populations. Thus, tr-FRET is an 
ideal, unbiased assay to identify small molecule that preferentially stabilize the native 
dimeric state of the A4V SOD1. Small molecule screening under conditions favoring the 
monomer A4V SOD1 resulted in robust Z-scores and the identification of  >50 potential 
stabilizing compounds, as observed by the enhanced population of the FRET-competent 
A4V SOD1 dimeric state. These putative lead compounds may serve as tools to modulate 
the free-energy landscape of SOD1 to investigate the cellular and phenotypic 
consequences of partially-folded states of SOD1. Structural and chemical optimization of 
these scaffolds, which directly target SOD1 and its mutant variants, could provide a 
critical pathway for the treatment of ALS.  
 
Materials and Methods 
Protein Expression and Purification 
 The T88C mutation for extrinsic fluorophore incorporation was introduced into 
the A4V pseudo-WT background containing the C6A/C111S mutations (AS-SOD1). The 
recombinant protein was expressed as previously described (105, 106).  After extraction, 
the proteins were purified using Q Sepharose (GE Healthcare) resin followed by 
demetallation of SOD1 prior to a second Q sepharose column (105). For the variants 
lacking the T88C mutation, each protein was purified further by size exclusion 
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chromatography using Superdex 75 resin (GE Healthcare). The demetallated apo AS-
SOD1 will be noted as SOD1 unless otherwise noted. The protein concentrations, in 
terms of monomer concentration, were calculated using an extinction coefficient at 280 
nm of 5,400 M-1 cm-1. All proteins were dialyzed against 10 mM KPi pH 7.2, 1 mM 
EDTA for further studies and labeling procedures. 
 The apo-A4V T88C SOD1 was labeled separately with the fluorophores, 
AlexaFluor 488 (A488), AlexaFluor 594 (A594) and QSY9 C5-maleimide (Life 
Technologies), for 4 - 6 hours at room temperature. The resulting protein-fluorophore 
conjugates were extensively dialyzed against 10 mM KPi pH 7,2, 1 mM EDTA at 4°C to 
remove excess unreacted dye. Further purification using size exclusion and cation 
exchange chromatography was necessary to remove residual unreacted fluorophore and 
unlabeled A4V SOD1 protein. After purification and labeling, the protein purity was 
determined as >98% by SDS-PAGE and reverse-phase MALDI-TOF mass spectrometry 
at the Proteomics and Mass Spectrometry Facility at UMass Medical School. The 
labeling efficiency of the fluorophore-protein conjugate was determined from their 
absorbance at 280 nm and the appropriate fluorophore absorbance between 495 and 590 
nm followed by comparison of the CD spectra to unlabeled samples. The labeling 
efficiency for all samples was determined as >95% for these studies. 
 
Time Resolved Förster Resonance Energy Transfer (tr-FRET) Lifetime Assay  
 The FRET lifetime assay was performed in 200 µL reactions consisting of 10 nM 
donor A4V SOD1 with increasing concentrations of acceptor (A594 or QSY9) labeled 
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protein. The samples were excited at 473 nm with a 3.8 MHz repetition rate Ti/Sapphire 
laser in a 96-well glass bottom plate (Greiner) using a plate reader setup with time 
correlated single photon counting (TCSPC) lifetime detection of donor fluorescence 
using a 525 ± 39 nm bandpass filter (Semrock FF01-525/39). The detector aperture was 
adjusted using 10 nM A488 as a standard to ensure a count rate between 80,000 and 
100,000 counts per second prior to acquisition. Lifetimes were measured for 1 min in 15 
sec intervals with >10,000 counts total in the peak channel. The donor lifetimes were 
corrected for buffer contributions and bleed through from the acceptor and fit to two 
exponential decays using the in-house data analysis software, Savuka (194). The donor 
excited state decay is characterized by a single exponential ~4.1 ns excited state decay 
with an additional ~2.5 ns component upon addition of the acceptor (Fig. 7.2B). The 
fraction dimer for each protein concentration was determined from the ratio of the 
amplitude of the shorter lifetime component (~2.5 ns) to the total amplitude as shown in 
Eqn. 7.1: 𝜃 = !"#$%&'() ~!.!!"#$%&'() ~!.! ! !"#$%&'() ~!.!                                   (Eqn. 7.1)
The percentage of dimer was calculated as a function of increasing protein concentration 
and modeled to a monomer-dimer equilibrium (2M D N2) as shown in Eqn. 7.2 using 
Graphpad Prism 6: 
𝜃 = 𝑏 + 𝑚 − 𝑏 ∗ !!! ! !!,!"" – !!!! ! !!,!"" !!!"!!!!!!      (Eqn. 7.2) 
 298 
where Mt is the total protein concentration in terms of monomer SOD1 subunits, Kd,app is 
the apparent dissociation constant, and b and m are the baseline and maximum percentage 
dimer, respectively. 
 
Tryptophan Anisotropy 
 The anisotropy assay was performed using A4V SOD1 lacking the T88C 
mutation in 500 µL reactions of increasing protein concentrations ranging from 300 nM 
to 60 µM. The samples were excited at 295 nm in a 50 µL S1UV cuvette (Hellma) 
equipped with an autosampler and syringe pump. Samples were flowed in an oscillating 
pattern to minimize photo bleaching of the single intrinsic tryptophan in SOD1 (Trp32) 
and detected using TCSPC lifetime detection with a 357 ± 44 nm bandpass filter 
(Semrock FF01-357/44). N-acetyl-tryptophanamide (NATA) was used to adjust the 
photon counts to ensure a count rate between 80,000 and 100,000 for each sample with 
increasing protein concentration. An automated polarizer was incorporated into the 
configuration for data collection in the vertical and horizontal planes. Each sample was 
measured for total of 3 minutes in each orientation alternating in 30 sec intervals. The 
anisotropy decays were calculated from the vertical and horizontal detectors using Eqn. 
7.3: 𝐴𝑛𝑖𝑠𝑜𝑡𝑟𝑜𝑝𝑦 = !"#$%&'( – !∗!"#$%"&'()!"#$%&'( ! !!∗!"#$%"&'()                                      (Eqn. 7.3) 
The anisotropy as a function of protein concentration was modeled to a monomer-dimer 
equilibrium (Eqn. 7.2) using GraphPad Prism 6 to obtain the Kd,app of the A4V SOD1 
association in the absence of extrinsic fluorophores. The G-factor (G) was determined 
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from the integrated fluorescence of the vertical and horizontal polarized NATA decays 
with the first ns after excitation excluded. 
 
High Throughput Small Molecule Screen (HTS) 
 The tr-FRET small molecule screens were prepared in the Small Molecule 
Screening Facility at UMass Medical School and performed at the Single Molecule 
Fluorescence Facility within the Department of Biochemistry and Molecular 
Pharmacology at UMass Medical School. Each well of columns B through K on a glass 
bottom 96-well plate (Greiner) contained 195 µL of 330 nM labeled A4V SOD1 with a 
1:10 ratio of donor (A488) to acceptor (A594) to maximize the FRET competent state 
and minimize A594 bleed through into the donor channel. On each plate, 16 wells served 
as controls with eight 330 nM donor only samples containing 300 nM unlabeled A4V 
SOD1 as a negative control in the first column and eight containing increasing 
concentrations (> 1 µM) of acceptor labeled protein as a positive control in the last 
column. Compounds from the LOPAC (Sigma-Aldrich) and FDA-approved US and 
international drug collection (Microsource) were added to the plates at a final 
concentration of 100 µM and incubated at room temperature for 4 hours. The count rate 
was optimized using a 30 nM A488 control and the A488 excited state decay of each well 
was measured for 3 seconds. Each plate was read three times to minimize potential photo 
bleaching of the donor fluorophores. The data was analyzed to obtain the center-of-mass 
and FL total intensity of each well for each plate. The Z-score of each plate was 
calculated using the positive and negative controls (489). Compounds with a center-of-
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mass and FL total intensity lower than five standard deviations over the mean of the 
negative hits were considered potential hits for further studies. A subsequent assay using 
30 nM Alexa Fluor 488 in the absence of A4V SOD1 removed possible hits that directly 
result in quenching of the donor fluorescent probe. The small molecules alone were 
examined (i.e. no protein or A488) to exclude fluorescent compounds from consideration. 
A fast model independent analysis of the excited state decay utilized the first 
moment, alternatively referred to as the center-of-mass (COM), which is calculated 
according to Equation 7.3: 
   (Eqn 7.3)  
where Ii is the photon counts in the ith TCSPC channel, ti is the time of the ith channel 
and to  is the pulse arrival time.  It can be shown that the COM is mathematically 
equivalent to a quantum yield weighted average lifetime, as shown in Equation 7.4: 
   (Eqn 7.4)    
where αi is the amplitude of the ith exponential phase with relaxation time constant τi 
(490). 
 
Dose Response Titrations 
 The binding affinities of the potential hits were measured using the tr-FRET 
assay. Each compound was serial diluted to span nM to µM concentrations and 5 µL of 
< τ >=
Ii (ti − to )
i
∑
Ii
i
∑
< τ >=
αiτ i
2
i
∑
αiτ i
i
∑
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each compound was incubated with 195 µL of 330 nM labeled A4V SOD1 for 12 hours 
at room temperature. The amplitude and lifetimes were measured for each sample for 10 
seconds and repeated until >10,000 photons were obtained in the peak channel. The 
percentage of dimer as a function of compound concentration was determined using Eqn. 
1 and fit to the Hill Equation using GraphPad Prism 6 to determine the concentration with 
50% efficacy (EC50) as shown in Eqn. 7.4: 𝜃 = 𝑏 + 𝑚 − 𝑏 ∗ !!!! ! !"!"!                                               (Eqn. 7.4) 
where L is the concentration of the small molecule, n is the Hill coefficient, EC50 is the 
concentration of ligand with 50% efficacy, and b and m are the baseline and maximum 
percent dimer, respectively. Similarly, the tr-FRET dose response titrations were modeled 
using GraphPad Prism 6 to two simultaneous equilibria: the pre-existing monomer-dimer 
equilibrium in the absence of small molecule (2M D N2), which depends solely on the 
dissociation constant (Kd,app) of A4V SOD1, and the monomer-dimer equilibrium as a 
result of ligand binding (2M + nL D N2Ln) with the dissociation constant (KE) describing 
the ligand contribution to the monomer-dimer equilibrium as shown in Eqn. 7.5: 
𝜃 = 𝑚 – !! ! ! ! ! !!!,!""!!!!!! !!! !!!,!""!!!!!! !!                                          (Eqn. 7.5)
where L is the concentration of small molecule, Mt is the concentration of SOD1, n is the 
number of small molecules required for apo-A4V SOD1 dimerization, Kd,app is the 
dissociation constant of the monomer-dimer equilibrium in the absence of ligand and KE 
is the binding affinity of the small molecule for apo-A4V SOD1.  
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Fluorescence Correlation Spectroscopy 
 Fluorescence Correlation Spectroscopy (FCS) was performed on 200 µL samples 
containing 100 nM Alexa Fluor 488 labeled A4V AS-SOD1 with increasing 
concentrations of compounds after incubation for 12 hours at room temperature. The 
fluorophores were excited using a 488 nm laser through a 60x water immersion objective 
(Olympus UPlanSApo) in conjunction with a plate reader setup to create a confocal 
volume 30 microns above the coverslip glass-bottom 96-well plate. The fluorescence 
fluctuations were collected for 60 second acquisitions over 5 minutes using the SPC-150 
counting card and software. The autocorrelation functions were calculated for each trace 
using the Burst Analyzer Software 2.0 (Becker & Hickl). For a homogeneous sample, the 
diffusion time (ms) and number of particles (N) within the confocal volume was 
determined using the Burst Analyzer Software (Becker & Hickl) using the following 
equation (Eqn. 7.6): 
𝐺 𝜏 = !! ∗ 1 + !!! !! 1+ 𝜔! !!! !!/!                 (Eqn. 7.6) 
where N is the number of particles, τ is the delay time, ω defines the confocal volume 
through the radius ratio of the z-axis to the xy-plane and τD is the diffusion time. In some 
cases, the heterogeneity of the sample required the addition of a second diffusion time as 
described in Eqn. 7.7:  
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𝐺 𝜏 = !! 𝐴 1 + !!!! !! 1+ 𝑤! !!!! !!! + 1− 𝐴 1 + !!!! !! 1+
𝑤! !!!! !!!   (Eqn. 7.7)
where τD1 and τD2 are the diffusion times of the first and second species and A is the 
fractional population of the species with the diffusion time, τD1. The number of particles 
and diffusion coefficients as a function of small molecule concentration were modeled 
Eqn. 4 to determine the EC50 of the various compounds on A4V AS-SOD1 through the 
FCS measurements. 
 
Results 
Probing the monomer-dimer equilibrium of the A4V SOD1 variant using tr-FRET 
 The AS-SOD1 variant was used for these experiments as the removal of the free 
cysteine residues at positions 6 and 111 (C6A/C111S) enhances the thermodynamic 
reversibility of SOD1 folding and eliminates alternative cysteine donor and acceptor 
labeling sites that require maleimide chemistry for irreversible fluorophore insertion. The 
thermodynamic and kinetic folding properties of this dual mutant are similar to the WT 
SOD1 (105) supporting its usage as a model system for the SOD1 small molecule screen. 
Furthermore, the copper and zinc metal ions (Fig. 7.2A) greatly stabilize the protein (64), 
and their removal enhances the population of the SOD1 monomer and unfolded  
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Figure 7.2: Probing the monomer-dimer equilibrium using tr-FRET. (A) Ribbon 
diagram of the SOD1 homodimer. Each monomer contains an 8-strand β-barrel (yellow), 
a zinc binding loop (blue) and an electrostatic loop (green). The T88C mutation for 
extrinsic fluorophore incorporation is shown in red on β5, away from the dimer interface. 
Green and red spheres represent the donor (A488) and acceptor (A594) fluorophores, 
respectively. SOD1 was labeled with either A488 or A594, which result in FRET-
competent SOD1 dimers upon re-equilibration. (B) The donor FL excited state decay can 
quantitatively discriminate between monomer and dimer SOD1 populations. At monomer 
SOD1 favoring concentrations, the donor SOD1 exhibits a single exponential excited 
state decay (green). Dimerization at higher protein concentration with acceptor-labeled 
SOD1 results in quenching of the donor fluorescence and faster lifetime component (red). 
The amplitude of each lifetime component is proportional to the SOD1 monomer and 
dimer population (Eqn. 1). 
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states, especially in ALS variants (106). Indeed, metal analysis on SOD1 extracted from 
ALS patient and mouse model tissues have suggested that incomplete metal ion loading 
may play a role in the initial toxicity, aggregation and pathogenesis of ALS (106, 491–
493). Thus, the apo-AS-SOD1 is an ideal model system to specifically target partially 
folded SOD1 species with small molecules, without the complexities associated with 
proper metal loading and potential non-native disulfide bonds. In this study, the apo-AS-
SOD1 protein is referred to as SOD1 for simplicity, unless otherwise noted. 
 In order to identify small molecule binders, which alter the energy landscape of 
A4V SOD1, a tr-FRET assay coupled with time-correlated single photon counting 
(TCSPC) was devised to specifically monitor the SOD1 monomer-dimer equilibrium. A 
non-native cysteine at threonine 88 (T88C) was introduced on β5, away from the dimer 
interface (Fig. 7.2A, red). Pools of the non-native external cysteine variant, A4V T88C 
SOD1, was labeled using either the donor (A488) or the acceptor (A594) fluorophores, 
which re-equilibrate upon mixing to form a FRET-competent pool of A488-A594 A4V 
SOD1 dimer. This FRET pair has the high quantum yield, brightness and photostability 
that allows for highly sensitive quantification of association at nanomolar and sub-
nanomolar concentrations. As the dissociation constant (Kd,app) for SOD1 has been 
previously reported in the nanomolar regime (106), the A488-A594 donor–acceptor pair 
is ideally suited for directly quantifying the monomer-dimer equilibrium populations at 
these concentrations. At concentrations significantly below the Kd,app, the monomer is 
favored and the donor (A488) fluorophore approaches a single exponential decay with a 
~4.1 ns lifetime (Fig. 7.2B, green). At increased protein concentrations, the equilibrium 
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shifts towards the native dimeric SOD1. In this case, the donor has the opportunity to 
form a dimer with an acceptor-labeled SOD1 monomer resulting in dynamically 
quenched donor fluorescence due to the presence of the acceptor. As a result of the 
dimerization, a shorter lifetime component (~2.0 ns) contributes to the donor lifetime 
decay leading to a reduced lifetime center of mass (COM) (first moment) and total 
fluorescence (FL) intensity compared to the donor only (Fig. 7.2B, red). The amplitude of 
each excited state decay component directly correlates to the populations of the monomer 
and dimer states of SOD1 (Fig. 7.2B) using Equation 1 to determine the fraction dimer at 
a given protein concentration. 
 Using this approach, increasing concentrations of the A594-labeled A4V T88C 
SOD1, ranging from nM to µM, was titrated into a fixed concentration of A488-labeled 
A4V T88C AS-SOD1. Representative lifetime decays for the donor only and a donor-
A594 samples are shown in the inset of Figure 7.3A. The A488 fluorescence excited state 
decay was fit to a single exponential with a lifetime of 4.07 ± 0.03 ns (Fig. 7.3A inset, 
green), while addition of the excess acceptor results in a shorter 2.45 ± 0.01 ns 
component due to A488 quenching. The amplitudes of each component to the A488 
lifetime decay were used to determine the fraction dimer at each protein concentration 
(Eqn. 7.1) and fit to a monomer-dimer equilibrium using Eqn. 7.2 (Fig. 7.3A). The Kd,app 
for A4V AS-SOD1 was determined as 1.08 ± 0.21 µM, an order of magnitude weaker 
than previously reported (106). Due to significant bleed through of the A594 fluorescence  
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Figure 7.3: Measurement of the monomer-dimer equilibrium of A4V SOD1 by tr-
FRET using AlexaFluor 594 and QSY9 acceptor fluorophores. (A) Fraction dimer as 
function of total A4V SOD1 protein concentration calculated from the amplitudes of the 
donor and A594 acceptor fluorophores at each concentration. Representative excited state 
decays of donor-only (green) and donor + A594 (red) A4V SOD1 are shown in the inset 
after correcting for buffer and acceptor fluorescence contributions. The ratio of amplitude 
of the donor (4.07 ± 0.03 ns) and acceptor (2.45 ± 0.01 ns) lifetime components is 
proportional to the dimer population (Eqn. 1). (B). Fraction dimer as a function of protein 
concentration using the quencher, QSY9, as an acceptor to overcome the significant bleed 
through of A594 in the donor fluorescence channel at high concentrations. Representative 
excited state decays of the donor-only (green) and donor-QSY9 (red) A4V SOD1 are 
shown in the inset. The lifetime of the donor-only and donor-acceptor between A594 and 
QSY9 were similar with the donor-only and donor + QSY9 samples having lifetimes of 
4.11 ± 0.01 ns and 2.49 ± 0.01 ns, respectively. The representative donor + QSY9 trace 
corresponds to the fraction dimer indicated by the red arrow. In both cases, the apparent 
dissociation constant (Kd,app) was 1.23 ± 0.04 µM, over three orders of magnitude weaker 
than the reported Kd,app for WT (106). This agreement with Kd,app measurements made 
using unlabeled A4V SOD1 (using Trp Anisotropy as a probe suggests A594 bleed 
through does not affect the accuracy of the measurement. 
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Figure 7.4: Fluorescent bleed through effects of A594 and QSY9. FL lifetime 
measurements of A594 (A) and QSY9 (B) reveal significant contribution from the A594 
fluorophore at >45-fold the donor concentration, where as QSY9 does not significantly 
fluoresce at concentrations >20,000-fold the donor. Insets depict the same data as shown 
in A and B, but on a log scale. Both acceptors resulted in the measurement of similar 
dissociation constants and, thus, a 1:10 donor to A594 ratio was employed for the HTS, 
as this ratio does not significantly contribute to the donor fluorescence signal.  
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Figure 7.5: The extrinsic fluorophores do not perturb the association reaction of 
A4V SOD1. Trp anisotropy measurements at increasing concentrations of total A4V 
SOD1 ranging from 0.3 to 60 µM, reveal a Kd,app of 0.97 ± 0.40 µM, comparable to the 
dissociation constant obtained through tr-FRET. The Trp anisotropy experiment was 
performed in the absence of the T88C mutation to mitigate non-native disulfide bond 
formation at this exposed cysteine. 
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into the A488 channel (Fig. 7.4A), the acceptor was replaced with the quencher, QSY9, 
to identify whether contributions from the acceptor may cause the 10-fold weaker 
observed Kd,app obtained through tr-FRET.  In comparison to A594, which contributes 
significantly to fluorescence bleed through at concentrations >45-fold the donor 
concentration (Fig. 7.4A), the QSY9 fluorescence was relatively non-existent, even at 
concentrations >20,000-fold the donor concentration (Fig. 7.4B). This decrease in 
fluorescence contribution from the acceptor allowed the examination of total monomer 
concentrations greater than 100 µM (Fig. 7.3B). As a result, modeling both the A488-
A594 and A488-QSY9 FRET pairs to a monomer-dimer equilibrium resulted in similar 
Kd,app for each FRET pairs (A488-A594: 1.27 ± 0.07 µM, A488-QSY9: 1.37 ± 0.07 µM). 
Furthermore, to ensure the incorporation of extrinsic fluorophores itself did not perturb 
this equilibrium, the single Trp residue in SOD1 (Trp32) was used to measure Trp 
anisotropy in a non-T88C variant of A4V SOD1 (Fig. 7.5). As expected, the Kd,app 
obtained through this method (0.97 ± 0.10 µM) is in agreement with the tr-FRET assay, 
suggesting the fluorescent probes do not disturb the SOD1 structure or destabilize the 
monomer-dimer equilibrium. Global fitting of all the monomer-dimer equilibrium data 
sets revealed a Kd,app of 1.23 ± 0.04 µM for the A4V SOD1 variant, over three orders of 
magnitude weaker than WT (106) and would result in a significant population of the 
monomeric species at cellular SOD1 concentrations (10 – 100 µM; ~25 – 10% monomer) 
(Fig. 7.1). Thus, the tr-FRET assay using the A488-A594 FRET pair is a highly sensitive 
and robust assay that can selectively monitor and quantify subtle shifts in the monomer-
dimer equilibrium of A4V SOD1 in the nM to µM concentration range. 
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tr-FRET HTS assay 
 The Kd,app for the A4V ALS-variant (1.23 ± 0.04 µM) is three-orders of 
magnitude weaker than WT (106) leading to a significant increase in the monomer 
population for this ALS variant at µM concentrations compared to WT (Fig. 7.1). Thus, 
the tr-FRET assay is optimal to identify putative compounds that preferentially stabilize 
the native dimeric form of A4V SOD1 and reduce the population of the potentially-
aggregation prone monomers (Fig. 7.1). In order to enhance the probability of A488-
A594 A4V SOD1 dimers, a 1:10 ratio of the A488 to A594 SOD1 was used, which 
results in <1% donor homodimers and a signal-to-noise increase of 21.8-fold compared to 
equimolar A488 and A595 A4V SOD1, while simultaneously limiting A594 bleed 
through effects (Fig. 7.4A) 
Two 1280-compound libraries were chosen for small molecule screening, the 
Library of Pharmacologically Active Compounds (LOPAC) and the Microsourse FDA-
approved Drug Library. The LOPAC library contains a large selection of bioactive small 
molecules that cover most drug target classes, including receptor inhibitor, ligands and 
hormone among others, while the FDA-approved library was chosen as all compounds 
provided in the small molecule library have a high degree of drugability and have been 
approved for the treatment of various human diseases. These libraries provide a range of 
compounds that may be adapted for use in stabilizing the native dimer of A4V dimer.  
For the small molecule screening, the A4V SOD1 monomer-dimer equilibrium was  
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Figure 7.6: HTS for small molecule stabilizers of the A4V SOD1 dimer. (A) Plate 
setup of the HTS screen. Wells containing different compounds are in columns B through 
K (blue). Negative (green) and positive (rainbow) controls for each plate were in columns 
A and L, respectively. (B). Raw excited state decays from plate 12, row 2. The donor-
only (green) control displays a single exponential decay while the positive control (red) 
has a shorter component and decreased fluorescence intensity. Negative hits (blue) show 
no change in the A488 FL lifetime upon addition of small molecule. A positive hit 
(black) has a large amplitude contribution from the shorter lifetime component resulting 
from quenching of the donor fluorophores, suggesting this compound increases the 
population of the dimer in a FRET-competent state. 
 
 
 317 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 318 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7: Comparison of the lifetime COM and FL total intensity of plate 12. (A). 
COM analysis of the excited state decay and (B) total FL intensity upon integration of the 
excited state decay. The cutoff value for potential hits (dashed line) is represented as 5X 
the standard deviation of the negative controls (green). The acceptor titration (red) shows 
decreasing COM and FL intensity of the donor FL lifetime due to dynamic quenching via 
FRET. Negative hits are shown in blue with positive hits encased in a black square. The 
Z-score for each analysis of plate 12, COM (0.90) and FL total intensity (0.64), suggest 
an enhanced reliability of lifetime analysis to discriminate between the negative and 
positive controls compared with measuring FL intensity alone. The Z-scores from the 
COM analysis (LOPAC: 0.91 ± 0.02, FDA: 0.88 ± 0.05) suggests that the lifetime 
measurement provides a more reliable assay due to the fluorophore concentration and 
laser power independence of the FL lifetime compared to FL intensity (LOPAC: 0.75 ± 
0.10, FDA: 0.52 ± 0.11). 
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poised to favor the formation of monomeric A4V SOD1 with ~20% dimer to allow for 
the identification of small molecules with µM binding affinity. Based on the Kd,app of 
A4V SOD1 (Fig. 7.3), 30 nM A488-labeled and 300 nM A594-labeled A4V SOD1, 
resulting in ~25% dimer, was incubated with 100 µM final concentration of compound in 
2.5% DMSO. The 96-well plate setup is shown in Fig. 7.6A as described in Material and 
Methods with negative and donor + acceptor controls in the first and last columns, 
respectively. The compounds were incubated with the 330 nM A488-A594 A4V SOD1 in 
wells B through K. The A488 excited state decays for plate 12, row 2 of the LOPAC 
library is shown in Fig. 7.6B as an example, with the donor-only control in green, donor 
+ acceptor control in red, and sample wells in blue. In this case, the compound in well 16 
(Fig. 7.6B, black) showed a shorter lifetime component than in the negative sample wells 
suggesting this molecule shifted the equilibrium towards a FRET-competent 
conformation. COM analysis (quantum yield-weighted average lifetime)(Fig. 7.7A) and 
integration of the excited state decay (FL total intensity, Fig. 7.7B) were used to identify 
potential putative stabilizers of the native A4V SOD1 dimer, using 5 standard deviations 
from the negative controls as a cutoff value (Fig. 7, black dashed line). Indeed, in the case 
of plate 12, two compounds have a decrease in the COM and FL total intensity (Fig. 7.7, 
black squares). Analysis of all of the plates of the LOPAC (Fig. 7.8) and FDA (Fig. 7.9) 
libraries through COM (Figs. 7.8A and 7.9A) and FL total intensity (Figs. 8B and 9B) 
revealed >30 hits per library that resulted in a decrease in COM and FL total intensity. 
For some compounds, the analysis revealed an increase in the COM beyond 4.1 ns, the 
average lifetime of the A488 (Fig. 7.8A and 7.9A) suggesting these specific compounds  
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Figure 7.8: COM (A) and FL total intensity (B) analysis of all compound wells of the 
HTS of the LOPAC library. The negative and positive controls for each plate have been 
removed for clarity. The solid line in each analysis method represents the cutoff value for 
potential hits, defined as 5X the standard deviation of the negative controls. The small 
variations between wells analyzed by the COM method resulted in more reliable Z-scores 
than the corresponding plates measured by the FL total intensity, which is more sensitive 
to laser power and fluorophore concentration. Compounds below these cutoff values were 
chosen for further analysis using an A488 only control (i.e. no A4V SOD1) to remove 
natural quenchers of the A488 fluoresence. Due to improper plate setup on plate 15 
(wells 1344-1440) with variable volumes of 300 nM A4V T88C AS-SOD1, these “hits” 
were not considered for future experiments. 
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Figure 7.9: COM (A) and FL total intensity (B) analysis of all compound wells of the 
HTS of the FDA-approved library. The negative and positive controls for each plate 
have been removed for clarity. The solid line in each analysis method represents the 
cutoff value for potential hits, defined as 5X the standard deviation of the negative 
controls. 
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are fluorescent themselves and contribute to the observed FL excited state decay (Fig. 
7.7A, well 46). In addition, several compounds result of in a COM comparative to the 
donor only controls (COM = ~4.1) suggesting that these compounds shift the equilibrium 
further away from the A4V SOD1 dimer towards a more monomeric state. These types of 
small molecule were similar in abundance as the potential hits (~20 per plate) and were 
immediately discarded in further analyses. All of the potential hits were re-screened using 
only 30 nM A488 (i.e. no A4V SOD1) to eliminate compounds that directly quench the 
donor fluorescence (~10 per library). A complete list of the putative hits, including their 
library position, COM, intensity and the Sigma-Aldrich catalog number (LOPAC) or 
CAS Number (FDA-approved), are provided for each small molecule library in Tables 
7.1 and 7.2. Compounds that were selected for further study, based on availability, are 
denoted with an asterisk (*). Interestingly, the compound, niclosamide, present in both 
the LOPAC and FDA-approved libraries, was designated as a potential hit during 
screening and served as a successful reproducibility control for the tr-FRET HTS. 
The Z-score (489) of each plate was determined using lifetime COM and FL total 
intensity to determine the reliability of these two complementary detection methods to 
identify changes in the dimerization state of A4V SOD1. The average Z-score for the 
COM analysis for the LOPAC and FDA libraries was 0.91 ± 0.02 (Fig. 7.8A) and 0.88 ± 
0.05 (Fig. 7.9A), respectively. These high Z-scores are indicative of the reliability of the 
tr-FRET to distinguish between the positive and negative controls leading to a robust and 
highly sensitive assay to identify lead compounds to stabilize the native A4V SOD1 
dimer. Conversely, the Z-scores by FL intensity (LOPAC: 0.75 ± 0.09; FDA: 0.52 ±  
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0.11) are indicative of the higher FL total intensity variability from plate to plate. The 
differences between the two analysis methods result from relative insensitivity of the 
COM analysis to variations in the fluorophore concentration, as the COM solely depends 
on the population of monomer and dimer A4V SOD1. However, minute differences in 
pipetting and robotics would result in higher well-to-well variability in fluorophore 
concentration, as well as altered laser power, would directly impact the FL total intensity 
and lead to a lower signal to noise ratio compared to FL lifetime measurements (Figs. 
7.7-7.9, black lines). Indeed, as shown in Figure 7.8, the A488 excited state decays of 
wells 865-1536 were measured on an alternate day than wells 1-864. Small differences in 
laser power or A488 and A594 concentration drastically affected the FL total intensity 
(Fig. 7.8B) but have little effect on COM (Fig. 7.8A). These results further strengthen the 
power of time-resolved lifetime-based fluorescence techniques as a sensitive and highly 
robust method for the identification of lead compounds to shift populations between 
monomeric and dimeric states over FL total intensity alone. 
 
Secondary screens identify 4-amino-1,8-naphthalimide as a scaffold for further 
optimization 
 From the initial compounds obtained from the tr-FRET HTS (Tables 7.1-7.2), 
eleven compounds were selected for further characterization through secondary screens. 
Through the use of the tr-FRET assay, EC50 binding affinities were obtained for each 
selected compound through dose response curves as shown in Figures 7.10 and 7.11. The 
structure of the respective compounds (obtained from the Sigma-Aldrich website) are  
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Figure 7.10: Small molecules stabilize the A4V SOD1 dimer with micromolar 
affinity by tr-FRET. Dose response curves at a fixed protein concentration A4V SOD1 
and increasing concentration of small molecule compound. The dose response curves of 
4-amino-1,8-naphthalimide (A), oleic acid (B), L-ascorbyl palmitate (C) and retinoic acid 
(D) are shown with their corresponding structures obtained from the Sigma-Aldrich 
website (4-amino-1,8-naphthalimide: A0966, oleic acid: O1008, L-ascorbyl palmitate: 
A1968, retinoic acid: R2625). 4-amino-1,8-naphthalimide has the tightest EC50 amongst 
the compounds tested (0.91 ± 0.07 µM) with the remaining 3 compounds having EC50 
values ranging between 30.8 – 1010 µM.  
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Figure 7.11: tr-FRET dose response curves of L701,324 (A), niclosamide (B), 
GW5074 (C), p-phenylene diisothiocyanate (D), K114 (E) and β-estradiol 17-acetate (F) 
with corresponding structures obtained from the Sigma-Aldrich website (L701,324: 
L0258, niclosamide: N3510, GW5074: G6416, p-phenylene diisothiocyanate: CAS 
Number 4044-65-9, K114: K1015, β-estradiol 17-acetate: E7879). Each compound with 
the exception of L701,324, has an EC50 value >100 µM. Furthermore, all compounds, 
except K114, form A4V AS-SOD1 dimers by FCS measurements. 
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also shown in Figures 7.10 and 7.11. These molecules have a wide range of functions 
(Table 7.3) ranging from vitamin derivatives (ascorbyl palmitate and retinoic acid), 
hormone and steroid derivatives (betamethasone-17,21-dipronoionate and estradiol 
acetate) to inhibitors (4-amino-1,8-nahthalimide, L-701,324, GW5074), The hits also 
tend to contain aromatic groups with some compounds, such as oleic acid, ascorbyl 
palmitate and retinoic acid, containing large alkyl groups. In these experiments, each 
small molecule compound was titrated into a fixed protein concentration and the 
amplitudes of the donor and donor-acceptor A488 lifetimes were monitored with 
increasing compound concentration. At concentrations significantly below the EC50, the 
fraction dimer (% dimer) remains between ~10-15% due to the positioning of the A4V 
SOD1 monomer-dimer equilibrium (Fig. 7.3) for these experiments. At higher 
concentrations, the small molecule enhances the formation of the native A4V SOD1 
dimer and promotes the formation of a FRET-competent state. By this assay, four of the 
examined compounds have a reported EC50 (Eqn. 7.4) below 100 µM (Table 7.3). The 
remaining molecules largely have EC50 values in the range of 200-400 µM, with one 
(Estradiol Acetate) having a low-affinity binding with an EC50 of >1 mM (Table 7.1). 
The small molecule, 4-amino-1,8-naphthalimide (Fig. 7.10A), showed the tightest 
apparent binding affinity in the tr-FRET assay with an EC50 of 0.91 ± 0.07 µM (Table 
7.3). In addition, the Hill coefficients ranged between ~1-2.5 (Table 7.3) suggesting the 
possibility of multiple ligands binding to A4V SOD1 through positive cooperativity. 
Alternatively, the fraction dimer of A4V SOD1 as a function of compound concentration  
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was modeled to two equilibria consisting of a pre-existing monomer-dimer equilibrium 
and a second equilibrium in the presence of compound (Materials and Methods, Eqn. 
7.5). In this model (Table 7.4), the number of ligands, n, is directly related to the 
cooperativity of the small molecule binding to A4V SOD1. In most cases, n is >1 and 
further suggests that either multiple small molecules can bind to the A4V SOD1 dimeric 
state or that the small molecules can stabilize the individual monomers, thus, enhancing 
dimerization. 
In addition to the tr-FRET assay, FCS was chosen as a complementary method to 
examine the A4V SOD1 monomer-dimer equilibrium, as this technique does not rely on 
FRET-competent states between two fluorophores. Furthermore, FCS can directly 
quantify the diffusion time and number of particles in a small confocal volume to identify 
differences between monomer, dimer and higher species, such as small oligomers and 
larger aggregates. Using this approach, the autocorrelation function of A488-labeled A4V 
SOD1 was determined in the presence of increasing concentrations of small molecule 
using single or double diffusion time models (Eqns. 7.6 and 7.7). The number of 
molecules and diffusion times as a function of concentration for two compounds, 4-
amino-1,8-naphthalimide and oleic acid, are shown in Figure 7.12. The titration with 4-
amino-1,8-naphthalimide revealed the expected decrease in the number of particles 
consistent with the formation of A4V SOD1 dimers (Fig. 7.12A), suggesting that this 
compound does stabilize the native state of A4V SOD1. Both the number of particles 
(Fig. 7.12A, closed circles) and diffusion time (Fig. 7.12A, open circles) revealed similar 
EC50 values (Table 7.5; number of particles: EC50 = 0.89 ± 0.45 µM, diffusion time: EC50  
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Figure 7.12: 4-amino-1,8-naphthtalimide induces the dimerization of A4V SOD1 by 
FCS. Dose response curves by FCS monitoring number of particles (closed circles) and 
diffusion time (open circles) upon addition of 4-amino-1,8-naphthalimide (A) and oleic 
acid (B) to 100 nM A488-labeled A4V SOD1. Solid and dashed lines represent the model 
to the Hill equation (Eqn. 3) for number of particles and diffusion time, respectively. 
Increasing 4-amino-1,8-naphthalimide concentrations results in a decrease in the number 
of particles (closed circles, solid line) by a factor of 2 suggesting a shift from monomer to 
dimer A4V T88C AS-SOD1. The EC50 values obtained through the FCS measurements 
(number of particles: 0.89 ± 0.45 µM, diffusion time: 0.79 ± 0.07 µM) are similar to those 
obtained by tr-FRET (0.91 ± 0.07 µM). In contrast, at low concentrations of oleic acid, 
aggregation is induced as evidenced by a >30-fold decrease in the number of particles 
and >15 increase in diffusion coefficient. Furthermore, the EC50 values are not coincident 
between the number of particles (0.02 ± 0.01 µM) and diffusion time (0.77 ± 0.43 µM) or 
with the EC50 obtained by tr-FRET (30.8 ± 2.0 µM), suggesting oleic acid induces 
oligomerization in a manner that appears as dimerization by tr-FRET. 
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= 0.79 ± 0.07 µM) that are in agreement with the EC50 obtained by tr-FRET (Table 7.3, 
0.91 ± 0.07 µM). Intriguingly, the autocorrelation functions of oleic acid (Fig. 7.12B), 
which has a reasonably tight binding affinity using the tr-FRET assay (30.8 ± 2.0 µM), 
revealed a drastic change in the number of particles and diffusion time compared to 4-
amino-1,8-naphthalimide. In this case, addition of oleic acid to A4V SOD1 resulted in a 
>30-fold decrease in the number of particles and a >15-fold increase in the diffusion 
time. Furthermore, neither dose-response curves (Fig. 7.12B) are coincident with the 
dose-response by tr-FRET (Fig. 7.10B, Tables 7.3 and 7.4) with EC50 values of 0.02 ± 
0.01 µM and 0.77 ± 0.43 µM, respectively. The large changes in number of particles and 
diffusion times suggests that oleic acid promotes the aggregation of A4V SOD1 rather 
than dimerization, even below the critical micelle concentration of oleic acid (494). The 
aggregation occurs at concentrations below the tr-FRET EC50 of oleic acid and likely 
positions SOD1 monomers in a FRET-competent state once these oligomers/aggregates 
are of a particular size. Further examination of the other compounds (Table 7.1) revealed 
similar A4V SOD1 aggregation-inducing tendencies for ascorbyl palmitate and K114. 
This data suggests that while tr-FRET is a robust method for identifying putative 
candidates for stabilizing the native conformation of A4V SOD, further secondary 
screening can validate some potential candidates because they do not cause A4V SOD1 
aggregation. Therefore, this highly sensitive and robust tr-FRET HTS has identified small 
molecules which stabilize the native A4V SOD1 dimer against the population of its 
monomeric and unfolded forms. These results have revealed a potential small molecule, 
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4-amino-1,8-naphthalimide, that may selectively target and stabilize the SOD1 native 
state in SOD1-mediated ALS. 
 
Discussion  
 Riluzole is the only FDA-approved treatment for ALS with a modest effect on 
prolonging life, typically three to six months (112–114). This treatment is not specific, 
but rather interferes with glutamate receptors (115). This off-target effect results in the 
treatment of ALS symptoms but does not directly target a specific or subset of ALS-
related proteins. The lack of specificity to drug treatments is a critical gap in the 
therapeutic development of ALS treatments. Here, a novel tr-FRET assay coupled to 
time-correlated single photon counting was developed to leverage the biophysical 
understanding of the folding energy pathway of SOD1 to specifically target the 
monomer-dimer equilibrium (Fig. 7.3) with small molecules stabilizers of the native A4V 
SOD1. Using lifetime-based detection, Z-scores that were significantly more robust than 
with fluorescence intensity (Figs. 7.7-7.9) with the identification of ~50 potential lead 
therapeutics (Tables 7.1 and 7.2) from the 1280 compounds in each of the LOPAC and 
FDA-approved libraries. Further examination of eleven compounds has revealed EC50 
values under 1 mM with the molecule, 4-amino-1,8-naphthalimide, showing the highest 
binding affinity using tr-FRET and FCS (Figs. 7.10A and 7.12A, Tables 7.3-7.5). Other 
compounds, such as oleic acid, ascorbyl palmitate and K114, bind and stabilize A4V 
SOD1 using tr-FRET but were shown to enhance the formation of larger oligomeric 
species and aggregates of A4V SOD1 via FCS (Fig. 7.12B and Table 7.3). This tr-FRET 
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assay provides a robust, highly sensitive, novel high throughput approach to directly 
probe the populations of monomeric and dimeric SOD1 and identified a potential lead 
compound, 4-amino-1,8-naphthalimide, that can serve as a scaffold for further 
optimization for specific targeting of SOD1 in ALS. 
 A similar approach has been used for the design of therapeutics targeting TTR, 
where mutations act in a similar manner as SOD1 and cause the dissociation of the native 
tetramer to form folded and unfolded monomers (88, 89, 495). Unlike SOD1, which has 
no known natural ligand, TTR contains a thyroxin binding site and served as a target for 
the design of stabilizers of the TTR tetramer (116, 118, 496). Indeed, small molecules 
have been developed against a wide-range of targets ranging from SIRT1 activation in 
type 2 diabetes (125), p53 inhibition in cancer (497) and polyglutamine inhibition in 
Huntington’s Disease (498). However, no known small molecule therapeutic specifically 
targeting an ALS-linked protein has been developed. In 2004, Lansbury and collegues 
(122) used structural studies coupled with computational modeling to identify compounds 
to stabilize the native SOD1 against misfolding. Though specifically targeting a cavity at 
the SOD1 dimer interface, subsequent structural studies revealed an alternative binding 
site near Trp32 with little to no effect on the aggregation of ALS-linked variants (123). 
The ability of the compounds identified in the in vitro tr-FRET assay to inhibit 
aggregation has yet to be examined. To our knowledge, this study is the first in vitro 
assay to specifically target the SOD1 monomer-dimer equilibrium and provided several 
putative compounds, which when used in combination with computational methods, can 
serve as potential scaffolds for further optimization for therapeutics. Structure-based 
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design has been used successfully in the development of inhibitors targeting viral 
proteases (499) as these proteins have high mutation rate and rapid resistance to available 
therapeutics (500). 
 Protein-protein interaction and protein folding have long been studied using tr-
FRET-based approaches to understand the dynamics and interactions at near single 
molecule level (501, 502). tr-FRET has been extensively used to probe the association 
and oligomerization of cell-cell surface receptors (503–505), the ensembles of partially-
folded states in intrinsically disordered proteins (502, 506–510) and globular proteins 
(511–513). As a result of the distance and population information afforded by this 
technique, tr-FRET has been used to identify small molecule inhibitors of a host of cell 
surface receptor-ligand interactions including the estrogen receptor (514), mitotic kinase 
haspin (515) and growth hormone secretagogue receptor 1a (516). Here, a novel tr-FRET 
assay was developed to selectively probe the association reaction of the soluble, 
cytoplasmic protein, SOD1 (Fig. 7.2) and identify small molecules that drive the 
formation of dimers in the weakly dimeric variant, A4V (Fig. 7.1). In this assay, the 
monomer and dimer populations of A4V SOD1 were directly quantified based on the 
amplitudes of the donor and donor-acceptor excited state decays (Fig. 7.3). tr-FRET 
offers greater signal-to-noise compared with fluorescence intensity alone (Fig. 7.5) and 
the excited state decays are independent of fluorophore concentration and laser power. 
Indeed, COM analysis of the A488 lifetimes identified ~20 potential lead compounds that 
would have been under the cutoff imposed by FL total intensity (Figs. 7.8 and 7.9). 
Therefore, tr-FRET with bright and photostable fluorophores is an ideal technique for 
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monitoring association reactions and complex formation in a robust, highly sensitive and 
high throughput manner, where the populations of the individual species are the sole 
determinants of the FL excited state decay.  
 A majority of the putative lead compounds from the HTS contain five- and six-
membered aromatic rings (Figs 7.10 and 7.11), however, oleic acid stands out as unique 
due to its long, hydrophobic alkyl group. Membranes in neurons and the central nervous 
system are composed of this multifunctional long chain fatty acid (517) and has been 
shown to reduce blood pressure (518), directly excite neurons (519), regulate 
apolipoprotein B secretion (520) and inhibit an RNA-binding protein in stem cells (494). 
Although oleic acid was initially identified to stabilize the SOD1 dimer (Fig. 7.10B), FCS 
studies (Fig. 7.12B) indicated that oleic acid triggers SOD1 aggregation at low 
concentrations below the critical micelle concentration (494). This aggregation 
propensity was not shared by the dissimilar compound, 4-amino-1,8-naphthalimide, 
which promoted dimerization by both tr-FRET (Fig. 7.10A) and FCS (Fig. 7.12A) 
techniques. While this compound has shown significant fluorescence in organic solvents 
(521), the fluorescence intensity, quantum yield and lifetime are drastically reduced in an 
aqueous environment and do not contribute to the Alexa488 donor fluorescence decay. A 
number of compounds identified have been associated with alleviating various disorders 
including cancers (522) and neurodegeneration (523). Indeed, the anti-oxidants α-
tocopherol (Vitamin E), retinoic acid (Vitamin A) and ascorbyl palmitate (Vitamin C 
derivative) reduce reactive oxygen species and apoptosis induced neurodegeneration, 
particularly in Alzheimers and ALS (524–529). In this study, retinoic acid (Fig. 7.10D) 
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and ascorbyl palmitate (Fig. 7.10C) directly participated in mediating SOD1 
dimerization, a potential mechanism for the delay in neurodegenerative phenotypes in 
disease patients. In contrast, the antibiotic, ivermectin, which has been shown to target 
AMPA receptors and prolong life span in ALS animal models, was originally identified 
as a potential compound but showed little to no binding upon secondary screening (530). 
Intriguingly, the hormone derivative, estradiol acetate (Fig. 7.11F), bound to SOD1 with 
a relatively weak affinity (Table 7.3), but has shown promise in cell culture models (531) 
and mouse models including the G93A SOD1 overexpression model (532, 533). 
Furthermore, evidence has suggested that females have a reduced propensity for ALS and 
other neurodegenerative disorders due to the presence of estrogen (534–536). In the case 
of SOD1, estrogen may enhance the stability of the SOD1 dimer and prevent aggregation 
and toxicity associated with ALS and other neurodegenerative diseases.  
The compounds identified from the tr-FRET HTS have a wide range of proposed 
cellular functions but possess similar aromatic structures, suggesting that these 
compounds may bind to similar regions on the SOD1 structure. One location for potential 
small molecule binding is the zinc binding (Fig. 7.2A, blue) and electrostatic (Fig. 7.2A, 
green) loop region of SOD1, which become disordered upon the loss of metal binding 
(109, 295, 537). Small molecules could possible stabilize these loops, in a similar manner 
as zinc (64), and drive SOD1 dimerization to reduce the population of the monomeric and 
unfolded SOD1 states. This mechanism may serve as a possible explanation for the 
positive cooperativity of the small molecule binding observed in the tr-FRET dose 
response assays (Tables 7.3 and 7.4) and suggests that the small molecules may stabilize 
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the SOD1 dimer indirectly through the stabilization of the monomer. Alternatively, some 
molecules bind to A4V SOD1 with a Hill-coefficient of 1, such as 4-amino-1,8-
naphthalimide and ascorbyl palmitate (Table 7.3), suggesting the requirement of only one 
molecule for stabilization of the native SOD1 dimer. These molecules may act through a 
mechanism similar to the computational screen (122), where small molecules were 
docked at the dimeric interface between two SOD1 monomers. These results suggest that 
the small molecules may act through different mechanisms to achieve the same goal, the 
stabilization the native dimer of SOD1. However, a computational screen would not take 
alternative binding sites on SOD1 into account and further supports the necessity of an 
unbiased in vitro small molecule screen. The compounds identified using this novel tr-
FRET assay could serve as scaffolds for further optimizations in binding affinity, cell 
permeability and reduced toxicity and are the foundation to develop therapeutics to delay 
disease onset and progression through the direct stabilization of the native state of SOD1 
and its ALS variants.  
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Chapter VIII – Summary and Future Directions 
The continued interest in TDP-43 and SOD1 pertain to the roles these proteins 
play in mediating neurodegeneration, particularly ALS, where each protein is associated 
with a large percentage of sporadic and familial ALS, respectively (53). While different 
structurally and functionally, TDP-43 (30, 49), SOD1 (159) and a host of other ALS-
linked proteins, including FUS/TLS (51), profilin 1 (52), c9orf72 (54, 55) among others 
(53), may exert their toxic effects through similar mechanisms. Using a biophysical 
approach, the equilibrium folding free-energy landscapes of SOD1 (105, 106) and the 
RRM domains of TDP-43 (Chapter II) have identified key higher energy species that may 
serve as decision points between the formation of the native, functional three-dimensional 
structure and a misfolded conformation leading to aggregation. Structural insights via 
NMR revealed that the NES sequence in the intermediate state of the RRM2 domain of 
TDP-43 was shown to have a low propensity for secondary structure formation, 
suggesting a possible role for this partially-folded state in normal TDP-43 function 
(Chapter III). Further folding studies of other RRM domains from ALS-linked RNA-
binding proteins (Chapter IV) revealed that TDP-43, FUS/TLS and hnRNP A1 contain an 
RRM intermediate state adjacent to a prion-like domain, suggesting interplay between 
ordered and disordered regions of these proteins may contribute to function and 
misfolding. In Chapter V, several alanine mutants of ILV residues in RRM2 of TDP-43 
were used to enhance the population of the intermediate state to serve as a diagnostic tool 
for the development of novel antibodies targeting this species and to identify the cellular 
consequences of the RRM2 intermediate state.  
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TDP-43 functions in multiple different RNA processing pathways and likely 
needs to populate multiple native and partially-folded conformations for proper function, 
resulting in complicated folding and misfolding energy surfaces. SOD1, on the other 
hand, is a relatively simpler system due to its two-state unfolding mechanism (105) and 
gain-of-function toxicity (158, 159, 166, 398), that provides a model system to connect 
the folding and misfolding pathways in neurodegeneration. Several groups have shown 
that a set of ALS mutations perturbs the native dimeric species of SOD1 to favor the 
monomer and unfolded states (103, 106). Using a ThT-based aggregation assay in 
conjunction with known aggregation models (Chapter VI), the monomeric unfolded state 
was identified as the critical nucleus for SOD1 aggregation and suggests a potential target 
for therapeutic intervention. Indeed, leveraging the insights obtained from the biophysical 
studies into the folding mechanism of SOD1, a tr-FRET-based high throughput screen 
identified several lead compounds that stabilize the native SOD1 dimer of the ALS-
variant, A4V (Chapter VII). An understanding of the folding and aggregation energy 
landscapes are widely applicable to other protein systems, as several therapeutics 
targeting TTR in amyloid diseases have used similar approaches (116, 118, 119, 481). 
The results of these studies reveal the strengths in applying basic science concepts to 
inform the rational design of novel therapeutics to reduce the population of partially-
folded and misfolded conformation of proteins associated with this devastating 
neurodegenerative disease.  
 With these advancements in the ALS field, future directions for these projects will 
focus on three gaps in knowledge whose insights would provide critical details of the 
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mechanisms by which TDP-43 and SOD1 exert their toxic effects and result in neuronal 
cell death. 1) What are the roles of the RRM intermediates in the normal and abnormal 
functions of the ALS-linked RNA-binding proteins? 2) What are the species that initiate 
cell toxicity and neurodegeneration? Does the formation of oligomers and aggregates 
connect to a loss of normal TDP-43 function? 3) Can specifically targeting ALS-related 
proteins with small molecules and antibodies provide therapeutic benefit to ALS 
patients?  
 
The RRM Intermediate State 
 The unfolding pathway of the RRM domain may allow for this small domain to 
accomplish a variety of different functions, including DNA- and RNA-binding as well as 
protein-protein interactions (327). As shown in Chapters II-VI, the RRM domains of 
TDP-43, FUS/TLS, matrin-3 and hnRNP A1 were shown to have variable and sometimes 
complex equilibrium unfolding profiles with several of the RRM domains populating a 
stable intermediate state. A key gap in knowledge pertains to the potential roles of these 
intermediate states in the normal functions of these RNA-binding proteins.  
In the case of TDP-43 and FUS/TLS, a NES sequence (224) is embedded within 
the folded RRM domain with NLS sequences present elsewhere in predicted disordered 
regions of the proteins. As both TDP-43 and FUS/TLS predominantly function in the 
nucleus (228, 538), the NES may reside in a folded domain to limit its possibility of 
exposure and recognition by the nuclear export machinery for cytoplasmic transport. 
Indeed, structural insights on RRM2 of TDP-43 may support this argument as the 
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intermediate state possesses residual structure localized to the N-terminal half of RRM2, 
leaving the NES region largely disordered (Chapter III). These results suggest a possible 
function in nucleocytoplasmic trafficking for the RRM2 intermediate state. Interestingly, 
while functionally similar to TDP-43, hnRNP A1 does not contain a leucine-rich NES 
sequence in an RRM domain. Rather, hnRNP A1 contains an M9 domain in its glycine-
rich domain (310, 311), which functions as both an NLS and an NES signal, suggesting 
the intermediate state present in RRM2 of hnRNP A1 may function in some other 
capacity. Whether the exposure of the NES signals of TDP-43 and FUS/TLS, in their 
respective intermediates, plays an active role in cytoplasmic transport or whether these 
proteins are merely passengers along with other factors has yet to be determined.  
To understand the role of the RRM2 intermediate state in TDP-43 function and 
misfolding, a series of alanine mutants of core ILV residues were identified that disrupt 
the folding of RRM2 and enhance the population of the intermediate state (Chapter V). A 
majority of the mutants examined were severely destabilizing (Group I) with little 
secondary structure. Further studies into the structures of these RRM2 ILV mutants could 
potentially identify variants, which populate the intermediate state under native 
conditions. Interestingly, three of the four necessary hydrophobic residues of the NES 
sequence contribute to the highly networked ILV cluster present in RRM2 (Chapter II) 
and suggest that alanine mutations in any of these residues could serve a dual purpose by 
enhancing the intermediate state population and preventing cytoplasmic export. Work 
performed by Virginia Lee’s group (225) revealed that mutation of these residues to 
alanine resulted in the formation of nuclear restricted TDP-43 and the formation of 
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nuclear inclusions. However, in our cell culture model, the Group I mutant, I250A, was 
largely diffuse throughout the cytoplasm. These results could suggest that the 
enhancement of the RRM2 intermediate, through the Group I mutants, increased 
cytoplasmic transport and that mutation of a single residue in the NES is insufficient to 
block this process. However, I250A is the only Group I mutant examined that 
exemplifies this behavior, as I257A remains nuclear. Further studies on the structure of 
these RRM2 intermediate-enhancing mutations may provide structural insights into the 
localization of these mutant forms of TDP-43. Furthermore, assay to monitor changes in 
the splicing activity, nuclear-cytoplasmic transport and the TDP-43 interactome may shed 
light into the role of the RRM2 intermediate state on TDP-43 function. 
 On the opposite side of the spectrum, the RRM intermediate states of TDP-43, 
FUS/TLS and hnRNP A1 may not play a role in cytoplasmic transport but may serve 
simply as a stepping stone towards the formation of the native state of their respective 
proteins. Upon population of the intermediate states, aggregation prone sequences, such 
as β3 and β5 of RRM2 of TDP-43 (152), could template misfolding and aggregation with 
the other domains of TDP-43 (NTD, RRM1 or the C-terminus) or other proteins. Recent 
evidence on the prion-like domains of these RNA-binding proteins indicate that the 
disordered domains can self-assemble reversibly into dynamic liquid-like structures 
(280–284) that could serve to increase the local concentration of these proteins for 
functional purposes, such as the formation of the spliceosome, stress granules, P-bodies 
or other compartmentalized structures inside the cell. Prolonged exposure to the assembly 
conditions could result in irreversible complexes and aggregates over time. Indeed, 
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mutant FUS/TLS and hnRNP A1 have an impaired capacity to disassemble compared to 
the WT sequences and suggests that repeated stresses or conditions that favor assembly 
could lead to disastrous outcomes for cell homeostasis (282, 283). Are these assemblies 
themselves toxic to cells through a gain-of-function mechanism? Or does sequestration 
into assemblies deplete the functional pool of these RNA-binding proteins leading to a 
loss-of-function mechanism? Or is some combination of both? Evidence has suggested 
that addition of RNA facilitates the assembly of liquid droplets (281), likely through 
RNA serving as a scaffold for multiple RNA-binding proteins, and that these assemblies 
can recruit other protein partners, such as RNA polymerase II with FUS/TLS assemblies 
(280). However, it is not clear whether the RRM2 intermediates or the oligomerization of 
the NTD of TDP-43 can mediate assembly, as the IDP sequences can assemble in the 
absence of the RNA-binding domains, but perhaps these partially-folded states trap these 
structures upon association and prevent disassembly to form the inclusions observed in 
patients with neurodegenerative disease. 
 
The Toxic Species 
 Despite the advances to elucidate the mechanisms of toxicity in 
neurodegeneration, the critical first steps contributed by SOD1 and TDP-43 towards 
neuronal death remain elusive. Indeed, SOD1 is thought to exert toxicity through gain-of-
function mechanism (158, 159, 166, 398) whereby the aggregates themselves are toxic, 
while TDP-43 is more complicated due to its vast functional diversity (79, 183), 
including regulation of its own mRNA (80). In this case, toxicity likely relies on the 
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interplay between loss of its RNA’s regulation (loss-of-function) as a result of misfolding 
and aggregation (gain-of-function) that may result in continuous TDP-43 expression and 
subsequent aggregation in a vicious cycle. Chapters II and VI have identified potential 
species that may play a key role in nucleating misfolding, including the RRM2 
intermediate state in TDP-43 (Chapters II-V) and the monomeric unfolded state in SOD1 
(Chapter VI). However, which species in the misfolding of these proteins results in the 
toxicity is a critical gap in our understanding of the progression of neurodegeneration. 
Furthermore, structural insights into these species could inform the design of 
therapeutics, such as antibodies targeting specific sequences or structures or small 
molecule compounds that inhibit the initial formation of these toxic conformations. 
 A key species on the misfolding pathway has recently moved to the forefront of 
initiating toxicity in cell culture models for various disease-causing proteins, such as Aβ 
(269), Huntingtin (399, 400) and α-synuclein (272): soluble misfolded oligomers. The 
mechanisms through which soluble oligomers exert toxicity is less clear, but evidence has 
emerged that normal cellular homeostasis maintenance systems, such as autophagy (539), 
the chaperone network (468), and the proteasome (540), are involved in attempting to 
remove these species. However, whether small oligomers play a toxic role in TDP-43 and 
SOD1-mediated neurodegeneration has yet to be seen. In the case of SOD1, there is some 
evidence that this protein can oligomerize at the mitochondrial membrane to form pore-
like structures that may disrupt mitochondrial function leading to cell death (414). To 
address the question of whether small oligomers of TDP-43 and SOD1 impact cell 
viability, a FCS-based assay was developed to monitor the aggregation of these proteins 
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in the cell in real time. Upon expression, the fluorescence fluctuations of fluorescently-
tagged proteins can be directly quantified to obtain populations and size distributions for 
each species in the confocal volume. As shown in Chapter VI, a single amino acid 
substitution can result in a dramatic impact on the size distribution and localization of the 
A4V SOD1 variant compared to the WT counterpart. Furthermore, fluorescence cross 
correlation spectroscopy (FCCS) experiments, using a dual or triple fluorophore system, 
can identify whether mutant protein can recruit their WT counterparts into aggregates or 
whether other protein partners, such as chaperones, the proteasome or splicing factors 
(for TDP-43) are recruited to SOD1 and TDP-43 oligomers. These quantification of the 
protein dynamics in real time in cell culture models allows for direct connection toward 
cellular phenotypic assays such as cell viability, mitochondrial homeostasis, stress 
granule formation, splicing (in collaboration with Zuoshang Xu and Daryl Bosco) and 
proteasome function (in collaboration with Alfred Goldberg at Harvard Medical School) 
to identify which species and the populations of these species that lead to toxicity and 
subsequent neurodegeneration. 
 As small oligomers may play a role in toxicity, structural insights into regions of 
SOD1 and TDP-43 will prove immensely beneficial to the design of therapeutics 
targeting sequences and structures that may promote further misfolding and aggregation. 
Recent data from our lab (Noah R. Cohen, C. Robert Matthews and Osman Bilsel, 
unpublished) have suggested that the C-terminal 30 amino acids of SOD1 can form 
collapsed structure under native conditions in an isolated peptide. Perhaps this bias in the 
unfolded state of SOD1 serves a nucleus for templating misfolding for the full-length 
 355 
SOD1. The C-terminal peptide was the most protected region against hydrogen-
deuterium exchange in aggregates isolated from a host of ALS patients with varying 
SOD1 mutations (417) and a hexapeptide sequence within this peptide is sufficient to 
form fibrils and initiate aggregation of the full-length protein (111). These results suggest 
that the conformation bias in the unfolded state of SOD1 in the C-terminal region may 
serve as a common mechanism for initiating aggregation across different ALS variants. 
Using the peptide as a potential “seed”, the aggregation reaction of SOD1 and its variants 
can be monitored for potential peptide-protein self-association using the assay described 
in Chapter VI. Furthermore, the purification of oligomers for SAXS (in collaboration 
with BioCAT, Argonne National Laboratory) and sequence-specific protection using fast 
photo-oxidation of proteins (FPOP) coupled with mass spectrometry (in collaboration 
with Michael Gross and Ben Niu at Washington University) would provide insights into 
the structures and sequences that may initiate misfolding of SOD1. Intriguingly, the 
formation of oligomers through the reduction of the disulfide bond, as shown in Chapter 
VI, results in unstable complexes that are maintained on a native gel (Chapter VI) but 
dissociate upon subjection to size exclusion chromatography (Brian C. Mackness, Jill 
Zitzewitz and Osman Bilsel, preliminary data). These results suggest that oligomers are 
reversible and can dissociate to monomers and dimers. Targeting the oligomers with 
antibodies and/or chaperones could provide therapeutic benefit if these cell homeostasis 
mechanisms can dissociate these potentially toxic species. Taken together, mapping of 
the misfolding pathway of SOD1 and TDP-43 provided several candidate species to 
target for therapeutic intervention to reduce the population of these potentially toxic 
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conformations: the collapse C-terminal SOD1 peptide, protected structures and sequences 
in oligomers and the oligomers themselves. 
 
Therapeutic Targeting of Misfolded Conformations 
 Riluzole is the only FDA-approved drug available for the treatment of ALS with a 
modest increase in life expectancy of 2-3 months (114). However, despite its usefulness, 
riluzole does not directly target any known ALS-related gene products, such as SOD1, 
TDP-43, FUS/TLS, c9orf72 among other, but rather acts as a glutamate receptor 
antagonist (115). Therefore, there is a critical need for therapeutics, specifically designed 
to target partially-folded or misfolded species, to reduced the propensity for toxic 
phenotypes and maintain the normal functions of the ALS-related proteins. This type of 
approach has been used to successfully and specifically target the tetrameric protein, 
TTR, to result in stabilization against misfolding in amyloid diseases (88, 116, 118). A 
computational screen has been performed on SOD1; specifically targeting a cavity 
located at the dimer interface between two SOD1 subunits (122), and has identified 
several potential hits, whose effects on SOD1 aggregation have been controversial (123). 
Leveraging our biophysical understanding of the folding energy landscape of 
SOD1, a tr-FRET-based screen was designed to directly monitor the monomer-dimer 
equilibrium (2M D N2). ALS Mutations in SOD1 disrupt the folding in a variety of 
different ways, including disruption of metal-binding, destabilization of the monomer 
folding reaction (U D M), perturb the monomer-dimer equilibrium (2M D N2) or in 
combination. Indeed, the tr-FRET assay described in Chapter VI, is ideal to monitor the 
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association reaction of the ALS variant, A4V, which selectively destabilizes the 
monomer-dimer equilibrium by three orders of magnitude compared to WT. Therefore, 
poising the equilibrium below the Kd,app of the A4V variant allowed for the search of 
compounds which increased the FRET-competent state of A4V SOD1 and suggested 
enhanced dimerization between A4V monomers. Screening two 1280-compound 
libraries, the LOPAC (Sigma-Aldrich) and FDA-approved (Microsource) libraries, 
resulted in the identification of several putative lead compounds that stabilize the native 
A4V SOD1 dimer. While a majority of compounds had weak affinity (EC50 >100 µM), 
one compound, 4-amino-1,8-naphthalimide, bound with relatively tight affinity (EC50 <1 
µM) and can possibly serve as a scaffold for further optimization, in a similar manner as 
the TTR substrate, thyroxine (118). Further studies will focus on structure based design 
to identify small molecule binding locations on the A4V SOD1 variant using a 
combination of X-ray crystallography and molecular dynamic simulations to optimize the 
structure and functional groups of our putative lead compounds to enhance binding 
affinity, reduce toxicity and allow passage through the blood brain barrier. In addition, 
screening the CNS library (OTAVA Chemicals) may identify compounds known to 
penetrate the blood brain barrier. The identification of small molecules can also serve as a 
tool to tune the monomer-dimer equilibrium of SOD1 to elucidate the role different 
populations of partially-folded species can impact disease phenotypes in cell culture and 
animal models. Previously developed antibodies targeting different conformations of 
SOD1, such as mutant, unfolded, monomeric or misfolded (541), can further enhance our 
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repertoire of diagnostic tools to identify how and when SOD1 misfolding can lead to 
toxicity.  
A similar approach has been proposed to stabilize the RRM1-RRM2 interaction 
of TDP-43 using small molecules to limit the population of the RRM2 intermediate state 
(Meme T. Tran, Jill A. Zitzewitz). Normally the RRM domains stabilize one another 
possibly through mutual interactions (Chapter II, (235)), however, fragmentation in or 
near RRM2 (49, 138, 140, 184), resulting in N- and C-terminal fragments, may play a 
role in propagating TDP-43 disease states. Multiple studies propose toxicity arises from 
the C-terminal fragments containing intact or partial RRM2 domains (138–141), which 
have an increased population of the intermediate when isolated from RRM1, at 
physiological temperatures and in RRM2 cleavage fragments. Small molecules that 
stabilize the interaction between RRM1-RRM2, even when fragmented, may aid in 
reducing the population of C-terminal fragments. Using an assay similar to the tr-FRET 
assay detailed in Chapter VI, compounds identified would increase the FRET-competent 
state between the two isolated RRM domains (i.e. no binding results in donor only 
fluorescence from RRM1, but small molecule binding stabilizes the RRM1-RRM2 
interaction to result in FRET) and stabilize the native structure of RRM2. Furthermore, 
this assay would provide insights into the binding constant between RRM1 and RRM2, 
which is likely in the µM range (Meme T. Tran, Jill A. Zitzewitz). Preliminary mutational 
analysis, for the insertion of exposed cysteine residues as sites for extrinsic fluorophore 
incorporation, identified one residue in each domain that does not disrupt the structure or 
stability of their respective domain (Meme T. Tran). Furthermore, each RRM domain 
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binds to RNA in isolation and, thus, contributes to the overall stability of the domains 
(73, 235). Can RRM1 and RRM2, when expressed separately, form this complex in 
isolation or does RNA mediate their interactions as is observed in the NMR structure 
(72)? Does stabilization of the native state of RRM2 impact the function of TDP-43 
through reduced exposure of the NES sequence? These questions suggest a balance 
between stability and function might exist for TDP-43, and even for SOD1 as well, as 
there is no clear indication whether stabilization of the native states of these proteins 
impacts their normal functions.  
 
Summary 
The work presented in this thesis provides strong support for a basic 
understanding of the folding free-energy surfaces of a protein in the development of 
therapeutics specifically targeting higher energy species of these systems. The folding 
and misfolding aggregation landscapes of a particular polypeptide sequence have long 
been thought to overlap at intermediate states, where these partially-folded states can 
serve to limit the conformational search to the native state or serve as templates to induce 
misfolding and subsequent aggregation.  Our studies of the folding of the RRM domains 
of TDP-43 have identified a novel folding intermediate state in an RRM domain, which 
may have evolved for a functional purpose, in cytoplasmic transport via an exposed NES 
sequence, or may mediate misfolding of TDP-43 into dysfunctional complexes and 
aggregates. Furthermore, several candidate mutations increase the population of this state 
and may serve as useful biomarkers for the design of antibodies for diagnostic and 
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therapeutic treatments of neurodegeneration. Similarly, ALS mutations in SOD1 result in 
enhanced populations of the unfolded and monomeric forms, which was demonstrated to 
play a critical role in the nucleation reaction during SOD1 aggregation. Using the 
biophysical details of the energy landscapes of TDP-43 and SOD1, high throughput small 
molecule screens were developed to directly target SOD1 and TDP-43 to stabilize their 
native conformations and reduce the population of these potentially toxic higher energy 
conformations.  
In conclusion, the insights gathered from basic science into the folding of several 
ALS-related proteins has resulted in targeted screening methods to identify candidate 
therapeutics that may reduce the burden on the cell homeostasis network and delay or 
inhibit onset and disease progression in patients suffering from neurodegenerative 
disease. 
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